"","drug","drug_drugbank_standard","drug_pubchem","biomarker","biomarker_ensembl_standard","biomarker_type","biomarker_direction","biomarker_relations","biomarker_description","disease","diseases_id_standard","drug_targets","QC","curator","raw_table","source","source_id","record_id"
"1","ABACAVIR","DB01048","29969962","HLA-B","ENSG00000234745","polymorphism","negative",NA,"HLA-B POLYMORPHISM NEGATIVE","AIDS","EFO_0000765","NRTI","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG594659457"
"2","ABEMACICLIB","DB12001","46220502","ESR, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression & amplification","positive, negative","AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","(HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","CDK4; CDK6","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1498962895"
"4","AFATINIB","DB08916","10184653","EGFR","ENSG00000146648","mutation","positive",NA,"EGFR MUTATION POSITIVE","LUNG CANCER","MONDO_0008903","EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; ErbB4","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1064188334"
"5","ALECTINIB","DB11363","53239799","ALK","ENSG00000171094","protein expression","positive",NA,"ALK PROTEIN EXPRESSION POSITIVE","NON-SMALL CELL LUNG CANCER THAT HAS SPREAD TO OTHER PARTS OF THE BODY","EFO_0003060","ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1932775397"
"6","ALPELISIB","DB12015","56649450","ESR, ERBB2, PIK3CA","ENSG00000091831, ENSG00000141736, ENSG00000121879","protein expression, protein expression & amplification,  mutation","positive, negative,positive","AND,AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND PIK3CA MUTATION POSITIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","PI3Kα; p110α; p110γ","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-955586545"
"7","AMIFAMPRIDINE","DB11640","9920716","NAT2","ENSG00000156006","polymorphism","positive",NA,"NAT2 POLYMORPHISM POSITIVE","LAMBERT-EATON MYASTHENIA SYNDROME IN ADULTS","MONDO_0023370","potassium channel","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1386474016"
"8","AMIFAMPRIDINE PHOSPHATE",NA,"9920716","NAT2","ENSG00000156006","polymorphism","positive",NA,"NAT2 POLYMORPHISM POSITIVE","LAMBERT-EATON SYNDROME","MONDO_0023370","potassium channel","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1029442076"
"9","AMITRIPTYLINE","DB00321","11065","CYP2D6","ENSG00000100197","polymorphism","positive",NA,"CYP2D6 POLYMORPHISM POSITIVE","DEPRESSION","EFO_0003761","5-HT; 5-HT2; 5-HT4; Norepinephrine receptor; σ1","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1233009142"
"10","AMOXAPINE","DB00543","2170","CYP2D6","ENSG00000100197","polymorphism","positive",NA,"CYP2D6 POLYMORPHISM POSITIVE","DEPRESSION","EFO_0003761","GlyT1b; GlyT2a","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG979588562"
"11","AMPHETAMINE","DB00182","5826","CYP2D7","ENSG00000205702","polymorphism","missing",NA,"CYP2D7 POLYMORPHISM MISSING","ATTENTION DEFICIT HYPERACTIVITY DISORDER,OBESITY","EFO_0001073",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2008815520"
"13","ARFORMOTEROL","DB01274","9827062","UGT1A1, CYP2D6","ENSG00000241635, ENSG00000100197","polymorphism, polymorphism","positive, positive","AND/OR","UGT1A1 POLYMORPHISM POSITIVE AND/OR CYP2D6 POLYMORPHISM POSITIVE","CHRONIC OBSTRUCTIVE PULMONARY DISEASE","EFO_0000341","β2-adrenergic receptor","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG445115987"
"14","ARIPIPRAZOLE   LAUROXIL",NA,"49831411","CYP2D6","ENSG00000100197","polymorphism","positive",NA,"CYP2D6 POLYMORPHISM POSITIVE","SCHIZOPHRENIA AND BIPOLAR DISORDER,MAJOR DEPRESSION,TOURETTE'S DISEASE OR AUTISM","EFO_0000289","5-HT2A","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-493957746"
"15","ARSENIC TRIOXIDE","DB01169",NA,"PML-RARA","ENSG00000133246","translocation","positive",NA,"PML-RARA TRANSLOCATION POSITIVE","BLOOD AND BONE MARROW CANCERS","MONDO_0021138","HK2(Hexokinase 2)","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1476585244"
"16","ARTICAINE, EPINEPHRINE","DB09009,DB00668","32170, 5816","G6PD","ENSG00000160211","protein expression","positive",NA,"G6PD PROTEIN EXPRESSION POSITIVE","ANESTHESIOLOGY,BEFORE DENTAL CARE TO NUMB THE AREA","OTAR_0000018",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1745727063"
"17","ATEZOLIZUMAB","DB11595",NA,"CD274","ENSG00000120217","protein expression","positive",NA,"CD274 PROTEIN EXPRESSION POSITIVE","BREAST BLADDER AND URINARY TRACT CANCERS, NON-SMALL CELL LUNG CANCER.","MONDO_0007254","hPD-L1","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1850603683"
"18","ATEZOLIZUMAB","DB11595",NA,"CD274, Gene Signature
(T-effector)","ENSG00000120217, NA","protein expression, others","positive, positive","AND","CD274 PROTEIN EXPRESSION POSITIVE AND GENE SIGNATURE
(T-EFFECTOR) OTHERS POSITIVE","METASTATIC CHEMOTHERAPY-NAIVE NON-SQUAMOUS NSCLC","EFO_0000707","hPD-L1","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG875467658"
"19","ATEZOLIZUMAB","DB11595",NA,"CD274, EGFR, ALK","ENSG00000120217, ENSG00000146648, ENSG00000171094","protein expression, mutation, mutation","positive, negative, negative","AND, AND","CD274 PROTEIN EXPRESSION POSITIVE AND EGFR MUTATION NEGATIVE AND ALK MUTATION NEGATIVE","NON-SMALL CELL LUNG CANCER.","EFO_0003060",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1616970176"
"20","ATOMOXETINE","DB00289","54841","CYP2D6","ENSG00000100197","polymorphism","positive",NA,"CYP2D6 POLYMORPHISM POSITIVE","HYPERACTIVE ATTENTION DEFICIT","EFO_0003888","5-HT; DA transporter; Norepinephrine (NE) transporter","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-292801829"
"21","ASCORBIC ACID, PEG-3350, POTASSIUM CHLORIDE, SODIUM ASCORBATE, SODIUM CHLORIDE, SODIUM SULFATE","DB00126,NA,DB00761,DB14482,DB09153,DB09472","54670067, 174, 4873, 23667548, 5234, 24436","G6PD","ENSG00000160211","polymorphism","negative",NA,"G6PD POLYMORPHISM NEGATIVE","GASTROINTESTINAL","EFO_0010282",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1600346418"
"22","AVATROMBOPAG","DB11995","9852519","F2, F5, PROC, PROS1, SERPINC1, CYP2C9","ENSG00000180210, ENSG00000198734, ENSG00000115718, ENSG00000184500, ENSG00000117601, ENSG00000138109","polymorphism, polymorphism, polymorphism, polymorphism, polymorphism, polymorphism","negative,negative,negative, negative,negative,negative","OR, OR, OR, OR, OR","F2 POLYMORPHISM NEGATIVE OR F5 POLYMORPHISM NEGATIVE OR PROC POLYMORPHISM NEGATIVE OR PROS1 POLYMORPHISM NEGATIVE OR SERPINC1 POLYMORPHISM NEGATIVE OR CYP2C9 POLYMORPHISM NEGATIVE","THROMBOTIC","Orphanet_183589","TPOreceptor","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG719702881"
"23","AVELUMAB","DB11945",NA,"CD274","ENSG00000120217","protein expression","positive",NA,"CD274 PROTEIN EXPRESSION POSITIVE","MERCKLE CELL CARCINOMA","EFO_0000707","PD-L1","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1188758294"
"24","AZATHIOPRINE","DB00993","2265","TPMT, NUDT15","ENSG00000137364, ENSG00000136159","polymorphism, polymorphism","negative, negative","AND/OR","TPMT POLYMORPHISM NEGATIVE AND/OR NUDT15 POLYMORPHISM NEGATIVE","AUTOIMMUNE DISEASES","EFO_1000870","HGPRT; Rac1;","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1048595055"
"25","BELINOSTAT","DB05015","6918638","UGT1A1","ENSG00000241635","polymorphism","negative",NA,"UGT1A1 POLYMORPHISM NEGATIVE","T CELL LYMPHOMA","EFO_0002913","HDAC","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2059480590"
"26","BINIMETINIB","DB11967","10288191","BRAF","ENSG00000157764","mutation","positive",NA,"BRAF MUTATION POSITIVE","MELANOMA","EFO_0000756","MEK1&2","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG736314554"
"28","BOCEPREVIR","DB08873","10324367","IFNL3
","ENSG00000197110","protein expression","positive",NA,"IFNL3 PROTEIN EXPRESSION POSITIVE","HEPATITIS C INFECTION","EFO_0004220","HCV NS3 protease","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-378943012"
"30","BRENTUXIMAB VEDOTIN","DB08870",NA,"ALK","ENSG00000171094","mutation","negative",NA,"ALK MUTATION NEGATIVE","CLASSICAL HODGKIN LYMPHOMA,ANAPLASTIC LARGE CELL LYMPHOMA","EFO_0000574","ADCs Linker","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-771556728"
"31","BRENTUXIMAB VEDOTIN","DB08870",NA,"TNFRSF8","ENSG00000120949","protein expression","positive",NA,"TNFRSF8 PROTEIN EXPRESSION POSITIVE","CLASSICAL HODGKIN LYMPHOMA,ANAPLASTIC LARGE CELL LYMPHOMA","EFO_0000574","ADCs Linker","pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1173989673"
"32","BREXPIPRAZOLE","DB09128","11978813","CYP2D6","ENSG00000100197","polymorphism","positive",NA,"CYP2D6 POLYMORPHISM POSITIVE","SCHIZOPHRENIA,SEVERE DEPRESSION,ALZHEIMER'S DISEASE","EFO_0000249",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG829815143"
"33","BRIGATINIB","DB12267","68165256","ALK","ENSG00000171094","mutation","positive",NA,"ALK MUTATION POSITIVE","NON-SMALL CELL LUNG CANCER THAT HAS SPREAD TO OTHER PARTS OF THE BODY","EFO_0003060",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1437695799"
"34","BRIVARACETAM","DB05541","9837243","CYP2C19","ENSG00000165841","polymorphism","positive",NA,"CYP2C19 POLYMORPHISM POSITIVE","EPILEPSY","EFO_0000474",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG282615554"
"35","CABOZANTINIB","DB08875","25102846","RET","ENSG00000165731","genetic others","positive",NA,"RET GENETIC OTHERS POSITIVE","NON-SMALL-CELL LUNG CANCER","EFO_0003060",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG816316872"
"36","CAPECITABINE","DB01101","60953","DPYD","ENSG00000188641","mutation","negative",NA,"DPYD MUTATION NEGATIVE","COLORECTAL CANCER,REAST CANCER","EFO_0005842",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1533469514"
"37","CARBAMAZEPINE","DB00564","2554","HLA-B, HLA-A","ENSG00000234745, ENSG00000206503","polymorphism, polymorphism","negative, negative","AND/OR","HLA-B POLYMORPHISM NEGATIVE AND/OR HLA-A POLYMORPHISM NEGATIVE","BRIVARACETAM,EPILEPSY,ANTICONVULSANTS","EFO_0000474",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG205847830"
"38","CARGLUMIC ACID","DB06775","121396","NAGS","ENSG00000161653","protein expression","positive",NA,"NAGS PROTEIN EXPRESSION POSITIVE","INBORN ERRORS OF METABOLISM,HIGH AMMONIA LEVELS","Orphanet_68367",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG541509081"
"39","CARIPRAZINE","DB06016","25096873","CYP2D6","ENSG00000100197","polymorphism","positive",NA,"CYP2D6 POLYMORPHISM POSITIVE","SCHIZOPHRENIA,BIPOLAR I DISORDER","EFO_0000289",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1069940068"
"40","CARISOPRODOL","DB00395","2576","CYP2C19","ENSG00000165841","polymorphism","positive",NA,"CYP2C19 POLYMORPHISM POSITIVE","SKELETAL MUSCLE DISEAS","Orphanet_206634",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1900108140"
"41","CARVEDILOL","DB01136","20631713","CYP2D6","ENSG00000100197","polymorphism","positive",NA,"CYP2D6 POLYMORPHISM POSITIVE","HEART FAILURE,HIGH BLOOD PRESSURE,HEART DISEASE","EFO_0003777",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1557071629"
"42","CELECOXIB","DB00482","2662","CYP2C9","ENSG00000138109","polymorphism","positive",NA,"CYP2C9 POLYMORPHISM POSITIVE","ARTHRITIS, ANKYLOSIS AND MENSTRUAL PAIN,RHEUMATOID ARTHRITIS","EFO_0000685",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG900270885"
"43","CEFTRIAXONE","DB01212","5479530","G6PD","ENSG00000160211","polymorphism","negative",NA,"G6PD POLYMORPHISM NEGATIVE","TREAT OR PREVENT BACTERIAL INFECTIONS","EFO_0000771",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG570155103"
"44","CERITINIB","DB09063","57379345","ALK","ENSG00000171094","mutation","positive",NA,"ALK MUTATION POSITIVE","LUNG CANCER","MONDO_0008903",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-413895656"
"45","CERLIPONASE ALFA","DB13173",NA,"TPP1","ENSG00000166340","mutation","positive",NA,"TPP1 MUTATION POSITIVE","TYPE 2 DISEASE OF CEROID LIPOFUSCINOSIS (CLN2)","EFO_1000051",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-2121880163"
"47","CRIZANLIZUMAB","DB15271",NA,"HBB","ENSG00000244734","mutation","positive",NA,"HBB MUTATION POSITIVE","PEOPLE WITH SICKLE CELL DISEASE","EFO_1000636",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1667727299"
"49","DABRAFENIB","DB08912","44516822","RAS","ENSG00000133703","mutation","positve",NA,"RAS MUTATION POSITVE","SKIN CANCER (MELANOMA)","MONDO_0002898",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1229781644"
"50","DENILEUKIN DIFTITOX","DB00004",NA,"IL2RA
","ENSG00000134460","protein expression","positve",NA,"IL2RA PROTEIN EXPRESSION POSITVE","LEUKEMIA","EFO_0000565",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-210842937"
"52","EFAVIRENZ","DB00625","64139","CYP2B6","ENSG00000197408","polymorphism","positve",NA,"CYP2B6 POLYMORPHISM POSITVE","HIV INFECTION","EFO_0000764",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG779147928"
"53","ELAGOLIX","DB11979","24785956","SLCO1B1","ENSG00000134538","protein expression","missing",NA,"SLCO1B1 PROTEIN EXPRESSION MISSING","MODERATE TO SEVERE PAIN CAUSED BY ENDOMETRIOSIS.","EFO_0003843",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1440571084"
"54","ELEXACAFTOR, IVACAFTOR, TEZACAFTOR","DB15444,DB08820,DB11712","134587348, 16220172, 46199646","CFTR","ENSG00000001626","mutation","positive",NA,"CFTR MUTATION POSITIVE","REPAIR THE DEFECTIVE CFTR PROTEIN","MONDO_0019755",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1184408474"
"59","ENASIDENIB","DB13874","90480031","IDH2","ENSG00000182054","mutation","positive",NA,"IDH2 MUTATION POSITIVE","ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WITH AN IDH2 MUTATION.","EFO_0000222",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1362059301"
"60","ENFORTUMAB VEDOTIN-EJFV","DB13007",NA,"NECTIN4","ENSG00000143217","protein expression","missing",NA,"NECTIN4 PROTEIN EXPRESSION MISSING","ADVANCED UROTHELIAL CARCINOMA, BLADDER CANCER","EFO_0009260",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1738472582"
"61","ENTRECTINIB","DB11986","25141092","NTRK","ENSG00000165300","gene fusion","positive",NA,"NTRK GENE FUSION POSITIVE","SOLID TUMOR","Orphanet_84",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-622383070"
"62","ERDAFITINIB","DB12147","67462786","FGFR","ENSG00000068078","mutation & gene fusion","positive",NA,"FGFR MUTATION & GENE FUSION POSITIVE","UROTHELIAL CARCINOMA","EFO_0008528",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-239734061"
"63","ESCITALOPRAM","DB01175","146570","CYP2C19","ENSG00000165841","polymorphism","positive",NA,"CYP2C19 POLYMORPHISM POSITIVE","DEPRESSION","EFO_0003761",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1869766997"
"64","ESTRADIOL, PROGESTERONE","DB00783,DB00396","5757, 5994","SERPINC1","ENSG00000117601","protein overexpression","positive",NA,"SERPINC1 PROTEIN OVEREXPRESSION POSITIVE","VASOMOTOR DISEASE","EFO_0003782",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-978387120"
"65","ETEPLIRSEN","DB06014",NA,"DMD","ENSG00000198947","mutation","positive",NA,"DMD MUTATION POSITIVE","DUCHENNE MUSCULAR DYSTROPHY","Orphanet_98896",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-998821726"
"66","FLUOROURACIL","DB00544","3385","DPYD","ENSG00000188641","mutation","positive",NA,"DPYD MUTATION POSITIVE","SKIN CANCER","MONDO_0002898",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG363506879"
"67","GILTERITINIB","DB12141","49803313","FLT3","ENSG00000122025","mutation","positive",NA,"FLT3 MUTATION POSITIVE","MYELOMATOSIS","EFO_0001378",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-23249570"
"70","IMATINIB","DB00619","123596","KIT, FIP1L1-PDGFRA","ENSG00000157404, ENSG00000282278","mutation, gene fusion","negative, positive","AND","KIT MUTATION NEGATIVE AND FIP1L1-PDGFRA GENE FUSION POSITIVE","AGGRESSIVE SYSTEMIC MASTOCYTOSIS","EFO_0000618",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1859447834"
"72","IMATINIB","DB00619","123596","PDGFRB","ENSG00000113721","translocation","positive",NA,"PDGFRB TRANSLOCATION POSITIVE","MYELODYSPLASTIC","MONDO_0020077",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1151651722"
"73","IMATINIB","DB00619","123596","FIP1L1-PDGFRA","ENSG00000282278","gene fusion","positive",NA,"FIP1L1-PDGFRA GENE FUSION POSITIVE","HYPEREOSINOPHILIC SYNDROME (HES) AND","EFO_0004842",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1147713356"
"74","INDACATEROL","DB05039","6918554","UGT1A1","ENSG00000241635","polymorphism","positive",NA,"UGT1A1 POLYMORPHISM POSITIVE","ASTHMA","EFO_0000270",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG166414512"
"75","INOTERSEN","DB14713","121493436","TTR","ENSG00000118271","protein expression","positive",NA,"TTR PROTEIN EXPRESSION POSITIVE","FAP(FAMILIAL AMYLOID POLYNEUROPATHY)","EFO_0002945",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-539500812"
"76","IPILIMUMAB","DB06186",NA,"HLA-A","ENSG00000206503","polymorphism","positive",NA,"HLA-A POLYMORPHISM POSITIVE","MELANOMA","EFO_0000756",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-848100356"
"77","ISOSORBIDE DINITRATE","DB00883","6883","CYB5R","ENSG00000100243","protein expression","positive",NA,"CYB5R PROTEIN EXPRESSION POSITIVE","ANGINA","EFO_0003913",NA,"pass","Ben","FDA-drug_biomarkers-v9_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1476229835"
"78","IVOSIDENIB","DB14568",NA,"IDH1","ENSG00000138413","mutation","positive",NA,"IDH1 MUTATION POSITIVE","LEUKEMIA","EFO_0000565",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG637500005"
"79","LAPATINIB","DB01259",NA,"HLA-DQA1","ENSG00000196735","polymorphism","positive",NA,"HLA-DQA1 POLYMORPHISM POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-726641820"
"80","LAPATINIB","DB01259",NA,"HLA-DRB1","ENSG00000196126","polymorphism","positive",NA,"HLA-DRB1 POLYMORPHISM POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG496745715"
"81","LAROTRECTINIB","DB14723",NA,"NTRK","ENSG00000165300","gene fusion","positive",NA,"NTRK GENE FUSION POSITIVE","ABNORMAL NTRK GENE CAUSES CERTAIN TUMORS","EFO_0000294",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG453634129"
"83","MIDOSTAURIN","DB06595",NA,"NPM1","ENSG00000181163","mutation","positive",NA,"NPM1 MUTATION POSITIVE","ACUTE MYELOID LEUKEMIA,CERTAIN RARE BLOOD DISORDERS, INCLUDING SYSTEMIC MASTOCYTOSIS WITH MAST CELL LEUKEMIA OR OTHER CANCERS AFFECTING THE BLOOD,BONE MARROW, OR LYMPHATIC TISSUE.","EFO_1000068",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG679917283"
"84","MIDOSTAURIN","DB06595",NA,"KIT","ENSG00000157404","mutation","positive",NA,"KIT MUTATION POSITIVE","ACUTE MYELOID LEUKEMIA,CERTAIN RARE BLOOD DISORDERS, INCLUDING SYSTEMIC MASTOCYTOSIS WITH MAST CELL LEUKEMIA OR OTHER CANCERS AFFECTING THE BLOOD,BONE MARROW, OR LYMPHATIC TISSUE.","EFO_1000068",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-49333377"
"85","MIGALASTAT","DB05018",NA,"GLA","ENSG00000242252","mutation","positive",NA,"GLA MUTATION POSITIVE","FABRY DISEASE","Orphanet_324",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1030127933"
"86","MIVACURIUM","DB01226",NA,"BCHE","ENSG00000114200","polymorphism","positive",NA,"BCHE POLYMORPHISM POSITIVE","CALM MUSCLES DURING SURGERY,CALM MUSCLES WHILE ON A BREATHING MACHINE","MONDO_0003939",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-280478680"
"87","MYCOPHENOLIC ACID","DB01024",NA,"HPRT1","ENSG00000165704","protein expression","positive",NA,"HPRT1 PROTEIN EXPRESSION POSITIVE","RGAN REJECTION AFTER A KIDNEY TRANSPLANT","EFO_0003086",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2104942858"
"88","NUSINERSEN","DB13161",NA,"SMN2","ENSG00000205571","protein expression","positive",NA,"SMN2 PROTEIN EXPRESSION POSITIVE","SPINAL MUSCULAR ATROPHY","EFO_0008525",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1086936591"
"89","OBINUTUZUMAB","DB08935",NA,"MS4A1","ENSG00000156738","protein expression","positive",NA,"MS4A1 PROTEIN EXPRESSION POSITIVE","LEUKEMIA，LYMPHOMA","EFO_0009119",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-558455940"
"90","OLAPARIB","DB09074",NA,"BRCA","ENSG00000012048","mutation","positive",NA,"BRCA MUTATION POSITIVE","OVARIAN CANCER, FALLOPIAN TUBE CANCER, OR PERITONEAL CANCER IN WOMEN WITH A CERTAIN ABNORMAL INHERITED GENE，HER2-NEGATIVE BREAST CANCER，CANCER HAS A SPECIFIC GENETIC MARKER (AN ABNORMAL ""BRCA"" GENE)","EFO_0000311",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG489011798"
"91","OLARATUMAB","DB06043",NA,"PDGFRA","ENSG00000134853","protein silencing","positive",NA,"PDGFRA PROTEIN SILENCING POSITIVE","SOFT TISSUE SARCOMA","EFO_1001968",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1388758583"
"92","PARATHYROID HORMONE","DB05829",NA,"CASR","ENSG00000036828","mutation","positive",NA,"CASR MUTATION POSITIVE","CONTROL LOW BLOOD CALCIUM LEVELS IN PEOPLE WHO HAVE LOW BLOOD PARATHYROID HORMONE LEVELS","EFO_0007937",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1323391694"
"93","PEGINTERFERON ALFA-2B","DB00022",NA,"IFNL3","ENSG00000197110","protein expression","positive",NA,"IFNL3 PROTEIN EXPRESSION POSITIVE","CHRONIC HEPATITIS","EFO_0008496",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG794218917"
"95","PRASUGREL","DB06209",NA,"CYP3A5","ENSG00000106258","protein expression","positive",NA,"CYP3A5 PROTEIN EXPRESSION POSITIVE","ATHEROSCLEROSIS","EFO_0003914",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1790679122"
"96","RUCAPARIB","DB12332",NA,"CYP1A2","ENSG00000140505","protein expression","positive",NA,"CYP1A2 PROTEIN EXPRESSION POSITIVE","OVARIAN CANCER","MONDO_0008170",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG149207443"
"98","USTEKINUMAB","DB05679",NA,"IL12A, IL12B, IL23A","ENSG00000168811, ENSG00000113302, ENSG00000110944","mutation,mutation,mutation","positive, positive, positive","AND/OR, AND/OR","IL12A MUTATION POSITIVE AND/OR IL12B MUTATION POSITIVE AND/OR IL23A MUTATION POSITIVE","COLITIS (UC)","EFO_0003872",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1053117702"
"99","VALPROIC ACID","DB00313",NA,"POLG","ENSG00000140521","mutation","positive",NA,"POLG MUTATION POSITIVE","EPILEPSY","EFO_0000474",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1944943287"
"100","VENETOCLAX","DB11581",NA,"TP53","ENSG00000141510","mutation","positive",NA,"TP53 MUTATION POSITIVE","LEUCOCYTHEMIA","EFO_0000222",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1127858044"
"101","VENETOCLAX","DB11581",NA,"IGH","ENSG00000116017","translocation","positive",NA,"IGH TRANSLOCATION POSITIVE","LEUCOCYTHEMIA","EFO_0000222",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1962047831"
"102","WARFARIN","DB00682",NA,"VKORC1","ENSG00000167397","polymorphism","positive",NA,"VKORC1 POLYMORPHISM POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","EFO_0004260",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-357946721"
"103","WARFARIN","DB00682",NA,"PROS1","ENSG00000184500","mutation","positive",NA,"PROS1 MUTATION POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","EFO_0004260",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2028368899"
"104","WARFARIN","DB00682",NA,"PROC","ENSG00000115718","mutation","positive",NA,"PROC MUTATION POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","EFO_0004260",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG313586149"
"105","SODIUM   PHENYLBUTYRATE",NA,NA,"ASS1, CPS1, OTC","ENSG00000130707, ENSG00000021826, ENSG00000036473","mutation,mutation,mutation","positive, positive, positive","OR,OR","ASS1 MUTATION POSITIVE OR CPS1 MUTATION POSITIVE OR OTC MUTATION POSITIVE","ENZYME DEFICIENCY","Orphanet_309005",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-2104469395"
"109","BGB-290, TEMOZOLOMIDE","NA,DB00853","135565554, 5394","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03150810","BiomarkerKG1499714249"
"112","CB-103","DB15279","2735289","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03422679","BiomarkerKG1950850360"
"113","BOS172722, PACLITAXEL","DB15498,DB01229","73386890, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03328494","BiomarkerKG-1350934379"
"115","AVELUMAB, TALAZOPARIB","DB11945,DB11760","NA, 135565082","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PDL1, PARP","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03330405","BiomarkerKG1795800692"
"116","AVELUMAB, TALAZOPARIB","DB11945,DB11760","NA, 135565082","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","PDL1, PARP","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03330405","BiomarkerKG958553622"
"117","AVELUMAB, TALAZOPARIB","DB11945,DB11760","NA, 135565082","BRCA1, BRCA2, ATM","ENSG00000012048, ENSG00000139618, ENSG00000149311","Mutation, Mutation, Mutation","Positive, Positive, Positive","AND/OR, OR","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE OR ATM MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","PDL1, PARP","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03330405","BiomarkerKG544633209"
"120","LY3295668",NA,"121333423","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03092934","BiomarkerKG-1363681835"
"125","FULVESTRANT, SY-1365","DB00947,NA","104741, 118426108","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03134638","BiomarkerKG-1669987101"
"126","TINOSTAMUSTINE","DB15147","46836227","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","AK-DAC","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03345485","BiomarkerKG2133471255"
"127","PERTUZUMAB, TRASTUZUMAB, ERIBULIN","DB06366,DB00072,DB08871","NA, 3001322, 17755248","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03264547","BiomarkerKG-666409512"
"128","CABOZANTINIB, ATEZOLIZUMAB","DB08875,DB11595","25102846, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03170960","BiomarkerKG1041310291"
"129","CONJUGATED ESTROGENS, BAZEDOXIFENE","DB00286,DB06401","23667301, 154256","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","DUCTAL BREAST CARCINOMA","EFO_0000186","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02694809","BiomarkerKG1810652996"
"130","AZD5363, FULVESTRANT","NA,DB00947","25227436, 104741","ESR1, AKT1, AKT2, AKT3","ENSG00000091831, ENSG00000142208, ENSG00000105221, ENSG00000117020","Protein Expression, Mutation, Mutation, Mutation","Positive, Postive, Positive, Positive","AND, AND/OR, AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND AKT1 MUTATION POSTIVE AND/OR AKT2 MUTATION POSITIVE AND/OR AKT3 MUTATION POSITIVE","RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03310541","BiomarkerKG553694292"
"134","DENOSUMAB, NAB-PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, CARBOPLATIN","DB06643,NA,DB00445,DB00531,DB00958","NA, 36314, 65348, 2907, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","RANKL, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02682693","BiomarkerKG1069686944"
"135","DENOSUMAB, NAB-PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","DB06643,NA,DB00445,DB00531,DB00958,DB00072,DB06366","NA, 36314, 65348, 2907, 56840877, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","RANKL, UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02682693","BiomarkerKG453408706"
"138","AFIMOXIFENE, TAMOXIFEN CITRATE","DB04468,NA","5352135, 2733525","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","DUCTAL CARCINOMA","EFO_0006318","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02993159","BiomarkerKG-1961479280"
"139","OLAPARIB, ONALESPIB","DB09074,DB06306","23725625, 11955716","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC OR UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PARP, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02898207","BiomarkerKG-1103811937"
"141","ATEZOLIZUMAB, COBIMETINIB, ERIBULIN","DB11595,DB05239,DB08871","NA, 71491931, 17755248","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC INFLAMMATORY BREAST CANCER","MONDO_0007254","UNK, MEK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03202316","BiomarkerKG1622022418"
"142","CARBOPLATIN, PEMBROLIZUMAB","DB00958,DB09037","56840877, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03213041","BiomarkerKG1353225719"
"143","GEMCITABINE, GEMCITABINE HYDROCHLORIDE, MIRVETUXIMAB SORAVTANSINE","DB00441,NA,DB12489","60750, 60749, 91810695","ERBB2, ESR1, PGR, Fralpha","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND FRALPHA PROTEIN EXPRESSION POSITIVE","RECURRENT OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, FOLR1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02996825","BiomarkerKG-729491284"
"144","NIVOLUMAB, DARATUMUMAB","DB09035,DB09331","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03098550","BiomarkerKG450384206"
"145","DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, CARBOPLATIN, DECITABINE, PEMBROLIZUMAB","DB00997,DB00531,DB01229,DB00958,DB01262,DB09037","443939, 2907, 36314, 56840877, 451668, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02957968","BiomarkerKG-1614818793"
"146","DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, DECITABINE, PEMBROLIZUMAB","DB00997,DB00531,DB01229,DB01262,DB09037","443939, 2907, 36314, 451668, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02957968","BiomarkerKG1086102404"
"147","ATEZOLIZUMAB, CARBOPLATIN, PACLITAXEL","DB11595,DB00958,DB01229","NA, 56840877, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02883062","BiomarkerKG-1112433816"
"148","H3B-6545",NA,"124091040","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Postitive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","Eralpha","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03250676","BiomarkerKG1596444665"
"149","ATEZOLIZUMAB, RUCAPARIB","DB11595,DB12332","NA, 9931954","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03101280","BiomarkerKG854764279"
"150","CAPECITABINE, PEMBROLIZUMAB","DB01101,DB09037","60953, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER (III-IV)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03044730","BiomarkerKG2123553173"
"151","UTOMILUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB","DB15113,DB05773,DB00072","NA, NA, 3001322","ERBB2","ENSG00000141736","Protein Expression/Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","41BB, ERBB2, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03364348","BiomarkerKG2129852658"
"152","DURVALUMAB, TREMELIMUMAB","DB11714,DB11771","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","B7H1, CTLA4","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03132467","BiomarkerKG-1911759364"
"153","ENOBOSARM, PEMBROLIZUMAB","DB12078,DB09037","11326715, NA","ERBB2, ESR1, PGR, AR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02971761","BiomarkerKG-2114519494"
"155","PEMBROLIZUMAB","DB09037",NA,"ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INFLAMMATORY BREAST CANCER (IIIB-IIIC)","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02971748","BiomarkerKG-2029749690"
"156","MIRVETUXIMAB SORAVTANSINE","DB12489","91810695","ERBB2, ESR1, PGR, Fralpha","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND FRALPHA PROTEIN EXPRESSION POSITIVE/NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03106077","BiomarkerKG692580012"
"157","TALAZOPARIB","DB11760","135565082","BRCA1, BRCA2","ENSG00000012048, ENSG00000139618","Mutation, Mutation","Positive, Positive","AND/OR","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03343054","BiomarkerKG-2000618498"
"158","BEMCENTINIB, PEMBROLIZUMAB","NA,DB09037","46215462, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER OR INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03184558","BiomarkerKG-1661691532"
"159","TVB-2640, PACLITAXEL, TRASTUZUMAB","NA,DB01229,DB00072","66548316, 36314, 3001322","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","FASN, UNK, HER2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03179904","BiomarkerKG1044190964"
"160","PALBOCICLIB, ENDOCRINE THERAPY","DB09073,NA","11478676, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03184090","BiomarkerKG-2074888963"
"161","DECITABINE, PACLITAXEL","DB01262,DB01229","451668, 36314","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03282825","BiomarkerKG1851469276"
"163","CB-839, PACLITAXEL","NA,DB01229","71577426, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03057600","BiomarkerKG-988190666"
"164","PEMBROLIZUMAB, ERIBULIN","DB09037,DB08871","NA, 17755248","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INORPERABLE LOCALLY RECURRENT METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03222856","BiomarkerKG-1951859245"
"165","RIBOCICLIB, BICALUTAMIDE","DB11730,DB01128","44631912, 56069","ERBB2, ESR1, PGR, AR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03090165","BiomarkerKG1629334512"
"166","METFORMIN, SIMVASTATIN, FULVESTRANT","DB00331,DB00641,DB00947","14219, 54454, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03192293","BiomarkerKG2064884861"
"167","LENVATINIB","DB09078","11237762","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03168074","BiomarkerKG-506583395"
"168","GSK525762, FULVESTRANT","NA,DB00947","46943432, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02964507","BiomarkerKG1066903332"
"169","ANASTROZOLE, PALBOCICLIB, TRASTUZUMAB, PERTUZUMAB","DB01217,DB09073,DB00072,DB06366","2187, 11478676, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03304080","BiomarkerKG743549424"
"170","TREMELIMUMAB, EXEMESTANE, DURVALUMAB","DB11771,DB00990,DB11714","NA, 60198, NA","ERBB2, ESR1, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02997995","BiomarkerKG-909189755"
"171","EPIRUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, GOSERELIN ACETATE, TAMOXIFEN, LETROZOLE","DB00445,DB00531,DB01248,NA,DB00675,DB01006","65348, 2907, 148124, 16052011, 2733526, 3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Postitive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03373708","BiomarkerKG-1481626248"
"173","TESETAXEL, CAPECITABINE","DB12019,DB01101","6918574, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03326674","BiomarkerKG-2093307115"
"174","ATEZOLIZUMAB, CARBOPLATIN","DB11595,DB00958","NA, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03206203","BiomarkerKG-949181766"
"175","DECITABINE, CARBOPLATIN","DB01262,DB00958","451668, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03295552","BiomarkerKG-1800969398"
"176","OLAPARIB","DB09074","23725625","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03109080","BiomarkerKG-678626156"
"177","PALBOCICLIB, AROMATASE INHIBITORS, FULVESTRANT","DB09073,NA,DB00947","11478676, NA, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Postitive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, Aromatase, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03079011","BiomarkerKG794682439"
"178","FLUZOPARIB, APATINIB","NA,DB14765","56649297, 45139106","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Positive/Negative, Positive/Negative","AND, AND, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND/OR BRCA1 MUTATION POSITIVE/NEGATIVE AND/OR BRCA2 MUTATION POSITIVE/NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PARP1/PARP2, VEGFR","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03075462","BiomarkerKG-567531731"
"179","EVEROLIMUS, EXEMESTANE","DB01590,DB00990","6442177, 60198","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Postitive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03312738","BiomarkerKG357861401"
"180","TRILACICLIB, GEMCITABINE, CARBOPLATIN","DB15442,DB00441,DB00958","68029831, 60750, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","CDK4/CDK6, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02978716","BiomarkerKG-27275931"
"181","PALBOCICLIB, FULVESTRANT, AVELUMAB","DB09073,DB00947,DB11945","11478676, 104741, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY RECURRENT UNRESECTABLE INVASIVE BREAST CANCER","MONDO_0007254","CDK4/CDK6, UNK, PD1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03147287","BiomarkerKG-2108612627"
"183","PEMBROLIZUMAB, CARBOPLATIN","DB09037,DB00958","NA, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH CHEST WALL DISEASE","EFO_0005537","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03095352","BiomarkerKG152477880"
"185","PEMBROLIZUMAB, CARBOPLATIN, TRASTUZUMAB","DB09037,DB00958,DB00072","NA, 56840877, 3001322","ERBB2","ENSG00000141736","Protein Expression/Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","ADVANCED BREAST CANCER WITH CHEST WALL DISEASE","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03095352","BiomarkerKG-81079484"
"186","DOXORUBICIN, CARBOPLATIN, PACLITAXEL, CYCLOPHOSPHAMIDE","DB00997,DB00958,DB01229,DB00531","443939, 56840877, 36314, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER (II-III)","EFO_0005537","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02978495","BiomarkerKG-270372530"
"189","RIBOCICLIB, PDR001, FULVESTRANT","DB11730,NA,DB00947","44631912, NA, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","CDK, PD1, ESR1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03294694","BiomarkerKG1852947756"
"190","CYCLOPHOSPHAMIDE, INDOMETHACIN, OMEPRAZOLE","DB00531,DB00328,DB00338","2907, 3715, 4594","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Positive/Negative, Positive/Negative","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02950259","BiomarkerKG-722965431"
"195","CORT125134, NAB-PACLITAXEL","DB14976,NA","73051463, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","GR, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02762981","BiomarkerKG-2105868595"
"199","PEMBROLIZUMAB, ITACITINIB, INCB050465","DB09037,DB12154,DB14867","NA, 53380437, 86677874","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02646748","BiomarkerKG697502692"
"201","LY3039478, GEMCITABINE, CARBOPLATIN","NA,DB00441,DB00958","71236992, 60750, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02784795","BiomarkerKG1569571224"
"203","NAB-PACLITAXEL, DURVALUMAB, TREMELIMUMAB, CARBOPLATIN, GEMCITABINE","NA,DB11714,DB11771,DB00958,DB00441","36314, NA, NA, 56840877, 60750","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02658214","BiomarkerKG-1591998744"
"207","OLAPARIB, MEDI4736","DB09074,NA","23725625, NA","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Mutation, Mutation","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02734004","BiomarkerKG566986498"
"208","OLAPARIB, MEDI4736","DB09074,NA","23725625, NA","ERBB2, BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L","ENSG00000141736, ENSG00000012048, ENSG00000139618, ENSG00000149311, ENSG00000138376, ENSG00000136492, ENSG00000167258, ENSG00000149554, ENSG00000183765, ENSG00000115392, ENSG00000083093, ENSG00000221914, ENSG00000182185, ENSG00000108384, ENSG00000185379, ENSG00000085224","Protein Expression, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","Negative, Negative, Negative, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND, AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND/OR ATM MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR CDK12 MUTATION POSITIVE AND/OR CHEK1 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR PPP2R2A MUTATION POSITIVE AND/OR RAD51B MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR RAD54L MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02734004","BiomarkerKG203676615"
"209","OLAPARIB, MEDI4736, BEVACIZUMAB","DB09074,NA,DB00112","23725625, NA, NA","ERBB2, ESR1, PGR, BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618, ENSG00000149311, ENSG00000138376, ENSG00000136492, ENSG00000167258, ENSG00000149554, ENSG00000183765, ENSG00000115392, ENSG00000083093, ENSG00000221914, ENSG00000182185, ENSG00000108384, ENSG00000185379, ENSG00000085224","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative,","AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND ATM MUTATION NEGATIVE AND BARD1 MUTATION NEGATIVE AND BRIP1 MUTATION NEGATIVE AND CDK12 MUTATION NEGATIVE AND CHEK1 MUTATION NEGATIVE AND CHEK2 MUTATION NEGATIVE AND FANCL MUTATION NEGATIVE AND PALB2 MUTATION NEGATIVE AND PPP2R2A MUTATION NEGATIVE AND RAD51B MUTATION NEGATIVE AND RAD51C MUTATION NEGATIVE AND RAD51D MUTATION NEGATIVE AND RAD54L MUTATION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02734004","BiomarkerKG707560414"
"210","AZACITIDINE, DURVALUMAB","DB00928,DB11714","9444, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Postitive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02811497","BiomarkerKG1397248733"
"215","CARBOPLATIN, PACLITAXEL, PANITUMUMAB","DB00958,DB01229,DB01269","56840877, 36314, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK,  UNK, EGFR","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02593175","BiomarkerKG-1782177340"
"216","FULVESTRANT","DB00947","104741","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","DUCTAL BREAST CARCINOMA","EFO_0000186","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02540330","BiomarkerKG1211146173"
"217","BEVACIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE","DB00112,NA","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","VEGF, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02456857","BiomarkerKG-1299819199"
"218","NIRAPARIB, PEMBROLIZUMAB","DB11793,DB09037","24958200, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02657889","BiomarkerKG-257867596"
"220","ATEZOLIZUMAB, NAB-PACLITAXEL","DB11595,NA","NA, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02530489","BiomarkerKG-1888592334"
"222","LETROZOLE, CTX, ANTHRACYCLINES, DOCETAXEL","DB01006,NA,NA,DB01248","3902, 6442245, NA, 148124","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (IIA-IIIC)","MONDO_0007254","Aromatase, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02769104","BiomarkerKG1735665347"
"223","FOXY-5","DB13034","44628955","WNT5A","ENSG00000114251","Protein Expression","Positive",NA,"WNT5A PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02655952","BiomarkerKG1861376112"
"224","OLAPARIB, ATEZOLIZUMAB","DB09074,DB11595","23725625, NA","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Mutation, Mutation","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","PARP, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02849496","BiomarkerKG932453111"
"226","ANASTROZOLE, LETROZOLE, PEMBROLIZUMAB","DB01217,DB01006,DB09037","2187, 3902, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER (IV)","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02648477","BiomarkerKG519898485"
"227","GALUNISERTIB, PACLITAXEL","DB11911,DB01229","10090485, 36314","ERBB2, ESR1, PGR, AR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER (IV)","EFO_0005537","TGFβR1, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02672475","BiomarkerKG1641397909"
"228","EXEMESTANE","DB00990","60198","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (0-IIB)","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02598557","BiomarkerKG1183058474"
"229","PAMIPARIB","DB14769","135565554","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03333915","BiomarkerKG-347555241"
"230","FULVESTRANT, PALBOCICLIB, AROMATASE INHIBITORS","DB00947,DB09073,NA","104741, 11478676, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (IA-IIIC)","MONDO_0007254","UNK, CDK, Aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02760030","BiomarkerKG-762311213"
"232","PALBOCICLIB, EXEMESTANE, LEUPROLIDE ACETATE","DB09073,DB00990,NA","11478676, 60198, 657180","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, GNRH","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02592746","BiomarkerKG-1302710924"
"234","REBASTINIB, PACLITAXEL, ERIBULIN MESYLATE","DB13005,DB01229,NA","25066467, 36314, 17755248","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","TIE2, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02824575","BiomarkerKG563076874"
"236","PALBOCICLIB, TAMOXIFEN","DB09073,DB00675","11478676, 2733526","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02668666","BiomarkerKG1777834779"
"238","RIBOCICLIB, LETROZOLE, GOSERELIN, LEUPROLIDE","DB11730,DB01006,DB00014,DB00007","44631912, 3902, 5311128, 657181","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02941926","BiomarkerKG1959357357"
"239","CISPLATIN, VELIPARIB","DB00515,DB07232","135804801, 11960529","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, PARP1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02595905","BiomarkerKG-1822087861"
"240","CISPLATIN, VELIPARIB","DB00515,DB07232","135804801, 11960529","BRCA1, BRCA2","ENSG00000012048, ENSG00000139618","Mutation, Mutation","Positive, Positive","OR","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, PARP1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02595905","BiomarkerKG-1595090512"
"241","EXEMESTANE, LETROZOLE, ANASTROZOLE, LEUPROLIDE ACETATE, PERTUZUMAB, TRASTUZUMAB","DB00990,DB01006,DB01217,NA,DB06366,DB00072","60198, 3902, 2187, 657180, NA, 3001322","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-II)","MONDO_0007254","Aromatase, Aromatase, Aromatase, LHRH, ERBB2, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02689921","BiomarkerKG-1074277714"
"243","GOSERELIN, AROMATASE INHIBITORS","DB00014,NA","5311128, NA","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, Aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02914158","BiomarkerKG-703502660"
"244","ABEMACICLIB, PEMBROLIZUMAB","DB12001,DB09037","46220502, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02779751","BiomarkerKG-145576559"
"245","ABEMACICLIB, PEMBROLIZUMAB, ANASTROZOLE","DB12001,DB09037,DB01217","46220502, NA, 2187","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02779751","BiomarkerKG1539147747"
"246","ENZALUTAMIDE","DB08899","15951529","ERBB2, ESR1, PGR, AR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","INVASIVE ADVANCED TRIPLE NEGATIVE BREAST CANCER (I-III)","EFO_0005537","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02750358","BiomarkerKG407827035"
"247","PALBOCICLIB, EVEROLIMUS, EXEMESTANE","DB09073,DB01590,DB00990","11478676, 6442177, 60198","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02871791","BiomarkerKG-1543082408"
"249","ANASTROZOLE, PALBOCICLIB","DB01217,DB09073","2187, 11478676","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02942355","BiomarkerKG-1263797821"
"250","TRASTUZUMAB EMTANSINE","DB05773",NA,"ERBB2","ENSG00000141736","Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02658734","BiomarkerKG-898666061"
"251","ME-344, BEVACIZUMAB","DB13062,DB00112","68026984, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (I-III)","MONDO_0007254","Mitochondria, VEGFA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02806817","BiomarkerKG1142966980"
"252","ABEMACICLIB, TRASTUZUMAB, FULVESTRANT","DB12001,DB00072,DB00947","46220502, 3001322, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02675231","BiomarkerKG-1040237091"
"255","PALBOCICLIB, LETROZOLE, FULVESTRANT","DB09073,DB01006,DB00947","11478676, 3902, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02692755","BiomarkerKG586349350"
"256","PEMBROLIZUMAB, NAB-PACLITAXEL, PACLITAXEL, GEMCITABINE, CARBOPLATIN","DB09037,NA,DB01229,DB00441,DB00958","NA, 36314, 36314, 60750, 56840877","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02819518","BiomarkerKG-392053993"
"257","COPANLISIB, TRASTUZUMAB","DB12483,DB00072","135565785, 3001322","ERBB2","ENSG00000141736","Protein Expression/Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02705859","BiomarkerKG1950704075"
"259","ENDOTAG-1, PACLITAXEL, GEMCITABINE HYDROCHLORIDE","NA,DB01229,NA","36314, 36314, 60749","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03002103","BiomarkerKG1166274354"
"260","BICALUTAMIDE","DB01128","56069","ERBB2, ESR1, PGR, AR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03055312","BiomarkerKG1369469100"
"261","DURVALUMAB, BEVACIZUMAB","DB11714,DB00112","NA, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","PDL1, VEGFA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02802098","BiomarkerKG-1488672938"
"262","ERIBULIN MESYLATE, PEGYLATED RECOMBINANT HUMAN HYALURONIDASE","NA,NA","17755248, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02753595","BiomarkerKG-293355652"
"263","SELUMETINIB, DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL","DB11689,DB00997,DB00531,DB01248","10127622, 443939, 2907, 148124","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY AND LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","MEK1/MEK2, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02685657","BiomarkerKG-1837789430"
"264","ATEZOLIZUMAB, TRASTUZUMAB EMTANSINE","DB11595,DB05773","NA, NA","ERBB2","ENSG00000141736","Protein Expression/Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02924883","BiomarkerKG537734734"
"265","DINACICLIB, PEMBROLIZUMAB","DB12021,DB09037","46926350, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT01676753","BiomarkerKG303327598"
"266","TAMOXIFEN, RIBOCICLIB, GOSERELIN","DB00675,DB11730,DB00014","2733526, 44631912, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, CDK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02586675","BiomarkerKG-2064582075"
"267","LAROTRECTINIB, VITRAKVI","DB14723,NA","67330085, 46188928","NTRK1, NTRK2, NTRK3","ENSG00000198400, ENSG00000148053, ENSG00000140538","gene fusion, gene fusion, gene fusion","Positive, Positive, Positive","AND/OR, AND/OR","NTRK1 GENE FUSION POSITIVE AND/OR NTRK2 GENE FUSION POSITIVE AND/OR NTRK3 GENE FUSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02576431","BiomarkerKG-1815218171"
"270","NIVOLUMAB, IPI-549","DB09035,NA","NA, 91933883","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE INFLAMMATORY BREAST CANCER","EFO_0005537","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02637531","BiomarkerKG57334040"
"272","DURVALUMAB, IBRUTINIB","DB11714,DB09053","NA, 24821094","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (STAGE III-IV)","MONDO_0007254","PDL1, BTK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02403271","BiomarkerKG1523716243"
"273","SEVITERONEL","DB12275","78357816","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","CYP17","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02580448","BiomarkerKG2075474641"
"274","SEVITERONEL","DB12275","78357816","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","CYP18","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02580449","BiomarkerKG2086959559"
"276","PYROTINIB","DB14993","51039030","ERBB2","ENSG00000141736","Protein Expression/Protein Expression & Amplification/Mutation","Positive",NA,"ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION/MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02500199","BiomarkerKG-1504794440"
"279","GS-5829, EXEMESTANE, FULVESTRANT","NA,DB00990,DB00947","86281210, 60198, 104741","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02392611","BiomarkerKG-208500328"
"280","AZD2014, AZD6244","NA,NA","25262792, 10127622","KRAS, NRAS, BRAF, PIK3CA, PTEN, AKT, LKB1, EGFR, FGFR, ERBB2, MET, RET, KIT, NF1","ENSG00000133703, ENSG00000213281, ENSG00000157764, ENSG00000121879, ENSG00000171862, ENSG00000166971, ENSG00000118046, ENSG00000146648, ENSG00000068078, ENSG00000141736, ENSG00000105976, ENSG00000165731, ENSG00000157404, ENSG00000196712","Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","KRAS MUTATION POSITIVE AND/OR NRAS MUTATION POSITIVE AND/OR BRAF MUTATION POSITIVE AND/OR PIK3CA MUTATION POSITIVE AND/OR PTEN MUTATION POSITIVE AND/OR AKT MUTATION POSITIVE AND/OR LKB1 MUTATION POSITIVE AND/OR EGFR MUTATION POSITIVE AND/OR FGFR MUTATION POSITIVE AND/OR ERBB2 MUTATION POSITIVE AND/OR MET MUTATION POSITIVE AND/OR RET MUTATION POSITIVE AND/OR KIT MUTATION POSITIVE AND/OR NF1 MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","mTORC1/mTORC2, MEK1/MEK2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02583542","BiomarkerKG-11602265"
"281","AZD2014, AZD6244","NA,NA","25262792, 10127622","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","mTORC1/mTORC2, MEK1/MEK2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02583542","BiomarkerKG1191933777"
"282","ENTINOSTAT, IPILIMUMAB, NIVOLUMAB","DB11841,DB06186,DB09035","4261, NA, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED URESECTABLE OR METASTATIC BREAST CANCER (III-IV)","MONDO_0007254","HDAC, CTLA4","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02453620","BiomarkerKG-1238035787"
"283","ENTINOSTAT, IPILIMUMAB, NIVOLUMAB","DB11841,DB06186,DB09035","4261, NA, NA","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","LOCALLY ADVANCED URESECTABLE OR METASTATIC BREAST CANCER (III-IV)","MONDO_0007254","HDAC, CTLA4","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02453620","BiomarkerKG927136869"
"286","TREMELIMUMAB, MEDI4736","DB11771,NA","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02527434","BiomarkerKG893899226"
"287","CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, CARBOPLATIN","DB00531,NA,DB01229,DB00958","2907, 443939, 36314, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER (IB-IIIC)","EFO_0005537","UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02488967","BiomarkerKG-1384635077"
"288","CARBOPLATIN, CISPLATIN, CAPECITABINE","DB00958,DB00515,DB01101","56840877, 135804801, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER (II-III)","EFO_0005537","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02445391","BiomarkerKG947320690"
"289","CYCLOPHOSPHAMIDE, LETROZOLE","DB00531,DB01006","2907, 3902","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02583828","BiomarkerKG157393243"
"290","FULVESTRANT, VANDETANIB","DB00947,DB05294","104741, 3081361","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ESR1, VEGFR","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02530411","BiomarkerKG-1513054128"
"292","PM01183, OLAPARIB","NA,DB09074","57327016, 23725625","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02684318","BiomarkerKG-1977326047"
"294","PEMIGATINIB, GEMCITABINE, CISPLATIN, PEMBROLIZUMAB, DOCETAXEL, TRASTUZUMAB, INCMGA00012","DB15102,DB00441,DB00515,DB09037,DB01248,DB00072,NA","86705695, 60750, 135804801, NA, 148124, 3001322, NA","FGF, FGFR","ENSG00000162344, ENSG00000068078","gene others, gene others","Positive, Positive","AND/OR","FGF GENE OTHERS POSITIVE AND/OR FGFR GENE OTHERS POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02393248","BiomarkerKG1662110747"
"295","AVELUMAB, UTOMILUMAB","DB11945,DB15113","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PDL1, 41BB","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02554812","BiomarkerKG-9935330"
"296","CYCLOPHOSPHAMIDE, PACLITAXEL, TRASTUZUMAB","DB00531,DB01229,DB00072","2907, 36314, 3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-II)","MONDO_0007254","UNK, UNK, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02654119","BiomarkerKG1850261349"
"299","MARGETUXIMAB, CAPECITABINE, ERIBULIN, GEMCITABINE, VINORELBINE","DB14967,DB01101,DB08871,DB00441,DB00361","NA, 60953, 17755248, 60750, 5311497","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02492711","BiomarkerKG-1535116097"
"300","PALBOCICLIB, FULVESTRANT, TAMOXIFEN","DB09073,DB00947,DB00675","11478676, 104741, 2733526","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02384239","BiomarkerKG-800062053"
"301","ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, DOCETAXEL, CARBOPLATIN","DB11595,DB06366,DB00072,DB05773,DB01248,DB00958","NA, NA, 3001322, NA, 148124, 56840877","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR EARLY BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02605915","BiomarkerKG-2005931595"
"302","ATEZOLIZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB11595,DB00997,DB00531","NA, 443939, 2907","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR EARLY BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02605915","BiomarkerKG992071428"
"303","ICOTINIB","DB11737","44609731","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02362230","BiomarkerKG-770749269"
"304","METFORMIN, TOREMIFENE, MELATONIN","DB00331,DB00539,DB01065","14219, 3005573, 896","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER (IIB-IIIC)","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02506790","BiomarkerKG-94465509"
"305","TALAZOPARIB TOSYLATE",NA,"135565654","ERBB2, BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, Rad51c, Rad51d, MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL","ENSG00000141736, ENSG00000012048, ENSG00000139618, ENSG00000171862, ENSG00000083093, ENSG00000183765, ENSG00000149311, ENSG00000104320, ENSG00000138376, ENSG00000136492, ENSG00000113522, ENSG00000108384, ENSG00000185379, ENSG00000020922, ENSG00000175054, ENSG00000187741, ENSG00000158169, ENSG00000144554, ENSG00000112039, ENSG00000183161, ENSG00000221829, ENSG00000115392","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","Negative, Negative, Negative, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND, AND, AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 PROTEIN EXPRESSION NEGATIVE AND BRCA2 PROTEIN EXPRESSION NEGATIVE AND PTEN MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR ATM MUTATION POSITIVE AND/OR NBN MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR RAD50 MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR MRE11 MUTATION POSITIVE AND/OR ATR MUTATION POSITIVE AND/OR FANCA MUTATION POSITIVE AND/OR FANCC MUTATION POSITIVE AND/OR FANCD2 MUTATION POSITIVE AND/OR FANCE MUTATION POSITIVE AND/OR FANCF MUTATION POSITIVE AND/OR FANCG MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","PARP","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02401347","BiomarkerKG29199886"
"306","TASELISIB, FULVESTRANT","DB12108,DB00947","51001932, 104741","ERBB2, ESR1, PIK3CA","ENSG00000141736, ENSG00000091831, ENSG00000121879","Protein Expression, Protein Expression, Mutation","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02340221","BiomarkerKG1906523027"
"307","LETROZOLE, PALBOCICLIB","DB01006,DB09073","3902, 11478676","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (II-IIIA)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02400567","BiomarkerKG-413287604"
"309","NIVOLUMAB, IPILIMUMAB","DB09035,DB06186","NA, NA","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","Protein Expression, Protein expression, Protein Expression","Negative, Negative, Negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PD1, CTLA4","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03818685","BiomarkerKG1514699161"
"310","IMIPRAMINE","DB00458","8228","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","Protein Expression, Protein expression, Protein Expression & amplification","Negative, Negative, Negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","FoxM1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03122444","BiomarkerKG-1435553749"
"312","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11478676, 3902","ERBB2, PGR, ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","Protein Expression, Protein expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","CDK4/CDK6, aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04047758","BiomarkerKG-1899271805"
"314","PYROTINIB, ETOPOSIDE","DB14993,DB00773","51039030, 36462","ERBB2","ENSG00000141736","Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ERBB2, Topoisomerase II/DNA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03923179","BiomarkerKG809776760"
"315","DOCETAXEL, RITONAVIR","DB01248,DB00503","148124, 392622","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","RECURRENT BREAST CANCER","MONDO_0007254","Microtubles, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03890744","BiomarkerKG-1915782920"
"316","DURVALUMAB, TRASTUZUMAB, PERTUZUMAB","DB11714,DB00072,DB06366","NA, 3001322, NA","ERBB2, PGR, ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (I-II)","MONDO_0007254","PDL1, ERBB2, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03820141","BiomarkerKG-156769428"
"317","PACLITAXEL, TRASTUZUMAB, CARBOPLATIN, PERTUZUMAB","DB01229,DB00072,DB00958,DB06366","36314, 3001322, 56840877, NA","ERBB2, PGR, ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (STAGE II-III)","MONDO_0007254","Bcl2, ERBB2, DNA/Protein, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03820063","BiomarkerKG-1013990068"
"318","ONAPRISTONE","DB12637","5311505","ESR1, PGR, ERBB2, Ki67","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression, Protein expression","Positive, Positive, Negative, Positive","AND, AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-II)","MONDO_0007254","progesterone receptor","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04142892","BiomarkerKG-447481596"
"319","PEMBROLIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN","DB09037,NA","NA, NA","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","Protein Expression, Protein Expression","Positive, Negative","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER (III-IV)","MONDO_0007254","PD1, Topoisomerase II/DNA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03591276","BiomarkerKG-859329038"
"320","PYROTINIB, CAPECITABINE","DB14993,DB01101","51039030, 60953","ERBB2","ENSG00000141736","Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER","MONDO_0007254","ERBB2, DNA/RNA/Protein Synthesis","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03923166","BiomarkerKG687053448"
"321","PEMBROLIZUMAB, PACLITAXEL","DB09037,DB01229","NA, 36314","ESR1, ERBB2, Ki67","ENSG00000091831, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression","Positive, Negative, Positive","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC LUMINAL B BREAST CANCER","MONDO_0007254","PDL, Bcl2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03841747","BiomarkerKG-889764113"
"322","PYROTINIB, ALBUMIN-BOUND PACLITAXEL, TRASTUZUMAB, EPRIRUBICIN, CYCLOPHOSPHAMIDE","DB14993,NA,DB00072,NA,DB00531","51039030, NA, 3001322, NA, 2907","ERBB2","ENSG00000141736","Protein Expression &Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION &AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-III)","MONDO_0007254","ERBB2, GP60/Bcl2, ERBB2, Topoisomerase II/DNA, DNA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04066790","BiomarkerKG-103720969"
"327","LETROZOLE, PYROTINIB, SHR6390","DB01006,DB14993,NA","3902, 51039030, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","Aromatase, ERBB2, CDK4/CDK6","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03772353","BiomarkerKG1827935371"
"328","CAPECITABINE","DB01101","60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","NON-METASTATIC INVASIVE BREAST CANCER","MONDO_0007254","DNA/RNA/Protein Synthesis","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03958721","BiomarkerKG1686449390"
"329","DOCETAXEL, CYCLOPHOSPHAMIDE, TRASTUZUMAB","DB01248,DB00531,DB00072","148124, 2907, 3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST NEOPLASMS","MONDO_0007254","microtubles/VEGF, DNA, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03705429","BiomarkerKG-435072881"
"333","IPATASERTIB, PALBOCICLIB, FULVESTRANT","DB11743,DB09073,DB00947","24788740, 11478676, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","MONDO_0007254","Akt, CDK4/CDK6, ER","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04060862","BiomarkerKG-316459000"
"334","ERIBULIN, BALIXAFORTIDE","DB08871,DB15370","17755248, 138752609","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","LOCALLY RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03786094","BiomarkerKG1503939067"
"336","VENETOCLAX, PALBOCICLIB, LETROZOLE","DB11581,DB09073,DB01006","49846579, 11478676, 3902","ESR1, Bcl2, ERBB2","ENSG00000091831, ENSG00000171791, ENSG00000141736","Protein Expression, Protein expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND BCL2 PROTEIN EXPRESSION POSITIVE AND/OR ERBB2 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, CDK4/CDK6, aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03900884","BiomarkerKG-2032842044"
"337","METFORMIN","DB00331","14219",NA,"ENSG00000183023",NA,NA,NA,"NA NA NA","METASTATIC BREAST CANCER (IV)","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04143282","BiomarkerKG1935542298"
"338","ATEZOLIZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB EMTANSINE","DB11595,DB00997,DB00531,DB01229,DB06366,DB05773","NA, 443939, 2907, 36314, NA, NA","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein expression, Protein Expression, Protein expression","Positive, Positive/Negative, Positive/Negative, Positive/Negative","AND, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER (I-III)","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03726879","BiomarkerKG276424285"
"339","FS-1502",NA,"2760428","ERBB2","ENSG00000141736","Protein Expression & Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03944499","BiomarkerKG1623818552"
"340","IPI-549, ATEZOLIZUMAB, NAB-PACLITAXEL","NA,DB11595,NA","91933883, NA, 36314","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PI3Kgamma, PDL1, microtubles","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03961698","BiomarkerKG-627703212"
"341","ALL-TRANS RETINOIC ACID, ANASTROZOLE","NA,DB01217","444795, 2187","ESR1, ERBB2, Ki67","ENSG00000091831, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression","Positive, Negative, Positive","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST NEOPLASM","EFO_0003869","RARα, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04113863","BiomarkerKG-1795461556"
"342","PYROTINIB, CAPECITABINE","DB14993,DB01101","51039030, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","EGFR/ERBB2/HER4, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04001621","BiomarkerKG1649159632"
"344","NIVOLUMAB, IPILIMUMAB, BICALUTAMIDE","DB09035,DB06186,DB01128","NA, NA, 56069","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER","MONDO_0007254","PD1, CTLA4, AR","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03650894","BiomarkerKG-1239420556"
"345","NAB-PACLITAXEL, CARBOPLATIN, CAPECITABINE","NA,DB00958,DB01101","36314, 56840877, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04159142","BiomarkerKG-2135616330"
"346","RIBOCICLIB, TRASTUZUMAB, LETROZOLE","DB11730,DB00072,DB01006","44631912, 3001322, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression and Amplification, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION AND AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","POSTMENOPAUSAL ADVANCED METASTATIC BREAST CANCER","MONDO_0007254","CDK4/CDK6, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03913234","BiomarkerKG2061889424"
"347","LETROZOLE, PALBOCICLIB","DB01006,DB09073","3902, 11478676","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (II-IIIB)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03819010","BiomarkerKG905609745"
"348","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","DB14993,DB00072,DB01248,DB00958","51039030, 3001322, 148124, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03756064","BiomarkerKG345427327"
"349","COPANLISIB, TRASTUZUMAB EMTANSINE","DB12483,DB05773","135565785, NA","ERBB2","ENSG00000141736","Protein Expression & Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","UNRESECTABLE LOCALLY ADVANCED OR METASTATIC  BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04042051","BiomarkerKG702885081"
"350","ATEZOLIZUMAB, CAPECITABINE","DB11595,DB01101","NA, 60953","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PDL1, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03756298","BiomarkerKG-1430355371"
"354","DURVALUMAB, OLAPARIB, FULVESTRANT","DB11714,DB09074,DB00947","NA, 23725625, 104741","ERBB2, ESR1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FAND2, FANCL, MRE11A, NBN, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, AKT1, FGFR1, FGFR2, FGFR3, PIK3CA","ENSG00000141736, ENSG00000091831, ENSG00000149311, ENSG00000138376, ENSG00000012048, ENSG00000139618, ENSG00000136492, ENSG00000167258, ENSG00000149554, ENSG00000183765, ENSG00000187741, NA, ENSG00000115392, ENSG00000020922, ENSG00000104320, ENSG00000083093, ENSG00000221914, ENSG00000182185, ENSG00000108384, ENSG00000185379, ENSG00000085224, ENSG00000142208, ENSG00000077782, ENSG00000066468, ENSG00000068078, ENSG00000121879","Protein Expression, Protein Expression/mutation, mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation, mutation, mutation, mutation","Negative, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION/MUTATION POSITIVE AND/OR ATM MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR CDK12 MUTATION POSITIVE AND/OR CHEK1 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR FANCA MUTATION POSITIVE AND/OR FAND2 MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE AND/OR MRE11A MUTATION POSITIVE AND/OR NBN MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR PPP2R2A MUTATION POSITIVE AND/OR RAD51B MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR RAD54L MUTATION POSITIVE AND/OR AKT1 MUTATION POSITIVE AND/OR FGFR1 MUTATION POSITIVE AND/OR FGFR2 MUTATION POSITIVE AND/OR FGFR3 MUTATION POSITIVE AND/OR PIK3CA MUTATION POSITIVE","METASTATIC OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04053322","BiomarkerKG-1139236655"
"355","PYROTINIB MALEATE, DOCETAXEL","NA,DB01248","138115215, 148124","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03876587","BiomarkerKG1505390240"
"357","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB","NA,NA,DB00072","138115215, NA, 3001322","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","MONDO_0007254","EGFR/ERBB2, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04152057","BiomarkerKG729598124"
"358","OLAPARIB","DB09074","23725625","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, mutation, mutation","Positive/Negative, Positive/Negative, Positive/Negative, Negative, Negative","AND/OR, AND/OR, AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","METASTATIC MALIGNANT NEOPLASM IN THE CHEST WALL","EFO_1000051","PARP","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03955640","BiomarkerKG-1616092040"
"359","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11478676, 3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER STAGE IV","MONDO_0007254","CDK4/CDK6, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03870919","BiomarkerKG-226063560"
"360","PYROTINIB, TRASTUZUMAB, DOCETAXEL","DB14993,DB00072,DB01248","51039030, 3001322, 148124","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03863223","BiomarkerKG-601099740"
"361","SACITUZUMAB GOVITECAN","DB12893","91668186","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC OR LOCALLY RECURRENT INOPERABLE BREAST CANCER","MONDO_0007254","Trop2/SN38/CL2A","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03901339","BiomarkerKG-274333150"
"362","NERATINIB, PACLITAXEL, CARBOPLATIN","DB11828,DB01229,DB00958","9915743, 36314, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY STAGE TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03812393","BiomarkerKG921194961"
"363","PALBOCICLIB, BOSUTINIB, FULVESTRANT","DB09073,DB06616,DB00947","11478676, 5328940, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03854903","BiomarkerKG-1540813963"
"365","LERONLIMAB, CARBOPLATIN","DB05941,DB00958","NA, 56840877","ERBB2, CCR5, ESR1, PGR","ENSG00000141736, ENSG00000160791, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Negative, Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND CCR5 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","CCR5, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03838367","BiomarkerKG1068866669"
"366","LY3023414, PREXASERTIB","NA,DB12008","57519748, 46700756","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","non-homologous end joining, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04032080","BiomarkerKG-1471164927"
"367","NAB-PACLITAXEL, CARBOPLATIN, EPIRUBICIN, CYCLOPHOSPHAMIDE","NA,DB00958,DB00445,DB00531","36314, 56840877, 65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04067102","BiomarkerKG-57313394"
"369","ABEMACICLIB, COPANLISIB, COPANLISIB HYDROCHLORIDE, FULVESTRANT","DB12001,DB12483,NA,DB00947","46220502, 135565785, 135565785, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, PI3K, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03939897","BiomarkerKG-617297347"
"370","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB, EPIRUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE","NA,NA,DB00072,NA,DB00531","138115215, NA, 3001322, 65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","MONDO_0007254","EGFR/ERBB2, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04152057","BiomarkerKG-891847787"
"372","PEMBROLIZUMAB, LENVATINIB","DB09037,DB09078","NA, 11237762","ERBB2, ESR1, PGR, LDH","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000134333","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND LDH PROTEIN EXPRESSION POSITIVE","ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03797326","BiomarkerKG1568508684"
"380","9-ING-41, GEMCITABINE, DOXORUBICIN, LOMUSTINE, CARBOPLATIN, NAB PACLITAXEL, PACLITAXEL, IRINOTECAN","NA,DB00441,DB00997,DB01206,DB00958,NA,DB01229,DB00762","44582816, 60750, 443939, 3950, 56840877, 36314, 36314, 60838","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","GSK-3β, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03678883","BiomarkerKG551843489"
"384","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","DB12807,DB11714","NA, NA","ERBB2, ESR1, PGR, 5T4","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000146242","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03983954","BiomarkerKG1477271139"
"385","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","DB12807,DB11714","NA, NA","ERBB2, ESR1, 5T4","ENSG00000141736, ENSG00000091831, ENSG00000146242","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03983954","BiomarkerKG285317920"
"387","REBASTINIB, CARBOPLATIN","DB13005,DB00958","25066467, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03717415","BiomarkerKG-482905584"
"394","VINORELBINE, CARBOPLATIN, GEMCITABINE","DB00361,DB00958,DB00441","5311497, 56840877, 60750",NA,"ENSG00000183023",NA,NA,NA,"NA NA NA","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04143906","BiomarkerKG627952349"
"395","PYROTINIB, SHR6390, LETROZOLE","DB14993,NA,DB01006","51039030, NA, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04095390","BiomarkerKG-1661914186"
"396","PYROTINIB, SHR6390, CAPECITABINE","DB14993,NA,DB01101","51039030, NA, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein expression & Amplification, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04095390","BiomarkerKG-1814161762"
"399","ATEZOLIZUMAB, IPATASERTIB, PACLITAXEL","DB11595,DB11743,DB01229","NA, 24788740, 36314","ERBB2, ESR1, PGR, PDL1, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04177108","BiomarkerKG-437004938"
"401","NIVOLUMAB, ABEMACICLIB, ANASTROZOLE, PALBOCICLIB","DB09035,DB12001,DB01217,DB09073","NA, 46220502, 2187, 11478676","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04075604","BiomarkerKG-1110084195"
"402","NIVOLUMAB, DOXORUBICIN","DB09035,DB00997","NA, 443939","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","RESECTABLE PRIMARY TRIPLE NEGATIVE BREAST CANCER (STAGE I-III)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03815890","BiomarkerKG1364396589"
"404","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB09035,DB01229,DB00997,DB00531","NA, 36314, 443939, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742986","BiomarkerKG-1448510916"
"405","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, TRASTUZUMAB, PERTUZUMAB","DB09035,DB01229,DB00997,DB00531,DB00072,DB06366","NA, 36314, 443939, 2907, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INFLAMMATORY BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742986","BiomarkerKG-2022083316"
"407","ABEMACICLIB, DURVALUMAB, AROMATASE INHIBITOR","DB12001,DB11714,NA","46220502, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER (II-III)","MONDO_0007254","UNK, UNK, aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04088032","BiomarkerKG356324322"
"408","PACLITAXEL, CARBOPLATIN, CYCLOPHOSPHAMIDE","DB01229,DB00958,DB00531","36314, 56840877, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE INVASIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03858322","BiomarkerKG-104675348"
"410","RIBOCICLIB, ENDOCRINE THERAPY","DB11730,NA","44631912, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","VISCERAL METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03905343","BiomarkerKG-1384231495"
"411","ENTINOSTAT, CAPECITABINE","DB11841,DB01101","4261, 60953","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression, protein expression, protein expression","Positve/negative, positive/negative, negative","OR, AND","ESR1 PROTEIN EXPRESSION POSITVE/NEGATIVE OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER, BREAST CANCER","MONDO_0007254","HDAC, DNA/RNA/Protein Synthesis","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03473639","BiomarkerKG34334946"
"412","TALAZOPARIB, SACITUZUMAB GOVITECAN","DB11760,DB12893","135565082, 91668186","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","PARP, Topoisomerase I-DNA covalent complexes","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04039230","BiomarkerKG1946912801"
"413","TRASTUZUMAB, GDC-0084","DB00072,DB15186","3001322, 57384863","ERBB2","ENSG00000141736","protein expression & amplification","Positve",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","ERBB2-POSITIVE BREAST CANCER BRAIN METASTASES","MONDO_0007254","ERBB2, PI3-Kinase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03765983","BiomarkerKG-1577117464"
"414","ASPIRIN, TAMOXIFEN, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","DB00945,DB00675,DB00997,DB00531,DB01229","2244, 2733526, 443939, 2907, 36314","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression","Positve, negative","AND","ESR1 PROTEIN EXPRESSION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (STAGE I-III)","MONDO_0007254","COX, Estrogen Receptors, DNA/DNA-topoisomerase II complex, DNA, Bcl2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04038489","BiomarkerKG-2085566364"
"416","NIVOLUMAB, IPILIMUMAB","DB09035,DB06186","NA, NA","ERBB2, ER, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR ER PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PD1, CTLA4","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03789110","BiomarkerKG-1494023734"
"417","SIMVASTATIN","DB00641","54454","ERBB2","ENSG00000141736","protein expression & amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER STAGE (STAGE IV)","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03324425","BiomarkerKG1251372237"
"418","PEMBROLIZUMAB, TAMOXIFEN","DB09037,DB00675","NA, 2733526","ESR1, ERBB2, PGR","ENSG00000091831, ENSG00000141736, ENSG00000082175","mutation, protein expression, protein expression","Positve, negative, positive","AND, AND/OR","ESR1 MUTATION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER FEMALE","MONDO_0007254","PD1, Estrogen Receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03879174","BiomarkerKG-153611909"
"419","APATINIB, PACLITAXEL, CISPLATIN","DB14765,DB01229,DB00515","45139106, 36314, 135804801","ERBB2","ENSG00000141736","protein expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","VEGFR2, Bcl2, Replication and transcription of DNA","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03982485","BiomarkerKG351003137"
"420","PALBOCICLIB","DB09073","11478676","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER STAGE (STAGE II-III)","MONDO_0007254","CDK4/CDK6","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03609047","BiomarkerKG-1579678160"
"422","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB, EPIRUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB, TRASTUZUMAB EMTANSINE","DB01248,DB00958,DB00072,DB06366,DB00445,DB00531,DB11595,DB05773","148124, 56840877, 3001322, NA, 65348, 2907, NA, NA","ERBB2, ESR1, PGR, PDl1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","protein expression & amplification, protein expression, protein expression, protein expression","Positive, positive, positive, positve","AND, AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND PDL1 PROTEIN EXPRESSION POSITVE","EARLY-STAGE BREAST CANCER","MONDO_0007254","VEGF/microtubule, DNA/Protein, ERBB2, ERBB2,  DNA/DNA-topoisomerase II complex, DNA, CD274, microtubules","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03894007","BiomarkerKG118603023"
"423","OLAPARIB, VORINOSTAT","DB09074,DB02546","23725625, 5311","ERBB2","ENSG00000141736","protein expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER METASTATIC, BREAST CANCER","MONDO_0007254","PARP, HDAC","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742245","BiomarkerKG1189074014"
"425","NIRAPARIB, TRASTUZUMAB","DB11793,DB00072","24958200, 3001322","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression & amplification, protein expression, protein expression","Positive, negativie/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVIE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER, ERBB2 POSITIVE BREAST CARCINOMA","MONDO_0007254","PARP1/PARP2, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03368729","BiomarkerKG-388096993"
"426","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","DB01248,DB00958,DB00072,DB06366","148124, 56840877, 3001322, NA","ERBB2","ENSG00000141736","protein expression & amplification","Positve",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","INVASIVE BREAST CARCINOMA","EFO_1000307","VEGF/microtuble, DNA/Protein, ERBB2, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04094896","BiomarkerKG1874182044"
"427","TALAZOPARIB, AVELUMAB","DB11760,DB11945","135565082, NA",NA,"ENSG00000183023",NA,NA,NA,"NA NA NA","ADVANCED BREAST CANCER","MONDO_0007254","PARP, PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03964532","BiomarkerKG-1495583654"
"429","NIVOLUMAB, PACLITAXEL, ANTHRACYCLINE, CYCLOPHOSPHAMIDE, ENDOCRINE THERAPY","DB09035,DB01229,NA,DB00531,NA","NA, 36314, NA, 2907, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER","MONDO_0007254","PD1, Bcl2, DNA/DNA-topoisomerase II complex, DNA,  hormone receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04109066","BiomarkerKG2087957969"
"431","RUCAPARIB","DB12332","9931954","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER  (STAGE I-III)","MONDO_0007254","PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03911453","BiomarkerKG1644765431"
"433","PALBOCICLIB, LETROZOLE, TRASTUZUMAB, PERTUZUMAB","DB09073,DB01006,DB00072,DB06366","11478676, 3902, 3001322, NA","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression/protein expression & amplification","Positive, Positive","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER","MONDO_0007254","CDK4/CDK6, aromatase, ERBB2, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03644186","BiomarkerKG-262451806"
"435","ERIBULIN","DB08871","17755248","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative/positive, negative/positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","Tubulin","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03637868","BiomarkerKG-1083648118"
"436","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","DB11730,NA,DB00014","44631912, NA, 5311128","ERBB2, PGR,ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","CDK4/CDK6, aromatase OR aromatase, GnRH receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03822468","BiomarkerKG-225817822"
"437","IPILIMUMAB, NIVOLUMAB","DB06186,DB09035","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER","MONDO_0007254","CTLA4, PD1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03546686","BiomarkerKG-2009160467"
"438","METFORMIN HYDROCHLORIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","NA,DB00997,DB00531,DB01229","14219, 443939, 2907, 36314",NA,"ENSG00000183023",NA,NA,NA,"NA NA NA","BREAST CANCER","MONDO_0007254","NADPH:ubiquinone oxidoreductase, DNA/DNA-topoisomerase II complex, DNA, Bcl2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04170465","BiomarkerKG-2103591184"
"439","PALBOCICLIB, EXEMESTANE, GOSERELIN","DB09073,DB00990,DB00014","11478676, 60198, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","CDK4/CDK6, aromatase, GnRH receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02917005","BiomarkerKG-1723002468"
"441","RIBOCICLIB, LETROZOLE","DB11730,DB01006","44631912, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, Positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","NON-METASTATIC PRIMARY LUMINAL BREAST CANCER (STAGE II-III)","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03283384","BiomarkerKG-604627963"
"442","ERIBULIN, NIVOLUMAB","DB08871,DB09035","17755248, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, negative/positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04061863","BiomarkerKG-1030601521"
"443","PEMBROLIZUMAB, TRASTUZUMAB BIOSIMILAR ABP 980, PERTUZUMAB","DB09037,NA,DB06366","NA, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression & amplification, protein expression, protein expression","Positive, negative/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03988036","BiomarkerKG138689674"
"444","CFI-400945, DURVALUMAB","NA,DB11714","58486178, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER","MONDO_0007254","PLK4, PDl1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04176848","BiomarkerKG397892956"
"445","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","DB11730,NA,DB00014","44631912, NA, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","PREMENOPAUSAL OR PERIMENOPAUSAL LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03839823","BiomarkerKG721208190"
"447","CHIDAMIDE, CISPLATIN","DB06334,DB00515","9800555, 135804801","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04192903","BiomarkerKG1288315268"
"448","PYROTINIB, FULVESTRANT","DB14993,DB00947","51039030, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression&amplification, protein expression, protein expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","TK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04034589","BiomarkerKG-2056951534"
"449","LASOFOXIFENE","DB06202","216416","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ER Receptor","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03781063","BiomarkerKG-1897970195"
"451","OLAPARIB, TRASTUZUMAB","DB09074,DB00072","23725625, 3001322","BRCA1,BRCA2, ERBB2","ENSG00000012048, ENSG00000139618, ENSG00000141736","mutation, mutation, protein expression&amplification","Positive, Positive, Positive","AND/OR, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03931551","BiomarkerKG996483862"
"455","ABEMACICLIB, FULVESTRANT","DB12001,DB00947","46220502, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04031885","BiomarkerKG-1884678499"
"457","PEMBROLIZUMAB","DB09037",NA,"ESR1, PGR","ENSG00000091831, ENSG00000082175","protein expression, protein expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","STAGE IV METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03492918","BiomarkerKG1863117410"
"458","GOSERELIN","DB00014","5311128",NA,"ENSG00000183023",NA,NA,NA,"NA NA NA","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03936933","BiomarkerKG907159947"
"459","PYROTINIB, VINORELBINE","DB14993,DB00361","51039030, 5311497","ERBB2","ENSG00000141736","Protein expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03997539","BiomarkerKG289580844"
"461","DURVALUMAB, ENDOCRINE THERAPY","DB11714,NA","NA, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein expression, protein expression","negative, positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, aromatase inhibitor","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03874325","BiomarkerKG1360761977"
"462","LYNPARZA",NA,"23725625","BRCA1,BRCA2, ERBB2, ESR1, PGR","ENSG00000012048, ENSG00000139618, ENSG00000141736, ENSG00000091831, ENSG00000082175","Mutation, mutation, protein expression, protein expression, protein expression","Positive, positive, negative, negative, negative","AND/OR, AND, AND, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04041128","BiomarkerKG1586324685"
"465","VINORELBINE, APATINIB","DB00361,DB14765","5311497, 45139106","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, VEGF2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03932526","BiomarkerKG-1645794555"
"466","ABEMACICLIB, ANASTROZOLE, FULVESTRANT, LETROZOLE, PALBOCICLIB, RIBOCICLIB","DB12001,DB01217,DB00947,DB01006,DB09073,DB11730","46220502, 2187, 104741, 3902, 11478676, 44631912","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein expression, protein expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","CDK4/CDK6, UNK, UNK, UNK, CDK4/CDK6, CDK4/CDK6","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04256941","BiomarkerKG-1304175737"
"467","PACLITAXEL, NAB-PACLITAXEL, ATEZOLIZUMAB","DB01229,NA,DB11595","36314, 36314, NA","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein expression, protein expression, protein expression, protein expression","Negative, negative, negative, positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04148911","BiomarkerKG-1019298398"
"469","CARBOPLATIN, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB00958,DB01229,DB00997,DB00531","56840877, 36314, 443939, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04083963","BiomarkerKG67951044"
"470","NIRAPARIB","DB11793","24958200","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03945721","BiomarkerKG1857107666"
"473","CAMRELIZUMAB, NAB-PACLITAXEL, FAMITINIB","DB14776,NA,DB11741","NA, 36314, 16662431","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04129996","BiomarkerKG735236579"
"475","NAB-PACLITAXEL, EPIRUBICIN, CARBOPLATIN","NA,DB00445,DB00958","36314, 65348, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04138719","BiomarkerKG-800369839"
"477","CRIZOTINIB, FULVESTRANT","DB08865,DB00947","11626560, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, oestrogen receptor","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03620643","BiomarkerKG-835107575"
"479","PEMBROLIZUMAB","DB09037",NA,"ERBB2, APOBEC3B, ER","ENSG00000141736, ENSG00000179750, ENSG00000091831","protein expression, mutation, protein expression","Negative, Positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND APOBEC3B MUTATION POSITIVE AND ER PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03989089","BiomarkerKG-1189924932"
"480","PEMBROLIZUMAB, CARBOPLATIN, GEMCITABINE, OLAPARIB","DB09037,DB00958,DB00441,DB09074","NA, 56840877, 60750, 23725625","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04191135","BiomarkerKG-1632658776"
"482","PYROTINIB, TRASTUZUMAB, VINORELBINE","DB14993,DB00072,DB00361","51039030, 3001322, 5311497","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression&amplification/protein expression, protein expression, protein expression","Positive, negative/positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","HER1/HER2, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03947242","BiomarkerKG358990573"
"483","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","DB14993,DB00072,DB01248,DB00958","51039030, 3001322, 148124, 56840877","ERBB2","ENSG00000141736","protein expression&amplification/protein expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03847818","BiomarkerKG-1876496357"
"484","DOCETAXEL, ATEZOLIZUMAB, TRASTUZUMAB SC, PERTUZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, HERCEPTIN SC","DB01248,DB11595,NA,DB06366,DB00997,DB00531,NA","148124, NA, NA, NA, 443939, 2907, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression&amplification/protein expression, protein expression","Positive, negative/positive","AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED","EFO_0005856","UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03881878","BiomarkerKG-33556113"
"485","TUCATINIB, T-DM1","DB11652,DB05773","51039094, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Positive, negative/positive, negative/positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03975647","BiomarkerKG-599028211"
"486","SPARTALIZUMAB, LAG525, NIR178, CAPMATINIB, MCS110, CANAKINUMAB","DB14892,NA,NA,DB11791,NA,DB06168","NA, NA, NA, 25145656, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742349","BiomarkerKG1688452319"
"489","DOCETAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, HUMAN RECOMBIANT ENOSTATIN","DB01248,DB00445,DB00531,NA","148124, 65348, 2907, NA",NA,"ENSG00000183023",NA,NA,NA,"NA NA NA","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT01907529","BiomarkerKG1378145659"
"491","CARBOPLATIN, PACLITAXEL","DB00958,DB01229","56840877, 36314","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein expression, Protein expression, Mutation, Mutation","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03876886","BiomarkerKG-453264115"
"492","BERZOSERTIB","DB11794","59472121","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","ATR Kinase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04052555","BiomarkerKG-1503610555"
"495","OLECLUMAB, DURVALUMAB","DB15088,DB11714","NA, NA","ERBB2, ERS1, Ki67, PDL1","ENSG00000141736, NA, ENSG00000148773, ENSG00000120217","Protein Expression, Protein expression, Protein expression, Protein Expression","Negative, Positive, Negative/Positive, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","LUMINAL B BREAST CANCER","MONDO_0007254","CD73, PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03875573","BiomarkerKG179888471"
"496","CARBOPLATIN, IPATASERTIB, PACLITAXEL","DB00958,DB11743,DB01229","56840877, 24788740, 36314","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03853707","BiomarkerKG1995732573"
"497","PALBOCICLIB, ENDOCRINE THERAPY","DB09073,NA","11478676, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03809988","BiomarkerKG1739611934"
"498","CAPIVASERTIB, PACLITAXEL","DB12218,DB01229","25227436, 36314","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03997123","BiomarkerKG-915701665"
"500","ALPELISIB, ENZALUTAMIDE","DB12015,DB08899","56649450, 15951529","ERBB2, ERS1, PGR, AR, PTEN","ENSG00000141736, NA, ENSG00000082175, ENSG00000169083, ENSG00000171862","Protein Expression, Protein expression, Protein expression, Protein Expression, Mutation","Negative,Positive,Positive, Positive, Positive","AND, AND/OR, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","Phosphoinositide 3-kinase, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03207529","BiomarkerKG-689338926"
"502","IPATASERTIB, RUCAPARIB","DB11743,DB12332","24788740, 9931954","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03840200","BiomarkerKG-975392028"
"504","PERTUZUMAB, TRASTUZUMAB, COPANLISIB","DB06366,DB00072,DB12483","NA, 3001322, 135565785","ERBB2, ERS1, PGR, PTEN, PIK3CA","ENSG00000141736, NA, ENSG00000082175, ENSG00000171862, ENSG00000121879","Protein expression&amplification, Protein Expression, Protein expression, Mutation, Mutation","Positive, Negative/Positive, Negative/Positive, Positive, Positive","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PTEN MUTATION POSITIVE AND PIK3CA MUTATION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, ERBB2, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04108858","BiomarkerKG2065001521"
"505","PACLITAXEL, TALIMOGENE LAHERPAREPVEC","DB01229,DB13896","36314, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03554044","BiomarkerKG-170542798"
"506","TAMOXIFEN, TALIMOGENE LAHERPAREPVEC, LETROZOLE, FULVESTRANT, EXEMESTANE, ANASTROZOLE","DB00675,DB13896,DB01006,DB00947,DB00990,DB01217","2733526, NA, 3902, 104741, 60198, 2187","ERBB2, ERS1","ENSG00000141736, NA","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03554044","BiomarkerKG-743019303"
"507","COPANLISIB, FULVESTRANT","DB12483,DB00947","135565785, 104741","ERBB2, ERS1, PIK3CA, PTEN","ENSG00000141736, NA, ENSG00000121879, ENSG00000171862","Protein Expression, Protein Expression, Mutation, Mutation","Negative, Positive, Negative/Positive, Negative/Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION NEGATIVE/POSITIVE AND PTEN MUTATION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PI3K, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03803761","BiomarkerKG302277995"
"508","AVELUMAB, BINIMETINIB, PF-04518600, UTOMILUMAB","DB11945,DB11967,NA,DB15113","NA, 10288191, NA, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","STAGE IV TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, OX40, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03971409","BiomarkerKG-635888986"
"509","PYROTINIB, TRASTUZUMAB, AROMATASE INHIBITORS","DB14993,DB00072,NA","51039030, 3001322, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED INVASIVE BREAST CANCER","MONDO_0007254","UNK, UNK, Aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04088110","BiomarkerKG-544075815"
"511","LEFLUNOMIDE","DB01097","3899","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","dihydroorotate dehydrogenase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03709446","BiomarkerKG-820225238"
"512","TESETAXEL, NIVOLUMAB, PEMBROLIZUMAB, ATEZOLIZUMAB","DB12019,DB09035,DB09037,DB11595","6918574, NA, NA, NA","ERBB2, ERS1, PGR, PDL1","ENSG00000141736, NA, ENSG00000082175, ENSG00000120217","Protein Expression, Protein expression, Protein expression, protein expression","Negative, Negative, Negative, Negative/positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03952325","BiomarkerKG-10442632"
"513","TESETAXEL","DB12019","6918574","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03952325","BiomarkerKG-1944338472"
"514","TAMOXIFEN","DB00675","2733526","BRCA1, BRCA2, ESR1","ENSG00000012048, ENSG00000139618, ENSG00000091831","Mutation, Mutation, Protein Expression","Negative, Negative, Positive","AND, AND","BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST DUCTAL CARCINOMA IN SITU","EFO_0000432","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04046159","BiomarkerKG-1575067713"
"515","CELECOXIB, CYCLOPHOSPHAMIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, RECOMBINANT INTERFERON ALFA-2B, RINTATOLIMOD","DB00482,DB00531,DB00997,NA,DB01229,NA,NA","2662, 2907, 443939, 443939, 36314, NA, 135537060","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY STAGE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04081389","BiomarkerKG-1945881394"
"516","ATEZOLIZUMAB, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB","DB11595,DB01229,DB06366,DB00072","NA, 36314, NA, 3001322","ERBB2, ERS1, PGR, PDL1","ENSG00000141736, NA, ENSG00000082175, ENSG00000120217","Protein expression&amplification, Protein Expression, Protein expression, protein expression","Positive, Negative/Positive, Negative/Positive, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03199885","BiomarkerKG-1955995515"
"517","CYCLOPHOSPHAMIDE, LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN","DB00531,NA","2907, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03749850","BiomarkerKG1825741352"
"518","ATORVASTATIN","DB01076","60823","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","STAGE IIB-III TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03872388","BiomarkerKG156569843"
"519","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","DB06186,DB09035,DB13896","NA, NA, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALIZED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04185311","BiomarkerKG-179581873"
"520","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","DB06186,DB09035,DB13896","NA, NA, NA","ERBB2, ERS1","ENSG00000141736, NA","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","LOCALIZED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04185311","BiomarkerKG-1062210253"
"523","PEMBROLIZUMAB, CYCLOPHOSPHAMIDE, GX-I7","DB09037,DB00531,NA","NA, 2907, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","REFRACTORY OR RELAPSED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03752723","BiomarkerKG2095042473"
"524","TRASTUZUMAB","DB00072","3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","EARLY BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04109391","BiomarkerKG-1855863757"
"525","RUCAPARIB, SACITUZUMAB GOVITECAN","DB12332,DB12893","9931954, 91668186","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03992131","BiomarkerKG1193506727"
"527","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11478676, 3902","ERBB2, ERS1, PGR, Ki67","ENSG00000141736, NA, ENSG00000082175, ENSG00000148773","Protein Expression, Protein expression, Protein expression, Protein Expression","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK. UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04130152","BiomarkerKG-563823741"
"529","ATEZOLIZUMAB, G100","DB11595,NA","NA, 159968","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03915678","BiomarkerKG1689293800"
"533","TREMELIMUMAB, DURVALUMAB","DB11771,DB11714","NA, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","CTLA4, PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03982173","BiomarkerKG1323565151"
"534","CB-839, TALAZOPARIB","NA,DB11760","71577426, 135565082","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03875313","BiomarkerKG3321966"
"535","IPATASERTIB, FULVESTRANT, LETROZOLE, PALBOCICLIB","DB11743,DB00947,DB01006,DB09073","24788740, 104741, 3902, 11478676","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","AKT, UNK, Aromatase, CDK4/CDK6","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03959891","BiomarkerKG1410798894"
"536","TAMOXIFEN CITRATE, LETROZOLE, EXEMESTANE","NA,DB01006,DB00990","2733525, 3902, 60198","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","INVASIVE DUCTAL BREAST CANCER (STAGES I-III)","EFO_0000186","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04129216","BiomarkerKG-37577398"
"541","PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, CARBOPLATIN, PEGFILGRASTIM","DB06366,DB00072,DB01229,DB00997,DB00531,DB01248,DB00958,DB00019","NA, 3001322, 36314, 443939, 2907, 148124, 56840877, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression&amplification, protein expression, protein expression","Positive, Negative/Positive, Negative/Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03329378","BiomarkerKG214156408"
"542","DURVALUMAB, OLAPARIB, AZD6738","DB11714,DB09074,NA","NA, 23725625, 54761306","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PDL1, PARP, ATR","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03740893","BiomarkerKG1059450097"
"543","NIVOLUMAB, NAB-PACLITAXEL, IPILIMUMAB","DB09035,NA,DB06186","NA, 36314, NA","ERBB2, ERS1","ENSG00000141736, NA","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04132817","BiomarkerKG-1378819185"
"545","FUTIBATINIB, FULVERSTRANT","DB15149,NA","71621331, NA","ERBB2, ERS1, PGR, FGFR2","ENSG00000141736, NA, ENSG00000082175, ENSG00000066468","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","FGFR, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04024436","BiomarkerKG-323468877"
"546","FUTIBATINIB","DB15149","71621331","ERBB2, ERS1, PGR, FGFR2","ENSG00000141736, NA, ENSG00000082175, ENSG00000066468","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","Negative, Negative, Negative, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","FGFR","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04024436","BiomarkerKG-1064188360"
"547","FUTIBATINIB, FULVERSTRANT","DB15149,NA","71621331, NA","ERBB2, ERS1, PGR, FGFR1","ENSG00000141736, NA, ENSG00000082175, ENSG00000077782","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR1 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","FGFR, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04024436","BiomarkerKG-1254885361"
"548","GEDATOLISIB, TALAZOPARIB","DB11896,DB11760","44516953, 135565082","ERBB2, ERS1, PGR, BRCA1, BRCA2","ENSG00000141736, NA, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein expression, Protein expression, Mutation, Mutation","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PI3K/mTOR, PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03911973","BiomarkerKG-1702088471"
"549","GEDATOLISIB, TALAZOPARIB","DB11896,DB11760","44516953, 135565082","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Mutation, Mutation","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PI3K/mTOR, PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03911973","BiomarkerKG535034914"
"550","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","NA,DB00958,NA","36314, 56840877, NA","ERBB2","ENSG00000141736","Protein Expression&amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03907800","BiomarkerKG716117938"
"551","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","NA,DB00958,NA","36314, 56840877, NA","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 PROTEIN EXPRESSION NEGATIVE AND BRCA2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03907800","BiomarkerKG107230865"
"553","FLX475, PEMBROLIZUMAB","DB15570,DB09037","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03674567","BiomarkerKG1670292329"
"554","REBASTINIB, PACLITAXEL","DB13005,DB01229","25066467, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER, INFLAMMATORY BREAST CANCER (IV)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03601897","BiomarkerKG1073688537"
"555","EOC317",NA,"23653175","FGFR","ENSG00000068078","missing","Positive",NA,"FGFR MISSING POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03583125","BiomarkerKG1597453582"
"566","PALBOCICLIB","DB09073","11478676","Rb","ENSG00000139687","Protein Expression","Positive",NA,"RB PROTEIN EXPRESSION POSITIVE","DCIS","EFO_0000432","Kinase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03535506","BiomarkerKG1795742479"
"569","DOCETAXEL, AZD8186","DB01248,NA","148124, 52913813","ERBB2, ESR1, PGR, PTEN, PIK3CB","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000171862, ENSG00000051382","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PTEN MUTATION POSITIVE AND/OR PIK3CB MUTATION POSITIVE","METASTATIC OR UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, PIK3CB","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03218826","BiomarkerKG-1112150392"
"570","DOCETAXEL, AZD8186","DB01248,NA","148124, 52913813","ERBB2, ESR1, PTEN, PIK3CB","ENSG00000141736, ENSG00000091831, ENSG00000171862, ENSG00000051382","Protein Expression, Protein Expression, Mutation, Mutation","Negative, Positive, Positive, Positive","AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE AND/OR PIK3CB MUTATION POSITIVE","METASTATIC OR UNRESECTABLE BREAST CANCER","MONDO_0007254","UNK, PIK3CB","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03218826","BiomarkerKG1099594919"
"574","CAPECITABINE, VINORELBINE TARTRATE","DB01101,NA","60953, 11607738","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","INFILTRATIVE BREAST CANCER (I-IIIB)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03703427","BiomarkerKG460609210"
"575","CAPECITABINE, VINORELBINE TARTRATE","DB01101,NA","60953, 11607738","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INFILTRATIVE TRIPLE NEGATIVE BREAST CANCER (I-IIIB)","EFO_0005537","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03703427","BiomarkerKG-22334710"
"576","NIRAPARIB","DB11793","24958200","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Mutation, Mutation","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","BREAST CANCER","MONDO_0007254","PARP1/PARP2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03329937","BiomarkerKG1145588410"
"577","PALBOCICLIB, LETROZOLE, PF-06952229","DB09073,DB01006,NA","11478676, 3902, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03685591","BiomarkerKG-1400644542"
"579","EXEMESTANE","DB00990","60198","ERBB2, ESR1, PGR, CYP2D6*10T/T","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","Protein Expression, Protein Expression, Protein Expression, Polymorphism","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND CYP2D6*10T/T POLYMORPHISM POSITIVE","BREAST CANCER","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03137368","BiomarkerKG527534200"
"580","OLAPARIB, DURVALUMIB","DB09074,NA","23725625, NA","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PARP, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03801369","BiomarkerKG-1317290656"
"583","HYDROXYCHLOROQUINE, LETROZOLE, PALBOCICLIB","DB01611,DB01006,DB09073","12947, 3902, 11478676","ERBB2, ESR1, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-III)","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03774472","BiomarkerKG-1034053422"
"587","DURVALUMAB, OLAPARIB","DB11714,DB09074","NA, 23725625","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","B7H1, PARP","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03544125","BiomarkerKG648245449"
"588","OLAPARIB, AZD6738","DB09074,NA","23725625, 54761306","ERBB2, ESR1, PGR, HRR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012504","Protein Expression, Protein Expression, Protein Expression, Mutation","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND HRR MUTATION POSITIVE/NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, ATR","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03330847","BiomarkerKG-734281255"
"590","DENOSUMAB","DB06643",NA,"ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER (I-II)","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03691311","BiomarkerKG-758780813"
"591","TRASTUZUMAB, PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","DB00072,DB01229,DB00445,DB00531","3001322, 36314, 65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST (II-IIIA)","EFO_0003869","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03556358","BiomarkerKG15122049"
"592","RIBOCICLIB, AROMATASE INHIBITOR","DB11730,NA","44631912, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","MESTASTATIC BREAST CANCER","MONDO_0007254","UNK, Aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03477396","BiomarkerKG1897197679"
"594","PACLITAXEL, CARBOPLATIN, DURVALUMAB, OLECLUMAB","DB01229,DB00958,DB11714,DB15088","36314, 56840877, NA, NA","ERBB2, ESR1, PGR, PDL1, CD73","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217, ENSG00000135318","Protein Expression, Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative, Positive/Negative","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND CD73 PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, PDL1, CD73","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03616886","BiomarkerKG-648527053"
"595","PALBOCICLIB, T-DM1","DB09073,DB05773","11478676, NA","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","RECURRENT OF METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03530696","BiomarkerKG-968301040"
"598","RIBOCICLIB, LETROZOLE, ALPELISIB, FULVESTRANT","DB11730,DB01006,DB12015,DB00947","44631912, 3902, 56649450, 104741","ERBB2, ESR1, PGR, PIK3CA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","Protein Expression, Protein Expression, Protein Expression, Mutation","Negative, Positive, Positive, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03439046","BiomarkerKG-1033722847"
"599","VENETOCLAX, FULVESTRANT","DB11581,DB00947","49846579, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03584009","BiomarkerKG1696516416"
"600","NIVOLUMAB, CAPECITABINE","DB09035,DB01101","NA, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PD1, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03487666","BiomarkerKG1837581867"
"601","PEMBROLIZUMAB, NAB-PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","DB09037,NA,DB00445,DB00531","NA, 36314, 65348, 2907","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03289819","BiomarkerKG672204679"
"606","PALBOCICLIB, EPIRUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","DB09073,DB00445,DB00531,DB01229","11478676, 65348, 2907, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03756090","BiomarkerKG-878912921"
"609","DURVALUMAB, ERIBULIN","DB11714,DB08871","NA, 17755248","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER (IV)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03430518","BiomarkerKG-745363586"
"611","FULVESTRANT, PALBOCICLIB","DB00947,DB09073","104741, 11478676","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03560856","BiomarkerKG1645197135"
"612","DAROLUTAMIDE, CAPECITABINE","DB12941,DB01101","67171867, 60953","ERBB2, ESR1, PGR, AR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","LOCALLY RECURRENT OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03383679","BiomarkerKG1525570353"
"613","APATINIB, CARBOPLATIN, ALBUMIN PACLITAXEL","DB14765,DB00958,NA","45139106, 56840877, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER (II-III)","EFO_0005537","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03650738","BiomarkerKG1930284753"
"617","PEMBROLIZUMAB","DB09037",NA,"ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","PD1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03197389","BiomarkerKG1732609082"
"618","CAPECITABINE","DB01101","60953","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-IIIB)","MONDO_0007254","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03684863","BiomarkerKG-1530143198"
"619","AB928, PEGYLATED LIPOSOMAL DOXORUBICIN, NANOPARTICLE ALBUMIN-BOUND PACLITAXEL, IPI-549","NA,NA,NA,NA","135242184, NA, 36314, 91933883","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","A2aR/A2bR, topoisomerase II, microtubules, phosphoinositide-3kinase-gamma","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03719326","BiomarkerKG1122870749"
"620","SAPACITABINE, OLAPARIB","DB06365,DB09074","153970, 23725625","BRCA1, BRCA2, ERBB2, ESR1, PGR","ENSG00000012048, ENSG00000139618, ENSG00000141736, ENSG00000091831, ENSG00000082175","Mutation, Mutation, Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive, Negative/Positive, Negative/Positive, Negative/Positive","AND/OR, AND, AND, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION NEGATIVE/POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","UNRESECTABLE BREAST CANCER","MONDO_0007254","UNK, PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03641755","BiomarkerKG-1654291266"
"621","NIVOLUMAB, CARBOPLATIN","DB09035,DB00958","NA, 56840877","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Negative/Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PD1, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03414684","BiomarkerKG1527489561"
"622","ATEZOLIZUMAB","DB11595",NA,"ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03483012","BiomarkerKG1555694068"
"624","GEDATOLISIB, PTK7-ADC","DB11896,NA","44516953, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03243331","BiomarkerKG50763736"
"625","VINORELBINE, TRASTUZUMAB, AVELUMAB, UTOMILUMAB","DB00361,DB00072,DB11945,DB15113","5311497, 3001322, NA, NA","ERBB2, PDL1","ENSG00000141736, ENSG00000120217","Protein Expression&Amplification/Protein Expression, Protein Expression","Positive, Negative/Positive","AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03414658","BiomarkerKG2044705796"
"626","T-DM1","DB05773",NA,"ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER (STAGE I-III)","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03587740","BiomarkerKG-353640244"
"627","TALAZOPARIB","DB11760","135565082","BRCA1, BRCA2, ERBB2","ENSG00000012048, ENSG00000139618, ENSG00000141736","Mutation, Mutation, Protein Expression","Positive, Positive, Negative","AND/OR, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03499353","BiomarkerKG-277316985"
"629","ALPELISIB","DB12015","56649450","ERBB2, ESR1, PGR, PIK3CA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","Protein Expression, Protein Expression, Protein Expression, Mutation","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03386162","BiomarkerKG1544168292"
"630","TRASTUZUMAB DERUXTECAN","DB14962",NA,"ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03523585","BiomarkerKG741800905"
"636","LETROZOLE","DB01006","3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE I-III)","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03747042","BiomarkerKG452080839"
"637","SGN-LIV1A, PEMBROLIZUMAB","DB15409,DB09037","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03310957","BiomarkerKG-520724971"
"642","MEN1611, TRASTUZUMAB, FULVESTRANT","NA,DB00072,DB00947","49784945, 3001322, 104741","ERBB2, PIK3CA","ENSG00000141736, ENSG00000121879","Protein Expression, Mutation","Positive, Positive","AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PI3K, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03767335","BiomarkerKG-611550358"
"643","PACLITAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","DB01229,DB00958,DB00072,DB06366","36314, 56840877, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04193059","BiomarkerKG-302172326"
"644","PACLITAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","DB01229,DB00958,DB00072,DB06366","36314, 56840877, 3001322, NA","ERBB2","ENSG00000141736","Protein Expression&Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04193059","BiomarkerKG1397632385"
"646","PEMBROLIZUMAB, MIFEPRISTONE","DB09037,DB00834","NA, 55245","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC  TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03225547","BiomarkerKG578304627"
"647","PEMBROLIZUMAB, MIFEPRISTONE","DB09037,DB00834","NA, 55245","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03225547","BiomarkerKG-1883166143"
"649","FULVESTRANT, PALBOCICLIB, GOSERELIN","DB00947,DB09073,DB00014","104741, 11478676, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE II, IIIA)","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03447132","BiomarkerKG78631894"
"650","PALBOCICLIB, TAMOXIFEN, GOSERELIN","DB09073,DB00675,DB00014","11478676, 2733526, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03423199","BiomarkerKG1999485518"
"653","CFI-400945",NA,"58486178","ERBB2, ESR1, PGR, PTEN","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000171862","Protein Expression, Protein Expression, Protein Expression, Mutation","Negative, Positive, Positive, Negative","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION NEGATIVE","METASTATIC  BREAST CANCER","EFO_1000984","PLK4","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03624543","BiomarkerKG1533557113"
"656","PEGFILGRASTIM, PEMBROLIZUMAB, DOCETAXEL, CARBOPLATIN","DB00019,DB09037,DB01248,DB00958","NA, NA, 148124, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER (STAGE I,II,III)","EFO_0005537","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03639948","BiomarkerKG-1014281306"
"657","TRASTUZUMAB, PACLITAXEL, PEGFILGRASTIM","DB00072,DB01229,DB00019","3001322, 36314, NA","ERBB2","ENSG00000141736","Protein Expression&Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03571633","BiomarkerKG1804392303"
"661","LETROZOLE, PALBOCICLIB, GOSERELIN","DB01006,DB09073,DB00014","3902, 11478676, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03628066","BiomarkerKG-1152658355"
"666","PALBOCICLIB, TAMOXIFEN, AVELUMAB","DB09073,DB00675,DB11945","11478676, 2733526, NA","ER","ENSG00000091831","Protein Expression","Positive",NA,"ER PROTEIN EXPRESSION POSITIVE","BREAST CANCER STAGE (II-III)","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03573648","BiomarkerKG2018741628"
"669","CFI-402257, PACLITAXEL","NA,DB01229","118086034, 36314","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03568422","BiomarkerKG1770688245"
"671","ELACESTRANT","DB06374","23642301","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03778931","BiomarkerKG-261616970"
"672","FASLODEX, ZOLADEX","NA,NA","104741, 16052011","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03591549","BiomarkerKG78021213"
"673","DOXORUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB, PACLITAXEL, IPATASERTIB","DB00997,DB00531,DB11595,DB01229,DB11743","443939, 2907, NA, 36314, 24788740","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03800836","BiomarkerKG-2102292157"
"674","IPATASERTIB, PACLITAXEL, ATEZOLIZUMAB","DB11743,DB01229,DB11595","24788740, 36314, NA","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03800836","BiomarkerKG2087114103"
"675","2X-121",NA,"135565981","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative/Positive, Negative/Positive, Negative/Positive, Negative/Positive, Negative/Positive","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION NEGATIVE/POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND BRCA1 MUTATION NEGATIVE/POSITIVE AND BRCA2 MUTATION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PARP1/PARP2/Tankyrase1/Tankyrase2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03562832","BiomarkerKG770386293"
"677","PEMBROLIZUMAB, FULVESTRANT","DB09037,DB00947","NA, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03393845","BiomarkerKG-911117187"
"680","PALBOCICLIB, LETROZOLE, T-DM1","DB09073,DB01006,DB05773","11478676, 3902, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Positive, Positive","AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03709082","BiomarkerKG-1466444488"
"681","CAPECITABINE, BEVACIZUMAB, PACLITAXEL, RIBOCICLIB, FULVESTRANT, AROMATASE INHIBITOR","DB01101,DB00112,DB01229,DB11730,DB00947,NA","60953, NA, 36314, 44631912, 104741, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK, UNK, aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03462251","BiomarkerKG1157328044"
"682","ZOLEDRONATE, ATORVASTATIN","DB00399,DB01076","23649597, 60823","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","NON-METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03358017","BiomarkerKG57336544"
"683","RIBOCICLIB, AROMATASE INHIBITORS, LHRH AGONIST","DB11730,NA,NA","44631912, NA, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, Aromatase, LHRH","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03944434","BiomarkerKG-911904952"
"686","IPILIMUMAB, NIVOLUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE","DB06186,DB09035,NA,DB00531","NA, NA, NA, 2907","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","CTLA4, PD1, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03409198","BiomarkerKG-486228165"
"687","PYROTINIB, CAPECITABINE, EVEROLIMUS, SHR3680, SHR6390, SHR1210, NAB-PACLITAXEL, APATINIB, FAMITINIB, VP-16","DB14993,DB01101,DB01590,NA,NA,NA,NA,DB14765,DB11741,NA","51039030, 60953, 6442177, NA, NA, NA, 36314, 45139106, 16662431, 36462","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","EGFR-TKI, UNK, mTOR, AR, CDK4/CDK6, PD1, UNK, VEGFR, UNK,","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03805399","BiomarkerKG-1882191710"
"688","PEMBROLIZUMAB, PACLITAXEL, DOXORUBICIN, EPIRUBICIN, CYCLOPHOSPHAMIDE, ENDOCRINE THERAPY","DB09037,DB01229,DB00997,DB00445,DB00531,NA","NA, 36314, 443939, 65348, 2907, NA","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Negative/Positive, Negative/Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","EARLY-STAGE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, Hormone Receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03725059","BiomarkerKG905266135"
"691","PEMBROLIZUMAB, CARBOPLATIN","DB09037,DB00958","NA, 56840877","BRCA1, BRCA2","ENSG00000012048, ENSG00000139618","Mutation, Mutation","Positive, Positive","AND/OR","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03732391","BiomarkerKG285097888"
"693","PEMBROLIZUMAB, PACLITAXEL, 5-FLUOROURACIL, EPIRUBICINE, CYCLOPHOSPHAMIDE","DB09037,DB01229,DB00544,DB00445,DB00531","NA, 36314, 3385, 41867, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","INFLAMMATORY BREAST CANCER","MONDO_0007254","PD1, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03515798","BiomarkerKG1905739885"
"694","TRASTUZUMAB, PERTUZUMAB, CARBOPLATIN, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB","DB00072,DB06366,DB00958,DB01229,DB00997,DB00531,DB11595","3001322, NA, 56840877, 36314, 443939, 2907, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","HER2, HER2, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03595592","BiomarkerKG1020150163"
"696","FULVESTRANT, PALBOCICLIB, TAMOXIFEN","DB00947,DB09073,DB00675","104741, 11478676, 2733526","ER","ENSG00000091831","Protein Expression","Positive",NA,"ER PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02913430","BiomarkerKG1026444782"
"697","RIBOCICLIB, ANASTROZOLE, LETROZOLE, EXEMESTANE, FULVESTRANT, TAMOXIFEN","DB11730,DB01217,DB01006,DB00990,DB00947,DB00675","44631912, 2187, 3902, 60198, 104741, 2733526","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03555877","BiomarkerKG-841715035"
"698","GOSERELIN","DB00014","5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","BREAST CANCER STAGE (II-III)","MONDO_0007254","LHRH","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03444025","BiomarkerKG-1810376634"
"699","TRASTUZUMAB, DOCETAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","DB00072,DB01248,DB00445,DB00531","3001322, 148124, 65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER STAGE (II-III)","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03013504","BiomarkerKG887966276"
"700","XENTUZUMAB, EVEROLIMUS, EXEMESTANE","DB14871,DB01590,DB00990","NA, 6442177, 60198","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03659136","BiomarkerKG-1856275316"
"701","FULVESTRANT","DB00947","104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04263298","BiomarkerKG-816911841"
"702","LETROZOLE, PROMETRIUM, TAMOXIFEN","DB01006,NA,DB00675","3902, 5994, 2733526","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03906669","BiomarkerKG2090505559"
"703","ENTINOSTAT, EXEMESTANE","DB11841,DB00990","4261, 60198","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03538171","BiomarkerKG835667669"
"704","DURVALUMAB, PACLITAXEL, CAPIVASERTIB, OLECLUMAB, TRASTUZUMAB DERUXTECAN","DB11714,DB01229,DB12218,DB15088,DB14962","NA, 36314, 25227436, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742102","BiomarkerKG860769988"
"705","CAPECITABINE, AROMATASE INHIBITOR","DB01101,NA","60953, NA","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, Aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04012918","BiomarkerKG-665369307"
"709","APATINIB, CAPECITABINE","DB14765,DB01101","45139106, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC  TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","VEGFR2, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03775928","BiomarkerKG-67572255"
"710","CYCLOPHOSPHAMIDE, DOXORUBICIN, DOCETAXEL, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB SC, HORMONE THERAPY","DB00531,DB00997,DB01248,DB01229,DB06366,NA,NA","2907, 443939, 148124, 36314, NA, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03493854","BiomarkerKG-1110856994"
"715","ATEZOLIZUMAB, PACLITAXEL, DOXORUBICIN, EPIRUBICIN","DB11595,DB01229,DB00997,DB00445","NA, 36314, 443939, 65348","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Negative/Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","NON-METASTATIC TRIPLE NEGATIVE BREAST CANCER STAGE (II-III)","MONDO_0007254","PDL1, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03498716","BiomarkerKG-1357256656"
"716","ATEZOLIZUMAB, SGN-LIV1A, BEVACIZUMAB, CAPECITABINE, RO6874281, COBIMETINIB, SELICRELUMAB, IPATASERTIB","DB11595,DB15409,DB00112,DB01101,NA,DB05239,DB14958,DB11743","NA, NA, NA, 60953, NA, 71491931, NA, 24788740","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03424005","BiomarkerKG967538948"
"717","PYROTINIB, TRASTUZUMAB, DOCETAXEL","DB14993,DB00072,DB01248","51039030, 3001322, 148124","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","HER1/HER2, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03735966","BiomarkerKG-323996395"
"718","ATEZOLIZUMAB, GEMCITABINE, CAPECITABINE, CARBOPLATIN","DB11595,DB00441,DB01101,DB00958","NA, 60750, 60953, 56840877","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Negative/Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","RECURRENT TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03371017","BiomarkerKG1482317837"
"724","PERTUZUMAB, TRASTUZUMAB","DB06366,DB00072","NA, 3001322","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED","EFO_0005856","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03674112","BiomarkerKG-2071500889"
"725","PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","DB01229,DB00072,DB06366","36314, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification,Protein Expression, Protein Expression","Positive, Negative/Positive, Negative/Positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER STAGE (II-III)","MONDO_0007254","UNK, HER2, HER2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03716180","BiomarkerKG-1974752895"
"727","NIVOLUMAB","DB09035",NA,"ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03316586","BiomarkerKG-871673121"
"728","NERATINIB, FULVESTRANT","DB11828,DB00947","9915743, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression/Protein Expression&Amplification, Protein Expression","Positive, Positive","AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","HER2, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03289039","BiomarkerKG1651699518"
"729","FULVESTRANT, ENZALUTAMIDE","DB00947,DB08899","104741, 15951529","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02953860","BiomarkerKG-1580038516"
"732","PEMBROLIZUMAB, NAB-PACLITAXEL","DB09037,NA","NA, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","PD1, Microtubles","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02999477","BiomarkerKG-1916652712"
"733","TRASTUZUMAB, IBRUTINIB","DB00072,DB09053","3001322, 24821094","ERBB2","ENSG00000141736","Protein Expression&Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, BTK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03379428","BiomarkerKG-2058737055"
"735","ABEMACICLIB, ADJUVANT ENDOCRINE THERAPY","DB12001,NA","46220502, NA","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive, Positive/Negative","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE","EARLY STAGE BREAST CANCER","MONDO_0007254","UNK, Hormone Receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03155997","BiomarkerKG-1981115273"
"736","APATINIB, PACLITAXEL, CISPLATIN","DB14765,DB01229,DB00515","45139106, 36314, 135804801","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03580395","BiomarkerKG1634813377"
"739","DAROLUTAMIDE","DB12941","67171867","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03004534","BiomarkerKG-70918532"
"740","CISPLATIN, AZD1775","DB00515,NA","135804801, 24856436","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","DNA, WEE1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03012477","BiomarkerKG-645228182"
"741","EPALRESTAT","DB15293","1549120","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03244358","BiomarkerKG-1948632702"
"743","RUXOLITINIB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB08877,DB01229,DB00997,DB00531","25126798, 36314, 443939, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INFLAMMATORY BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02876302","BiomarkerKG2045156743"
"744","ATEZOLIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE","DB11595,NA,DB00531","NA, NA, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PDL1, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03164993","BiomarkerKG268030188"
"746","PROXALUTAMIDE",NA,"60194102","AR","ENSG00000169083","Protein Expression","Positive",NA,"AR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04103853","BiomarkerKG1626152336"
"747","TAXOTERE, CARBOPLATIN, HERCEPTIN, PERTUZUMAB, METFORMIN","NA,DB00958,NA,DB06366,DB00331","148124, 56840877, NA, NA, 14219","HER2","ENSG00000141736","Protein Expression","Positive",NA,"HER2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03238495","BiomarkerKG-2024893270"
"748","PEMBROLIZUMAB","DB09037",NA,"ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive/Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03366844","BiomarkerKG1301936541"
"750","TAMOXIFEN, TOREMIFENE","DB00675,DB00539","2733526, 3005573","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03351062","BiomarkerKG1797119238"
"752","ABEMACICLIB","DB12001","46220502","ERBB2, ESR1, PGR, RB","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000139687","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND RB PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED","EFO_0005856","CDK4/CDK6","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03130439","BiomarkerKG1339207370"
"753","TAMOXIFEN","DB00675","2733526","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03211572","BiomarkerKG-1795012017"
"754","MIFEPRISTONE, NAB-PACLITAXEL","DB00834,NA","55245, 36314","ERBB2, ESR1, PGR, GR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000113580","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND GR PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE III-IV)","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02788981","BiomarkerKG-669478277"
"756","PEMBROLIZUMAB, PVX-410","DB09037,NA","NA, NA","ERBB2, ESR1, PGR, HLAA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND HLAA2 PROTEIN EXPRESSION POSITIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PD1, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03362060","BiomarkerKG739576048"
"757","CARBOPLATIN, ATEZOLIZUMAB","DB00958,DB11595","56840877, NA","E-cadherin","ENSG00000039068","Protein Expression","Negative",NA,"E-CADHERIN PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03147040","BiomarkerKG-1907373473"
"758","CAPECITABINE, AROMATASE INHIBITOR","DB01101,NA","60953, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, Aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02767661","BiomarkerKG1343148659"
"760","PERTUZUMAB, HERCEPTIN, EPIRUBICIN, CYCLOPHOSPHAMIDE, ANASTROZOLE, LETROZOLE, EXEMESTANE, PACLITAXEL, TAMOXIFEN, LEUPORELIN ACETATE, GOSERELIN","DB06366,NA,DB00445,DB00531,DB01217,DB01006,DB00990,DB01229,DB00675,NA,DB00014","NA, NA, 65348, 2907, 2187, 3902, 60198, 36314, 2733526, NA, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03272477","BiomarkerKG-1079364487"
"762","ANASTROZOLE, LETROZOLE, EXEMESTANE, TAMOXIFEN","DB01217,DB01006,DB00990,DB00675","2187, 3902, 60198, 2733526","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (STAGE I-II)","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03219476","BiomarkerKG-408096696"
"764","CYCLOPHOSPHAMIDE, CAPECITABINE, VINORELBINE","DB00531,DB01101,DB00361","2907, 60953, 5311497","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02954055","BiomarkerKG756185457"
"765","TAMOXIFEN","DB00675","2733526","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03045653","BiomarkerKG352370837"
"766","CYCLOPHOSPHAMIDE, PEMBROLIZUMAB","DB00531,DB09037","2907, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive/Negative","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, PD1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03139851","BiomarkerKG79788518"
"767","ERDAFITINIB, PALBOCICLIB, FULVESTRANT","DB12147,DB09073,DB00947","67462786, 11478676, 104741","ERBB2, ESR1, PGR, FGFR1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000077782","Protein Expression, Protein Expression, Protein Expression, Protein Expression/Protein Expression&Amplification","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR1 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","FGFR, CDK4/CDK6, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03238196","BiomarkerKG1151456220"
"768","PALBOCICLIB, TRASTUZUMAB, PERTUZUMAB, LETROZOLE, ANASTROZOLE, EXEMESTANE, FULVESTRANT","DB09073,DB00072,DB06366,DB01006,DB01217,DB00990,DB00947","11478676, 3001322, NA, 3902, 2187, 60198, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","UNRESECTABLE BREAST CANCER","MONDO_0007254","UNK, HER2, HER2, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02947685","BiomarkerKG647041563"
"769","TAK-228, TAMOXIFEN","NA,DB00675","45375953, 2733526","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE I-III)","MONDO_0007254","MTOR1/2, Estrogen","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02988986","BiomarkerKG1325069268"
"771","DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, LETROZOLE, LEUPRORELIN","DB00997,DB00531,DB01248,DB01006,DB00007","443939, 2907, 148124, 3902, 657181","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03497702","BiomarkerKG1432083835"
"772","TUCATINIB, PALBOCICLIB, LETROZOLE","DB11652,DB09073,DB01006","51039094, 11478676, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","HER2, CDK4/CDK6, aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03054363","BiomarkerKG-2080942422"
"774","ATEZOLIZUMAB, COBIMETINIB, IPATASERTIB, BEVACIZUMAB","DB11595,DB05239,DB11743,DB00112","NA, 71491931, 24788740, NA","ERBB2, ESR1, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER","MONDO_0007254","PDL1, MEK1/MEK2, AKT, VEGF","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03395899","BiomarkerKG-1194781878"
"776","APATINIB, ETOPOSIDE","DB14765,DB00773","45139106, 36462","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","VEGFR2, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03535961","BiomarkerKG872874309"
"777","TRASTUZUMAB, DOCETAXEL","DB00072,DB01248","3001322, 148124","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INFILTRATING PRIMARY BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03367676","BiomarkerKG-1746302945"
"778","LAPATINIB, HERCEPTIN","DB01259,NA","208908, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","IVASIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03085368","BiomarkerKG308998292"
"779","ALPELISIB, FULVESTRANT, GOSERELIN, LEUPROLIDE","DB12015,DB00947,DB00014,DB00007","56649450, 104741, 5311128, 657181","ERBB2, ESR1, PGR, PIK3CA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","Protein Expression, Protein Expression, Protein Expression, Mutation","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03056755","BiomarkerKG1904301603"
"780","OLAPARIB","DB09074","23725625","ERBB2, ESR1, PGR, BCRA1, BCRA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA, NA","Protein Expression, Protein Expression, Protein Expression, Mutation/Methylation, Mutation/Methylation","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BCRA1 MUTATION/METHYLATION POSITIVE AND/OR BCRA2 MUTATION/METHYLATION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03205761","BiomarkerKG-1259323554"
"781","FULVESTRANT, DEBIO 1347","DB00947,NA","104741, 66555680","ERBB2, ESR1, PGR, FGFR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000068078","Protein Expression, Protein Expression, Protein Expression, Protein Expression/Protein Expression&Amplification","Negative, Positive, Positive, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND FGFR PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03344536","BiomarkerKG868050889"
"782","CAPECITABINE, NERATINIB","DB01101,DB11828","60953, 9915743","ERBB2","ENSG00000141736","Protein Expression&Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03377387","BiomarkerKG1393021289"
"785","OPC",NA,"2754","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03092635","BiomarkerKG21641192"
"786","PEMETREXED, VINORELBINE","DB00642,DB00361","135413520, 5311497","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","folate, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03242616","BiomarkerKG1788523482"
"787","APATINIB, PACLITAXEL","DB14765,DB01229","45139106, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03348098","BiomarkerKG-530391371"
"791","LETROZOLE, CAPECITABINE","DB01006,DB01101","3902, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03507465","BiomarkerKG1830562034"
"793","TRASTUZUMAB, PERTUZUMAB, TOCILIZUMAB","DB00072,DB06366,DB06273","3001322, NA, NA","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","UNRESECTABLE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03135171","BiomarkerKG-669278264"
"794","MEGESTROL ACETATE, LETROZOLE","DB00351,DB01006","11683, 3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03306472","BiomarkerKG1819372313"
"795","DURVALUMAB, TREMELIMUMAB, FULVESTRANT","DB11714,DB11771,DB00947","NA, NA, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","PDL1, CTLA4, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03430466","BiomarkerKG-1360299440"
"797","TAK-228, LETROZOLE","NA,DB01006","45375953, 3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE I-IV)","MONDO_0007254","mTOR, aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02619669","BiomarkerKG-884828856"
"798","SAR439859, PALBOCICLIB, MIDAZOLAM","NA,DB09073,DB00683","130232326, 11478676, 4192","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03284957","BiomarkerKG2021754841"
"801","RIBOCICLIB, CAPECITABINE","DB11730,DB01101","44631912, 60953","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02754011","BiomarkerKG1829062358"
"802","ATEZOLIZUMAB, ENTINOSTAT, FULVESTRANT, IPATASERTIB, BEVACIZUMAB, EXEMESTANE, TAMOXIFEN, ABEMACICLIB","DB11595,DB11841,DB00947,DB11743,DB00112,DB00990,DB00675,DB12001","NA, 4261, 104741, 24788740, NA, 60198, 2733526, 46220502","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PDL1, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03280563","BiomarkerKG-1516206975"
"803","ESTETROL","DB12235","27125","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02718144","BiomarkerKG746928826"
"805","PALBOCICLIB, FULVESTRANT","DB09073,DB00947","11478676, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03322215","BiomarkerKG-1930811601"
"806","PU-H71, NAB-PACLITAXEL","DB12638,NA","9549213, 36314","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03166085","BiomarkerKG-1984030845"
"807","PACLITAXEL","DB01229","36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03315364","BiomarkerKG-91964507"
"808","PALBOCICLIB, LETROZOLE, TRASTUZUMAB, GOSERELIN","DB09073,DB01006,DB00072,DB00014","11478676, 3902, 3001322, 5311128","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Positive, Positive","AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE II-III)","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02907918","BiomarkerKG1548364630"
"809","PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, DURVALUMAB","DB01229,DB00445,DB00531,DB11714","36314, 65348, 2907, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOBULAR","EFO_0008509","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03356860","BiomarkerKG-487367009"
"811","ABRAXANE",NA,"36314","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02687490","BiomarkerKG-333099937"
"816","HYDROXYCHLOROQUINE, EVEROLIMUS","DB01611,DB01590","12947, 6442177","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03032406","BiomarkerKG-21443397"
"817","HYDROXYCHLOROQUINE, EVEROLIMUS","DB01611,DB01590","12947, 6442177","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03032406","BiomarkerKG591160150"
"818","XENTUZUMAB, ABEMACICLIB, LETROZOLE, ANASTROZOLE, FULVESTRANT","DB14871,DB12001,DB01006,DB01217,DB00947","NA, 46220502, 3902, 2187, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03099174","BiomarkerKG1771247202"
"819","TAK-228, TAK-117, CISPLATIN, NAB PACLITAXEL","NA,NA,DB00515,NA","45375953, 70798655, 135804801, 36314","ERBB2, ESR1, PGR, AR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","Homologous Recombination, Homologous Recombination, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03193853","BiomarkerKG-1712865141"
"822","ATEZOLIZUMAB","DB11595",NA,"ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03281954","BiomarkerKG1339315025"
"824","CARBOPLATIN, PEMBROLIZUMAB, NAB-PACLITAXEL","DB00958,DB09037,NA","56840877, NA, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03121352","BiomarkerKG-898081184"
"825","ATEZOLIZUMAB, NAB-PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, FILGRASTIM, PEGFILGRASTIM","DB11595,NA,DB00997,DB00531,DB00099,DB00019","NA, 36314, 443939, 2907, NA, NA","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","EARLY TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PDL1, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03197935","BiomarkerKG-1241583172"
"826","ATEZOLIZUMAB, PACLITAXEL","DB11595,DB01229","NA, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PDL1, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03125902","BiomarkerKG-681578463"
"828","FLUVESTRANT, VINORELBINE","NA,DB00361","104741, 5311497","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03939871","BiomarkerKG-1505417028"
"830","PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, DOXORUBICIN, EPIRUBICIN, CYCLOPHOSPHAMIDE, FILGRASTIM/PEGFILGASTRIM","DB09037,DB00958,DB01229,DB00997,DB00445,DB00531,NA","NA, 56840877, 36314, 443939, 65348, 2907, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK/UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03036488","BiomarkerKG593038470"
"831","ATEZOLIZUMAB, PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","DB11595,DB01229,DB00072,DB06366","NA, 36314, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED","EFO_0005856","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03125928","BiomarkerKG84680742"
"835","PEMBROLIZUMAB, PACLITAXEL","DB09037,DB01229","NA, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03018080","BiomarkerKG1907101527"
"837","T-DM1, PEMBROLIZUMAB","DB05773,DB09037","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03032107","BiomarkerKG-10237408"
"838","PACLITAXEL, CISPLATIN, EPIRUBICIN, CYCLOPHOSPHAMIDE","DB01229,DB00515,DB00445,DB00531","36314, 135804801, 65348, 2907","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03201861","BiomarkerKG-968287834"
"839","TAMOXIFEN, ENDOCRINE THERAPY, LETROZOLE, PALBOCICLIB","DB00675,NA,DB01006,DB09073","2733526, NA, 3902, 11478676","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (STAGE I-III)","MONDO_0007254","UNK, Hormone Receptors, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02764541","BiomarkerKG-1583232396"
"840","ENDOSTAR","DB11727",NA,"ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","angiogenesis","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03907098","BiomarkerKG-1780544698"
"841","CYCLOPHOSPHAMIDE","DB00531","2907","ERBB2, ESR1, PGR, TP53","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000141510","Protein Expression, Protein Expression, Protein Expression, Mutation","Positive/Negative, Positive/Negative, Positive/Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND TP53 MUTATION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02965950","BiomarkerKG883333641"
"842","RIBOCICLIB, FULVESTRANT","DB11730,DB00947","44631912, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02632045","BiomarkerKG-364115152"
"843","RIBOCICLIB, T-DM1, TRASTUZUMAB, FULVESTRANT","DB11730,DB05773,DB00072,DB00947","44631912, NA, 3001322, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02657343","BiomarkerKG87083995"
"844","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11478676, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02679755","BiomarkerKG422806181"
"845","ENTINOSTAT, EXEMESTANE","DB11841,DB00990","4261, 60198","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02833155","BiomarkerKG-1924527343"
"847","GEMCITABINE, CISPLATIN","DB00441,DB00515","60750, 135804801","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED","EFO_0003149","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02546934","BiomarkerKG2088229413"
"848","CAELYX",NA,"31703","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Negative, Positive","AND, AND, OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE OR KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03712956","BiomarkerKG1551184012"
"851","VISMODEGIB, PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","DB08828,DB01229,DB00445,DB00531","24776445, 36314, 65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02694224","BiomarkerKG-1724731618"
"855","PACLITAXEL, TRASTUZUMAB, PERTUZUMAB, CARBOPLATIN, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB01229,DB00072,DB06366,DB00958,DB00997,DB00531","36314, 3001322, NA, 56840877, 443939, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02789657","BiomarkerKG307870780"
"859","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB","DB01248,DB00958,DB00072","148124, 56840877, 3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (STAGE II-IIIB)","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03140553","BiomarkerKG1356607656"
"860","POZIOTINIB","DB12114","25127713","ERBB2","ENSG00000141736","Protein Expression&Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02659514","BiomarkerKG-1654237016"
"861","VINORELBINE","DB00361","5311497","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03007992","BiomarkerKG1096452891"
"862","ENTINOSTAT, EXEMESTANE","DB11841,DB00990","4261, 60198","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","HDAC, aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02820961","BiomarkerKG1145681156"
"866","APATINIB","DB14765","45139106","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative,Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02878057","BiomarkerKG-59848919"
"867","FULVESTRANT","DB00947","104741","ERBB2, ESR1, PGR, D1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000110092","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive/Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND D1 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02936206","BiomarkerKG1607802726"
"868","MIFEPRISTONE","DB00834","55245","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive/Negative, Negative","AND","ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","ER","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02651844","BiomarkerKG972719022"
"869","OLAPARIB, PACLITAXEL, CARBOPLATIN","DB09074,DB01229,DB00958","23725625, 36314, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INVASIVE BREAST CANCER","EFO_1000307","PARP, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03150576","BiomarkerKG-156831248"
"870","OLAPARIB, PACLITAXEL, CARBOPLATIN","DB09074,DB01229,DB00958","23725625, 36314, 56840877","ERBB2, ESR1, PGR, BCRA1, BCRA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA, NA","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Positive/Negative, Positive/Negative, Positive, Positive","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND BCRA1 MUTATION POSITIVE AND/OR BCRA2 MUTATION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","PARP, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03150576","BiomarkerKG-906215829"
"872","PALBOCICLIB, FULVESTRANT","DB09073,DB00947","11478676, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02536742","BiomarkerKG-1372296362"
"874","LETROZOLE, ATORVASTATIN","DB01006,DB01076","3902, 60823","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","aromatase, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02958852","BiomarkerKG-1594113816"
"875","PEMBROLIZUMAB, CARBOPLATIN, GEMCITABINE","DB09037,DB00958,DB00441","NA, 56840877, 60750","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02755272","BiomarkerKG-81443957"
"876","LETROZOLE, EVEROLIMUS, TRC105","DB01006,DB01590,NA","3902, 6442177, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE II-III)","MONDO_0007254","UNK,  UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02520063","BiomarkerKG-721697045"
"877","BICALUTAMIDE, AROMATASE INHIBITOR","DB01128,NA","56069, NA","ERBB2, ESR1, AR","ENSG00000141736, ENSG00000091831, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, Aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02910050","BiomarkerKG-399684071"
"878","TRASTUZUMAB, DOCETAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB00072,DB01248,DB00997,DB00531","3001322, 148124, 443939, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER (STAGE II-III)","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03425656","BiomarkerKG-628309927"
"879","LETROZOLE, RIBOCICLIB","DB01006,DB11730","3902, 44631912","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (II-III)","MONDO_0007254","Aromatase, CDK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02712723","BiomarkerKG-750715707"
"880","VINORELBINE, LETROZOLE","DB00361,DB01006","5311497, 3902","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive, Positive/Negative","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02802748","BiomarkerKG-2075884375"
"881","CARBOPLATIN, ABRAXANE, ATEZOLIZUMAB, ANTHRA","DB00958,NA,DB11595,NA","56840877, 36314, NA, 5359985","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, PDL1, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02620280","BiomarkerKG947735166"
"882","PACLITAXEL, DURVALUMAB","DB01229,DB11714","36314, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02628132","BiomarkerKG-1329345514"
"883","GEDATOLISIB, PALBOCICLIB, LETROZOLE, FULVESTRANT","DB11896,DB09073,DB01006,DB00947","44516953, 11478676, 3902, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02684032","BiomarkerKG522715413"
"884","RIBOCICLIB, EVEROLIMUS, EXEMESTANE","DB11730,DB01590,DB00990","44631912, 6442177, 60198","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02732119","BiomarkerKG974702214"
"885","PEMBROLIZUMAB, PACLITAXEL, CAPECITABINE","DB09037,DB01229,DB01101","NA, 36314, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED","EFO_0003149","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02734290","BiomarkerKG-1551051355"
"888","L-NMMA, DOCETAXEL, AMLODIPINE, PEGFILGRASTIM, ENTERIC-COATED ASPIRIN","DB11815,DB01248,DB00381,DB00019,NA","132862, 148124, 60496, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","Nitric Oxide Synthase, Mitosis, calcium channels, colony-stimulation, inflammation mechanisims","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02834403","BiomarkerKG-1165324978"
"890","IXAZOMIB, CARBOPLATIN","DB09570,DB00958","56844015, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02993094","BiomarkerKG1836350822"
"892","DOXORUBICIN, CYCLOPHOSPHAMIDE, SUNITINIB","DB00997,DB00531,DB01268","443939, 2907, 5329102","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","NON-METASTATIC BREAST CANCER","MONDO_0007254","UNK,  UNK, VEGFR","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02790580","BiomarkerKG-876107016"
"893","RIBOCICLIB, LETROZOLE, GOSERELIN","DB11730,DB01006,DB00014","44631912, 3902, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03096847","BiomarkerKG520740348"
"895","OLAPARIB","DB09074","23725625","BRCA1, BRCA2","ENSG00000012048, ENSG00000139618","Mutation, Mutation","Positive, Positive","OR","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02681562","BiomarkerKG401560374"
"896","DOCETAXEL, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, EPIRUBICIN","DB01248,DB01101,DB00531,DB00544,DB00445","148124, 60953, 2907, 3385, 65348","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","NON-METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02897050","BiomarkerKG1724463496"
"897","APATINIB, VINORELBINE","DB14765,DB00361","45139106, 5311497","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","VEGFR2, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02768415","BiomarkerKG1740692542"
"898","ALISERTIB, MLN0128","DB05220,NA","24771867, 45375953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","TORC1/TORC2, AURORA A","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02719691","BiomarkerKG-1321499911"
"899","ABEMACICLIB","DB12001","46220502","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02831530","BiomarkerKG1507974875"
"902","EVEROLIMUS, LETROZOLE","DB01590,DB01006","6442177, 3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","NON-METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02742051","BiomarkerKG1984253007"
"904","ABEMACICLIB, AROMATASE INHIBITOR, FULVESTRANT","DB12001,NA,DB00947","46220502, NA, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","And, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","CDK4/CDK6, aromatase, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02763566","BiomarkerKG312954487"
"905","ENTINOSTAT, ATEZOLIZUMAB","DB11841,DB11595","4261, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","HDAC, PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02708680","BiomarkerKG363600322"
"907","GEDATOLISIB, FULVESTRANT, PALBOCICLIB, ZOLADEX","DB11896,DB00947,DB09073,NA","44516953, 104741, 11478676, 16052011","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE I-IV)","MONDO_0007254","PI3K, ER, CDk4/CDK6, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02626507","BiomarkerKG-703533578"
"909","FULVESTRANT, MLN0128","DB00947,NA","104741, 45375953","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02756364","BiomarkerKG-750012459"
"910","DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, 5-FU","DB00997,DB00531,DB01229,DB00544","443939, 2907, 36314, 3385","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02688803","BiomarkerKG-2094516704"
"911","PEMBROLIZUMAB, NAB-PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, CARBOPLATIN","DB09037,NA,DB00997,DB00531,DB00958","NA, 36314, 443939, 2907, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02622074","BiomarkerKG-1402227528"
"912","DOCETAXEL, PERTUZUMAB, TRASTUZUMAB","DB01248,DB06366,DB00072","148124, NA, 3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02896855","BiomarkerKG-1054276273"
"916","TRASTUZUMAB, FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE, PERTUZUMAB, DOCETAXEL","DB00072,DB00544,DB00445,DB00531,DB06366,DB01248","3001322, 3385, 65348, 2907, NA, 148124","ERBB2","ENSG00000141736","Protein Expression&Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","INFLAMMATORY","EFO_0003767","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03144947","BiomarkerKG286186734"
"917","DURVALUMAB, TREMELIMUMAB","DB11714,DB11771","NA, NA","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","STAGE IV BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03608865","BiomarkerKG1779844733"
"918","FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, PERTUZUMAB, TRASTUZUMAB","DB00544,DB00445,DB00531,DB01248,DB06366,DB00072","3385, 65348, 2907, 148124, NA, 3001322","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02586025","BiomarkerKG2029503975"
"920","GDC-0077","DB15275","124173720","PIK3CA","ENSG00000121879","Mutation","Positive",NA,"PIK3CA MUTATION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03006172","BiomarkerKG-437210237"
"921","GDC-0077, FULVESTRANT, PALBOCICLIB, METFORMIN","DB15275,DB00947,DB09073,DB00331","124173720, 104741, 11478676, 14219","PIK3CA, ERBB2, ESR1, PGR","ENSG00000121879, ENSG00000141736, ENSG00000091831, ENSG00000082175","Mutation, Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Positive, Positive","AND, AND, AND/OR","PIK3CA MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03006172","BiomarkerKG-1389058042"
"922","RIBOCICLIB, PACLITAXEL","DB11730,DB01229","44631912, 36314","ERBB2, ESR1, PGR, RB","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000139687","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Positive/Negative, Positive/Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND RB PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02599363","BiomarkerKG93764203"
"923","FULVESTRANT, NERATINIB, AZD5363, OLAPARIB","DB00947,DB11828,NA,DB09074","104741, 9915743, 25227436, 23725625","ERBB2","ENSG00000141736","Protein Expression","Positive/Negative",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03182634","BiomarkerKG-611638003"
"924","FULVESTRANT, NERATINIB, AZD5363","DB00947,DB11828,NA","104741, 9915743, 25227436","ESR1","ENSG00000091831","Protein Expression","Positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03182634","BiomarkerKG1699762989"
"925","PALBOCICLIB, LETROZOLE, ANASTROZOLE, EXEMESTANE, FULVESTRANT","DB09073,DB01006,DB01217,DB00990,DB00947","11478676, 3902, 2187, 60198, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02894398","BiomarkerKG506029057"
"926","PQR309, ERIBULIN","NA,DB08871","58507717, 17755248","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PI3K/mTOR, microtubles","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02723877","BiomarkerKG32361465"
"927","DURVALUMAB, TRASTUZUMAB","DB11714,DB00072","NA, 3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC","EFO_0009709","UNK, HER2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02649686","BiomarkerKG-124600101"
"928","17B-ESTRADIOL, LETROZOLE, ANASTROZOLE, EXEMESTANE","NA,DB01006,DB01217,DB00990","5757, 3902, 2187, 60198","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","Aromatase, Aromatase,Aromatase,Aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02188745","BiomarkerKG626978084"
"929","PEMBROLIZUMAB, EXEMESTANE, LEUPROLIDE","DB09037,DB00990,DB00007","NA, 60198, 657181","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02990845","BiomarkerKG1199348840"
"930","CAPECITABINE, CYCLOPHOSPHAMIDE","DB01101,DB00531","60953, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative,Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02664103","BiomarkerKG-1605217831"
"931","ABEMACICLIB, TAMOXIFEN, PROPHYLACTIC LOPERAMIDE","DB12001,DB00675,NA","46220502, 2733526, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02747004","BiomarkerKG-475824106"
"933","RUCAPARIB","DB12332","9931954","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Mutation, Mutation","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02505048","BiomarkerKG-625443434"
"934","PEMETREXED, SORAFENIB","DB00642,DB00398","135413520, 406563","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND,AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02624700","BiomarkerKG1606446971"
"935","LSZ102, LEE011, BYL719","NA,NA,NA","118574930, 44631912, 56649450","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02734615","BiomarkerKG1637805116"
"936","PEMBROLIZUMAB, CYCLOPHOSPHAMIDE","DB09037,DB00531","NA, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02768701","BiomarkerKG1583796628"
"938","LAPATINIB, CAPECITABINE/VINORELBINE","DB01259,NA","208908, NA","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK/UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02362958","BiomarkerKG-811049943"
"939","OLAPARIB, MEDI4736","DB09074,NA","23725625, NA","ERBB2, ESR1, PGR, BCRA1, BCRA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA, NA","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Positive/Negative, Positive/Negative","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BCRA1 MUTATION POSITIVE/NEGATIVE AND BCRA2 MUTATION POSITIVE/NEGATIVE","ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","DNA, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02484404","BiomarkerKG-209612952"
"940","ZOLEDRONIC ACID","DB00399","68740","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02595138","BiomarkerKG-356307068"
"941","DOCETAXEL, DOXORUBICIN/EPIRUBICIN, CYCLOPHOSPHAMIDE, GEMCITABINE, CISPLATIN","DB01248,NA,DB00531,DB00441,DB00515","148124, NA, 2907, 60750, 135804801","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK/UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02641847","BiomarkerKG-324639317"
"942","NAB-PACLITAXEL, NIVOLUMAB","NA,DB09035","36314, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02309177","BiomarkerKG-1695804822"
"943","EVEROLIMUS, EXEMESTANE, FULVESTRANT","DB01590,DB00990,DB00947","6442177, 60198, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02404051","BiomarkerKG-700878458"
"944","TRASTUZUMAB, LETROZOLE","DB00072,DB01006","3001322, 3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression&Amplification/Protein Expression, Protein Expression","Positive, Positive","AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER (IB-IIIC)","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02214004","BiomarkerKG-1081448824"
"946","AFATINIB","DB08916","10184653","ERBB2, ESR1, PGR, EGFR","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000146648","Protein Expression, Protein Expression, Protein Expression, Protein Expression/Mutation","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND EGFR PROTEIN EXPRESSION/MUTATION POSITIVE/NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","ErbB","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02511847","BiomarkerKG-825131584"
"949","TRASTUZUMAB, PERTUZUMAB, PALBOCICLIB, FULVESTRANT","DB00072,DB06366,DB09073,DB00947","3001322, NA, 11478676, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression&Amplification/Protein Expression, Protein Expression","Positive, Positive","AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK,CDK4/CDK6, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02530424","BiomarkerKG-2073492504"
"950","TRASTUZUMAB, PERTUZUMAB, PALBOCICLIB, FULVESTRANT","DB00072,DB06366,DB09073,DB00947","3001322, NA, 11478676, 104741","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK,CDK4/CDK6, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02530424","BiomarkerKG-240862516"
"951","TAMOXIFEN, PEMBROLIZUMAB, VORINOSTAT","DB00675,DB09037,DB02546","2733526, NA, 5311","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Positive/Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","estrogen receptors, PD1, HDAC","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02395627","BiomarkerKG2020622219"
"952","PEMBROLIZUMAB, VORINOSTAT","DB09037,DB02546","NA, 5311","ERBB2, ESR1, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression","Positive/Negative,Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","PD1, HDAC","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02395627","BiomarkerKG-512463632"
"953","CARBOPLATIN, PACLITAXEL, BEVACIZUMAB","DB00958,DB01229,DB00112","56840877, 36314, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02436993","BiomarkerKG1550315666"
"954","CARBOPLATIN, PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","DB00958,DB01229,DB00072,DB06366","56840877, 36314, 3001322, NA","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02436993","BiomarkerKG-221541130"
"955","EVEROLIMUS, ERIBULIN","DB01590,DB08871","6442177, 17755248","ERBB2, ESR1, PGR, PI3K","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","Protein Expression, Protein Expression, Protein Expression, Mutation/Protein Expression/Amplification","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PI3K MUTATION/PROTEIN EXPRESSION/AMPLIFICATION POSITIVE/NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02616848","BiomarkerKG996988757"
"956","VINORELBINE, DDP","DB00361,DB12117","5311497, 6918194","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02607215","BiomarkerKG-2037733918"
"958","PERTUZUMAB, TRASTUZUMAB, DOCETAXEL, PACLITAXEL, VINORELBINE, CAPECITABINE, EXEMESTANE, RIBOCICLIB, FULVESTRANT, ANASTROZOLE, LETROZOLE, NAB-PACLITAXEL, ERIBULIN, LEUPRORELIN, GOSERELIN","DB06366,DB00072,DB01248,DB01229,DB00361,DB01101,DB00990,DB11730,DB00947,DB01217,DB01006,NA,DB08871,DB00007,DB00014","NA, 3001322, 148124, 36314, 5311497, 60953, 60198, 44631912, 104741, 2187, 3902, 36314, 17755248, 657181, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","HER2, HER2, UNK, UNK, UNK, UNK, UNK, CDK4/CDK6, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02344472","BiomarkerKG-608837041"
"961","EVEROLIMUS","DB01590","6442177","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02387099","BiomarkerKG-1029626634"
"963","PALBOCICLIB, TASELISIB, PICTILISIB","DB09073,DB12108,DB11663","11478676, 51001932, 17755052","PIK3CA, ESR1","ENSG00000121879, ENSG00000091831","Mutation, Protein Expression","Positive, Positive","AND","PIK3CA MUTATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","CDK4/CDK6, PI3K, PI3K","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02389842","BiomarkerKG590217804"
"964","PALBOCICLIB, TASELISIB, PICTILISIB","DB09073,DB12108,DB11663","11478676, 51001932, 17755052","PIK3CA, ESR1, ERBB2","ENSG00000121879, ENSG00000091831, ENSG00000141736","Mutation, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","PIK3CA MUTATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED BREAST CANCER","MONDO_0007254","CDK4/CDK6, PI3K, PI3K","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02389842","BiomarkerKG1113110042"
"965","PALBOCICLIB, TASELISIB, PICTILISIB","DB09073,DB12108,DB11663","11478676, 51001932, 17755052","ERBB2, ESR1, PGR, PIK3CA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","Protein Expression, Protein Expression, Protein Expression, Mutation","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PIK3CA MUTATION POSITIVE","ADVANCED TRIPLE NEGATIVE  BREAST CANCER","EFO_0005537","CDK4/CDK6, PI3K, PI3K","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02389842","BiomarkerKG-672908885"
"966","PALBOCICLIB, TASELISIB, PICTILISIB","DB09073,DB12108,DB11663","11478676, 51001932, 17755052","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","Protein Expression, Protein Expression","Positive, Negative","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","ADVANCED BREAST CANCER","MONDO_0007254","CDK4/CDK6, PI3K, PI3K","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02389842","BiomarkerKG-988141016"
"967","PALBOCICLIB, BICALUTAMIDE","DB09073,DB01128","11478676, 56069","ESR1, AR","ENSG00000091831, ENSG00000169083","Protein Expression, Protein Expression","Negative, Positive","AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02605486","BiomarkerKG1699519568"
"968","NAB-PACLITAXEL, ATEZOLIZUMAB","NA,DB11595","36314, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02425891","BiomarkerKG860581975"
"970","ABEMACICLIB, LOPERAMIDE, ANASTROZOLE","DB12001,DB00836,DB01217","46220502, 71421, 2187","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02441946","BiomarkerKG995467093"
"971","PEMBROLIZUMAB, CAPECITABINE, ERIBULIN, GEMCITABINE, VINORELBINE","DB09037,DB01101,DB08871,DB00441,DB00361","NA, 60953, 17755248, 60750, 5311497","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02555657","BiomarkerKG-682094159"
"972","GTX-024",NA,"11326715","ERBB2, ESR1, AR","ENSG00000141736, ENSG00000091831, ENSG00000169083","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02463032","BiomarkerKG1975043857"
"974","LEE011, LETROZOLE, TAMOXIFEN, FULVESTRANT, GOSERELIN","NA,DB01006,DB00675,DB00947,DB00014","44631912, 3902, 2733526, 104741, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02333370","BiomarkerKG507733816"
"976","PACLITAXEL, ALISERTIB","DB01229,DB05220","36314, 24771867","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02187991","BiomarkerKG-517147839"
"977","PACLITAXEL, ALISERTIB","DB01229,DB05220","36314, 24771867","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02187991","BiomarkerKG475536388"
"979","GEMCITABINE, TRASTUZUMAB, PERTUZUMAB","DB00441,DB00072,DB06366","60750, 3001322, NA","ERBB2","ENSG00000141736","Protein Expression&Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","METASTATIC  BREAST CANCER","EFO_1000984","UNK, HER2, HER2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02252887","BiomarkerKG1949044244"
"981","TRASTUZUMAB, PERTUZUMAB, DOCETAXEL, PACLITAXEL, NAB-PACLITAXEL, VINORELBINE, ERIBULIN, CAPECITABINE, GEMCITABINE","DB00072,DB06366,DB01248,DB01229,NA,DB00361,DB08871,DB01101,DB00441","3001322, NA, 148124, 36314, 36314, 5311497, 17755248, 60953, 60750","ERBB2","ENSG00000141736","Protein Expression&Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, HER2/HER3, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02514681","BiomarkerKG-1756957814"
"982","ATORVASTATIN","DB01076","60823","Ki67, TAZ","ENSG00000148773, ENSG00000102125","Protein Expression, Protein Expression","Positive, Positive","AND","KI67 PROTEIN EXPRESSION POSITIVE AND TAZ PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE I-IIA)","MONDO_0007254","TAZ","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02416427","BiomarkerKG-1478294987"
"984","POZIOTINIB","DB12114","25127713","ERBB2, EGFR, AR","ENSG00000141736, ENSG00000146648, ENSG00000169083","Mutation, Mutation/ Protein Expression & Amplification, Protein Epression","Positive, Positive, Positive","OR, OR","ERBB2 MUTATION POSITIVE OR EGFR MUTATION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE OR AR PROTEIN EPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02544997","BiomarkerKG-779000115"
"985","AZD2014, PALBOCICLIB, FULVESTRANT","NA,DB09073,DB00947","25262792, 11478676, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, CDK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02599714","BiomarkerKG-834016006"
"986","PALBOCICLIB, TRASTUZUMAB, ENDOCRINE THERAPY","DB09073,DB00072,NA","11478676, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02448420","BiomarkerKG488938447"
"990","5-FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, TRASTUZUMAB, PERTUZUMAB, CARBOPLATIN","DB00544,DB00445,DB00531,DB01248,DB00072,DB06366,DB00958","3385, 65348, 2907, 148124, 3001322, NA, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02339532","BiomarkerKG-426186071"
"992","EPIRUBICIN, CYCLOPHOSPHAMIDE","DB00445,DB00531","65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Postitive, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02549677","BiomarkerKG-887972557"
"994","PALBOCICLIB, FULVESTRANT, TAMOXIFEN, AROMATASE INHIBITOR","DB09073,DB00947,DB00675,NA","11478676, 104741, 2733526, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, Aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02630693","BiomarkerKG50269839"
"995","IPATASERTIB, PACLITAXEL","DB11743,DB01229","24788740, 36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER (IA-IIIA)","EFO_0005537","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02301988","BiomarkerKG-1515344029"
"996","CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB","DB00958,DB00531,DB01248,DB00997,DB01229,DB00072","56840877, 2907, 148124, 443939, 36314, 3001322","ERBB2","ENSG00000141736","Protein Expression&Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-IIIA)","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02419742","BiomarkerKG748789283"
"997","PACLITAXEL, CARBOPLATIN, ASLAN001","DB01229,DB00958,NA","36314, 56840877, 42642648","ERBB2","ENSG00000141736","Protein Expression&Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","BREAST CANCER (STAGE I-III)","MONDO_0007254","UNK, UNK, HER2/HER1/HER4","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02396108","BiomarkerKG396026660"
"1000","DOCETAXEL, TRASTUZUMAB, CARBOPLATIN","DB01248,DB00072,DB00958","148124, 3001322, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INVASIVE BREAST CANCER (II-III)","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02510781","BiomarkerKG594850092"
"1002","ROMIDEPSIN, CISPLATIN, NIVOLUMAB","DB06176,DB00515,DB09035","5352062, 135804801, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","STAGE III-IV TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02393794","BiomarkerKG-701006262"
"1003","ROMIDEPSIN, CISPLATIN, NIVOLUMAB","DB06176,DB00515,DB09035","5352062, 135804801, NA","BRCA1, BRCA2","ENSG00000012048, ENSG00000139618","Mutation, Mutation","Positive, Positive","OR","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","BREAST CANCER (STAGE III-IV)","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02393794","BiomarkerKG1402571616"
"1005","NIVOLUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, CISPLATIN","DB09035,DB00997,DB00531,DB00515","NA, 443939, 2907, 135804801","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02499367","BiomarkerKG-1967796883"
"1006","TAMOXIFEN, ANASTROZOLE, FULVESTRANT","DB00675,DB01217,DB00947","2733526, 2187, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02206984","BiomarkerKG-2059289397"
"1007","TAXANE, CARBOPLATIN","NA,DB00958","9548828, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE INVASIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02441933","BiomarkerKG-1060645712"
"1008","PEMBROLIZUMAB","DB09037",NA,"ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02447003","BiomarkerKG-174862049"
"1011","TRASTUZUMAB, NON-PEGYLATED LIPOSOMAL DOXORUBICIN","DB00072,NA","3001322, NA","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02562378","BiomarkerKG447144522"
"1012","FULVESTRANT","DB00947","104741","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02646735","BiomarkerKG-392050454"
"1013","EPIRUBICIN, CYCLOPHOSPHAMIDE, TAXANES, CARBOPLATIN","DB00445,DB00531,NA,DB00958","65348, 2907, NA, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02455141","BiomarkerKG-1556230322"
"1014","GOSERELIN, TAM, AI","DB00014,NA,NA","5311128, 1983, 53697","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02535221","BiomarkerKG-1428186891"
"1015","ANASTROZOLE, GOSERELIN","DB01217,DB00014","2187, 5311128","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","INVASIVE BREAST CANCER","EFO_1000307","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02440230","BiomarkerKG1386388611"
"1016","GDC-0927","DB14934","87055263","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02316509","BiomarkerKG-785904201"
"1017","GDC-0810","DB12253","56941241","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02569801","BiomarkerKG1016537772"
"1022","CYCLOPHOSPHAMIDE, CYTOKINE-BASED BIOLOGIC AGENT IRX-2, NIVOLUMAB","DB00531,NA,DB09035","2907, NA, NA","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","RECURRENT OR METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0000702","UNK, UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03655002","BiomarkerKG2139946516"
"1024","ANLOTINIB HYDROCHLORIDE",NA,"57380530","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","VEGFR, FGFR, PDGFR, CKIT","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT04213118","BiomarkerKG-1142743362"
"1025","COLCHICINE","DB01394","6167","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA (IIIB-IV)","EFO_0000707","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT04264260","BiomarkerKG2027096547"
"1036","PRAVASTATIN","DB00175","16759173","AFP","ENSG00000081051","Protein Expression","Positive/Negative",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03219372","BiomarkerKG683286200"
"1037","APATINIB","DB14765","45139106","VEGF, AFP","ENSG00000112715, ENSG00000081051","Protein Expression, Protein Expression","Positive, Positive","AND","VEGF PROTEIN EXPRESSION POSITIVE AND AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","VEGFR","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03511703","BiomarkerKG440468617"
"1073","ATG-008",NA,"58298316","HBV","ENSG00000112773","missing","Positive",NA,"HBV MISSING POSITIVE","ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03591965","BiomarkerKG329189688"
"1075","DERAZANTINIB","DB14889","46834118","FGFR2","ENSG00000066468","mutation/gene fusion/amplification","Positive",NA,"FGFR2 MUTATION/GENE FUSION/AMPLIFICATION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03230318","BiomarkerKG1352760165"
"1077","RAMUCIRUMAB, MEDI4736","DB05578,NA","NA, NA","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02572687","BiomarkerKG1751026797"
"1082","SORAFENIB","DB00398","406563","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03178656","BiomarkerKG-1685288106"
"1100","BAVITUXIMAB, SORAFENIB","DB05136,DB00398","NA, 406563","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARINOMA","EFO_0009709","UNK/UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01264705","BiomarkerKG626426273"
"1101","PD-0332991",NA,"5330286","RB","ENSG00000139687","Protein Expression","Positive",NA,"RB PROTEIN EXPRESSION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","CDK4/CDK6","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01356628","BiomarkerKG-1504368928"
"1103","LENALIDOMIDE","DB00480","216326","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01545804","BiomarkerKG-1815733615"
"1104","BEVACIZUMAB, ERLOTINIB","DB00112,DB00530","NA, 176871","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED LIVER CANCER","MONDO_0002691","VEGF, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01180959","BiomarkerKG-61478009"
"1106","AXITINIB","DB06626","6450551","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0000702","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01334112","BiomarkerKG1400964458"
"1107","EVEROLIMUS, PASIREOTIDE","DB01590,DB06663","6442177, 9941444","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01488487","BiomarkerKG936726893"
"1108","SORAFENIB, E7050","DB00398,NA","406563, 16118392","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HCC","EFO_0009709","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01271504","BiomarkerKG-595661003"
"1109","ADI-PEG 20","DB06592",NA,"Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01287585","BiomarkerKG-1250742185"
"1110","TYROSERLEUTIDE, MITOMYCIN, FLUOROURACIL","NA,DB00305,DB00544","10045387, 5746, 3385","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01489566","BiomarkerKG223828977"
"1114","TS-1, OXALIPLATIN","NA,DB00526","5386, 5310940","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01429961","BiomarkerKG-1086386656"
"1116","S-1, LEUCOVORIN","NA,DB00650","5462310, 135403647","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01533324","BiomarkerKG-1960843667"
"1119","ETHIODIZED OIL, DOXORUBICIN","DB00965,DB00997","NA, 443939","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01966133","BiomarkerKG912675784"
"1121","PRAVASTATIN, SORAFENIB","DB00175,DB00398","16759173, 406563","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01418729","BiomarkerKG-1583497180"
"1124","SORAFENIB TOSYLATE, VORINOSTAT","NA,DB02546","406563, 5311","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260",NA,"pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01075113","BiomarkerKG1436097858"
"1169","ASLAN001",NA,"42642648","HER3","ENSG00000065361","Protein Expression","Positive",NA,"HER3 PROTEIN EXPRESSION POSITIVE","METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0000702","EGFR/HER2/HER4","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03499626","BiomarkerKG1088441413"
"1208","APATINIB, SHR-1210","DB14765,NA","45139106, NA","AFP","ENSG00000081051","Protein Expression","neagative",NA,"AFP PROTEIN EXPRESSION NEAGATIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","VEGFR2, PD1","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03722875","BiomarkerKG76141553"
"1212","RAMUCIRUMAB","DB05578",NA,"AFP","ENSG00000081051","Protein expression","positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02435433","BiomarkerKG-2114961874"
"1213","GALUNISERTIB, NIVOLUMAB","DB11911,DB09035","10090485, NA","AFP","ENSG00000081051","Protein expression","positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","RECURRENT HEPATOCELLULAR CARCINOMA","EFO_0000707","Growth Factor-beta Receptor I Kinase, PD1","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02423343","BiomarkerKG1273878690"
"1216","FISOGATINIB",NA,"91885617","FGF19","ENSG00000162344","protein expression","positive/negative",NA,"FGF19 PROTEIN EXPRESSION POSITIVE/NEGATIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02508467","BiomarkerKG901214447"
"1224","ERDAFITINIB","DB12147","67462786","FGF19","ENSG00000162344","Protein expression&amplification","positive",NA,"FGF19 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02421185","BiomarkerKG320452314"
"1225","OXALIPLATIN, 5-FLUOROURACIL","DB00526,DB00544","5310940, 3385","AFP","ENSG00000081051","Protein expression","positve/negative",NA,"AFP PROTEIN EXPRESSION POSITVE/NEGATIVE","EARLY STAGE HEPATOCELLULAR CARCINOMA","EFO_0001663","UNK, UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02767375","BiomarkerKG-1047036954"
"1241","APATINIB","DB14765","45139106","AFP","ENSG00000081051","Protein expression","positive/negative",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED HEPATOCELLULAR CANCER","EFO_0000311","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03046979","BiomarkerKG1160551452"
"1242","PEMBROLIZUMAB","DB09037",NA,"AFP","ENSG00000081051","Protein expression","positive/negative",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED HEPATOCELLULAR CANCER","EFO_0000311","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02658019","BiomarkerKG1309435194"
"1253",NA,NA,"56956252","Annexin 2","ENSG00000182718","protein expression","positive",NA,"ANNEXIN 2 PROTEIN EXPRESSION POSITIVE","LUMINAL B AND HER2 BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32072035","BiomarkerKG-492740312"
"1254",NA,NA,"56956252","SLX4IP","ENSG00000149346","protein expression","SLX4IP positive",NA,"SLX4IP PROTEIN EXPRESSION SLX4IP POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32071280","BiomarkerKG-506374504"
"1255",NA,NA,"56956252","FUT3","ENSG00000171124","protein expression","high FUT3 levels",NA,"FUT3 PROTEIN EXPRESSION HIGH FUT3 LEVELS","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32062822","BiomarkerKG-1087636326"
"1257",NA,NA,"56956252","DEGS","ENSG00000143753","gene expression","positive",NA,"DEGS GENE EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32044879","BiomarkerKG-1002930887"
"1260",NA,NA,"56956252","TFF1","ENSG00000160182","protein expression","TFF1 overexpression",NA,"TFF1 PROTEIN EXPRESSION TFF1 OVEREXPRESSION","BREAST CANCER，TNBC,NON-TNBC","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31986408","BiomarkerKG-1373908122"
"1262",NA,NA,"56956252","TP53","ENSG00000141510","gene expression","TP53 deficiency or silence",NA,"TP53 GENE EXPRESSION TP53 DEFICIENCY OR SILENCE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31983017","BiomarkerKG2043192179"
"1267",NA,NA,"56956252","Twist","ENSG00000122691","gene expression","Twist overexpression",NA,"TWIST GENE EXPRESSION TWIST OVEREXPRESSION","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31942413","BiomarkerKG113594126"
"1275",NA,NA,"56956252","PPEF 1","ENSG00000086717","protein expression","positive",NA,"PPEF 1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32021267","BiomarkerKG1357281616"
"1276",NA,NA,"56956252","TP53TG1，Rp5-1061H20.4","ENSG00000182165, NA","gene expression, gene expression,","positive, positive","AND","TP53TG1 GENE EXPRESSION POSITIVE AND RP5-1061H20.4 GENE EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32020607","BiomarkerKG-2106662271"
"1281",NA,NA,"56956252","XIST，TSIX","ENSG00000229807, ENSG00000270641","gene expression, gene expression,","positive, positive","MISSING","XIST GENE EXPRESSION POSITIVE MISSING TSIX GENE EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31998636","BiomarkerKG651118600"
"1282",NA,NA,"56956252","BRCA1, BRCA2","ENSG00000012048, ENSG00000139618","mutation,mutation","positive, positive","OR","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31998560","BiomarkerKG-781343040"
"1285",NA,NA,"56956252","ESR1, PGR, ERBB2, Exo-AnxA 2","ENSG00000091831, ENSG00000082175, ENSG00000141736, NA","protein expression，protein expression, protein expression, protein expression","negative, negative, negative, positive","AND,AND,AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND EXO-ANXA 2 PROTEIN EXPRESSION POSITIVE","TRIPLE-NEGATIVE BREAST CANCER","EFO_0005537",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31992335","BiomarkerKG-840188861"
"1286",NA,NA,"56956252","ZNF367","ENSG00000165244","gene expression","positive",NA,"ZNF367 GENE EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31988454","BiomarkerKG-2015067218"
"1289",NA,NA,"56956252","LINC01140","ENSG00000267272","lncRNA","LINC01140 
overexpression",NA,"LINC01140 LNCRNA LINC01140 
OVEREXPRESSION","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31966045","BiomarkerKG-599220431"
"1304","BEVACIZUMAB","DB00112",NA,"HSP27","ENSG00000169271","protein expression",NA,NA,"HSP27 PROTEIN EXPRESSION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31989465","BiomarkerKG-658537557"
"1309",NA,NA,"56956252","ESR1, PGR, ERBB2, BRCA","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000012048","protein expression, protein expression, protein expression, mutation","negative, negative, negative, positive","MISSING, MISSING, MISSING","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE MISSING BRCA MUTATION POSITIVE","TRIPLE-NEGATIVE BREAST CANCER","EFO_0005537",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32052646","BiomarkerKG2095131510"
"1312",NA,NA,"56956252","BRCA","ENSG00000012048","mutation","positive",NA,"BRCA MUTATION POSITIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32013831","BiomarkerKG-326378391"
"1313","CAPECITABINE","DB01101","60953","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression, protein expression, protein expression","negative, negative, negative,","MISSING, MISSING","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","32005747","BiomarkerKG1610831866"
"1314","TAMOXIFEN","DB00675","2733526","SPP1,
OPN","ENSG00000118785, ENSG00000118785","gene expression, protein expression","positive, positive","OR","SPP1 GENE EXPRESSION POSITIVE OR OPN PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31996744","BiomarkerKG-186936700"
"1318","TRASTUZUMAB","DB00072","3001322","ERBB2, CA15.3,
CEA","ENSG00000141736, NA, ENSG00000105388","protein expression, protein expression, protein expression","positive, positive, positive,","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND CA15.3 PROTEIN EXPRESSION POSITIVE AND CEA PROTEIN EXPRESSION POSITIVE","HER2-POSITIVE METASTATIC BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31910438","BiomarkerKG-1070545292"
"1321","CHOLECALCIFEROL, TAMOXIFEN","DB00169,DB00675","5280795, 2733526","VEGF-A, Ang-2,
Hif-1, high-sensitivity C-reactive protein ","ENSG00000112715, ENSG00000091879, ENSG00000168209, NA","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","AND, AND, AND","VEGF-A PROTEIN EXPRESSION POSITIVE AND ANG-2 PROTEIN EXPRESSION POSITIVE AND HIF-1 PROTEIN EXPRESSION POSITIVE AND HIGH-SENSITIVITY C-REACTIVE PROTEIN PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31901710","BiomarkerKG424191494"
"1328","BAY 1125976",NA,"70817911","AKT","ENSG00000166971","mutation","positive",NA,"AKT MUTATION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31835495","BiomarkerKG-1256644265"
"1330","PALBOCICLIB, RIBOCICLIB, ABEMACICLIB","DB09073,DB11730,DB12001","11478676, 44631912, 46220502","CDK4, CDK6","ENSG00000135446, ENSG00000105810","protein expression, protein expression","positive, positive","AND","CDK4 PROTEIN EXPRESSION POSITIVE AND CDK6 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","CDK4/6","pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31777590","BiomarkerKG-1535801388"
"1331","NAPABUCASIN, TAMOXIFEN","DB12155,DB00675","10331844, 2733526","ESR1","ENSG00000091831","protein expression","positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31760402","BiomarkerKG-2145370017"
"1333","PEMBROLIZUMAB","DB09037",NA,"ESR1, PGR, ERBB2, PD-L1","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000120217","protein expression, protein expression,  protein expression, protein expression","negative, negative, negative, positive","MISSING, MISSING, MISSING","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE MISSING PD-L1 PROTEIN EXPRESSION POSITIVE","METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31747077","BiomarkerKG-502295530"
"1341","ATEZOLIZUMAB, NABPACLITAXEL","DB11595,NA","NA, NA","ESR1, PGR, ERBB2, PD-L1","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000120217","protein expression, protein expression, protein expression, protein expression","negative, negative, negative, positive","MISSING, MISSING, MISSING","ESR1 PROTEIN EXPRESSION NEGATIVE MISSING PGR PROTEIN EXPRESSION NEGATIVE MISSING ERBB2 PROTEIN EXPRESSION NEGATIVE MISSING PD-L1 PROTEIN EXPRESSION POSITIVE","METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31612573","BiomarkerKG-1083866288"
"1347","NIRAPARIB, PEMBROLIZUMAB","DB11793,DB09037","24958200, NA","BRCA","ENSG00000012048","mutation","positive",NA,"BRCA MUTATION POSITIVE","ADVANCED TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31194225","BiomarkerKG1414704644"
"1348",NA,NA,"56956252","Ki-67, p53,BCL-2","ENSG00000148773, ENSG00000141510, ENSG00000171791","protein expression,   protein expression, protein expression","positive,positive,positive","AND,AND","KI-67 PROTEIN EXPRESSION POSITIVE AND P53 PROTEIN EXPRESSION POSITIVE AND BCL-2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31289309","BiomarkerKG2092098073"
"1349",NA,NA,"56956252","EphB1,EphB2,EphB3, 
EphB4, EphB6","ENSG00000154928, ENSG00000133216, ENSG00000182580, ENSG00000196411, ENSG00000106123","protein expression, protein expression, protein expression, protein expression, protein expression","positive,
positive, positive, positive, positive","OR,OR,OR,OR","EPHB1 PROTEIN EXPRESSION POSITIVE OR EPHB2 PROTEIN EXPRESSION POSITIVE OR EPHB3 PROTEIN EXPRESSION POSITIVE OR EPHB4 PROTEIN EXPRESSION POSITIVE OR EPHB6 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31289549","BiomarkerKG1828007033"
"1351","CARBOPLATIN, CISPLATIN, OXALIPLATIN","DB00958,DB00515,DB00526","56840877, 135804801, 71301229","BRCA1, BRCA2, p53, p63, p73","ENSG00000012048, ENSG00000139618, ENSG00000141510, ENSG00000073282, ENSG00000078900","gene mutation, gene mutation, protein expression, protein expression, protein expression","positive,positive, positive, positive, positive","OR,AND, OR, OR","BRCA1 GENE MUTATION POSITIVE OR BRCA2 GENE MUTATION POSITIVE AND P53 PROTEIN EXPRESSION POSITIVE OR P63 PROTEIN EXPRESSION POSITIVE OR P73 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31295913","BiomarkerKG-34819425"
"1352",NA,NA,"56956252","PIK3CA","ENSG00000121879","gene mutation","positive",NA,"PIK3CA GENE MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31297647","BiomarkerKG-1006830416"
"1362","ESTROGEN, PROGESTERONE","NA,DB00396","448537, 5994","ESR1, PGR,ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression, protein expression, protein expression","positive, positive, positive","OR,OR","ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","human epidermal growth factor 2 receptors","pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31319941","BiomarkerKG2054558038"
"1365",NA,NA,"56956252","ALDH1A3, CD44+/CD24-, ITGA6,PROCR
","ENSG00000184254, NA, ENSG00000091409, ENSG00000101000","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","OR,OR,OR","ALDH1A3 PROTEIN EXPRESSION POSITIVE OR CD44+/CD24- PROTEIN EXPRESSION POSITIVE OR ITGA6 PROTEIN EXPRESSION POSITIVE OR PROCR PROTEIN EXPRESSION POSITIVE","T1-3, N0 BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31340763","BiomarkerKG-1921139321"
"1366",NA,NA,"56956252","ER,PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression","positive, positive, positive","OR,OR","ER PROTEIN EXPRESSION POSITIVE OR PR PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31348505","BiomarkerKG1575293218"
"1369",NA,NA,"56956252","Ki-67, ERBB2, H-MRS","ENSG00000148773, ENSG00000141736, NA","protein expression, protein expression, others","positive, positive, positive","OR,OR","KI-67 PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION POSITIVE OR H-MRS OTHERS POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31356383","BiomarkerKG-460484177"
"1370",NA,NA,"56956252","uPA,uPAR,PAI-1,PAI-2","ENSG00000122861, ENSG00000011422, ENSG00000106366, ENSG00000197632","protein expression, protein expression, protein expression, protein expression,","positive, positive, positive, positive","AND,AND,AND","UPA PROTEIN EXPRESSION POSITIVE AND UPAR PROTEIN EXPRESSION POSITIVE AND PAI-1 PROTEIN EXPRESSION POSITIVE AND PAI-2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31359505","BiomarkerKG-62292183"
"1374",NA,NA,"56956252","ESR1,ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression","positive, positive","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31385051","BiomarkerKG-184767054"
"1376",NA,NA,"56956252","FOXM1","ENSG00000111206","protein expression","positive",NA,"FOXM1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31391072","BiomarkerKG-1426230905"
"1383",NA,NA,"56956252","IL-6,CRP
","ENSG00000136244, ENSG00000132693","protein expression, protein expression
","positive, positive","OR
","IL-6 PROTEIN EXPRESSION POSITIVE OR CRP PROTEIN EXPRESSION POSITIVE","CHRONIC LOW-GRADE
INFLAMMATION AND CANCER.","MONDO_0016680",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31414667","BiomarkerKG-151376875"
"1386","DOXORUBICIN","DB00997","443939","CDK1, CCNA2, TOP2A, CCNB1, KIF11, MELK","ENSG00000170312, ENSG00000145386, ENSG00000131747, ENSG00000134057, ENSG00000138160, ENSG00000165304","gene expression, gene expression, gene expression, gene expression, gene expression,gene expression","positive, positive, positive, positive, positive, positive","OR,OR,OR,OR,OR","CDK1 GENE EXPRESSION POSITIVE OR CCNA2 GENE EXPRESSION POSITIVE OR TOP2A GENE EXPRESSION POSITIVE OR CCNB1 GENE EXPRESSION POSITIVE OR KIF11 GENE EXPRESSION POSITIVE OR MELK GENE EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31428132","BiomarkerKG-1487953606"
"1390",NA,NA,"56956252","CRP,HbA1c","ENSG00000132693, NA","protein expression, protein expression","positive, positive","AND","CRP PROTEIN EXPRESSION POSITIVE AND HBA1C PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31443226","BiomarkerKG-1525789734"
"1395",NA,NA,"56956252","MSH2, MSH6 ,MLH1,PMS2","ENSG00000095002, ENSG00000116062, ENSG00000076242, ENSG00000122512","gene expression, gene expression, gene expression,gene expression","negative, negative, negative, negative","OR,OR,OR","MSH2 GENE EXPRESSION NEGATIVE OR MSH6 GENE EXPRESSION NEGATIVE OR MLH1 GENE EXPRESSION NEGATIVE OR PMS2 GENE EXPRESSION NEGATIVE","BREAST CANCER:","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31522348","BiomarkerKG-390420793"
"1398","CAPIVASERTIB","DB12218","25227436","ESR1, pPRAS40, pGSK3β, Ki6","ENSG00000091831, NA, NA, NA","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","AND, OR,OR","ESR1 PROTEIN EXPRESSION POSITIVE AND PPRAS40 PROTEIN EXPRESSION POSITIVE OR PGSK3Β PROTEIN EXPRESSION POSITIVE OR KI6 PROTEIN EXPRESSION POSITIVE","ER+ INVASIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31836609","BiomarkerKG645678037"
"1399","CAPIVASERTIB, PACLITAXEL","DB12218,DB01229","25227436, 36314","ESR1, ERBB2, PIK3CA","ENSG00000091831, ENSG00000141736, ENSG00000121879","protein expression, protein expression, mutation","positive, negative, positive","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND PIK3CA MUTATION POSITIVE","ESTROGEN RECEPTOR-POSITIVE ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","30860570","BiomarkerKG50578849"
"1406",NA,NA,"56956252","ERBB2,ESR1, RB1","ENSG00000141736, ENSG00000091831, ENSG00000139687","protein expression, protein expression, protein expression","negative, negative, negative","AND,AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND RB1 PROTEIN EXPRESSION NEGATIVE","HER2-POSITIVE, ER-POSITIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","29326029","BiomarkerKG-662307732"
"1407","RAD001",NA,"6442177","mTOR","ENSG00000198793","protein expression",NA,NA,"MTOR PROTEIN EXPRESSION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","20941539","BiomarkerKG319407186"
"1408","LAPATINIB","DB01259","208908","Ki67,HER-3, FOXO3a, FOXM1, p-AKT","ENSG00000148773, NA, ENSG00000118689, ENSG00000111206, NA","protein expression, protein expression, protein expression, protein expression,  protein expression","negative, negative, negative,  negative,  negative","OR,OR,OR,OR","KI67 PROTEIN EXPRESSION NEGATIVE OR HER-3 PROTEIN EXPRESSION NEGATIVE OR FOXO3A PROTEIN EXPRESSION NEGATIVE OR FOXM1 PROTEIN EXPRESSION NEGATIVE OR P-AKT PROTEIN EXPRESSION NEGATIVE","HER-2-NEGATIVE EARLY BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","23233650","BiomarkerKG-1720524945"
"1409","MK-2206",NA,"24964624","PIK3CA, AKT","ENSG00000121879, ENSG00000166971","geneexpression, protein expression","positive, positive","OR","PIK3CA GENEEXPRESSION POSITIVE OR AKT PROTEIN EXPRESSION POSITIVE","ER-POSITIVE AND HER2-NEGATIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","28874413","BiomarkerKG423045398"
"1413",NA,NA,"56956252","Ki67,ERBB2","ENSG00000148773, ENSG00000141736","protein expression, protein expression","positive, negative","OR","KI67 PROTEIN EXPRESSION POSITIVE OR ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31570566","BiomarkerKG946377791"
"1416","LAPATINIB","DB01259","208908","EGFR,HER2,Ki67,PTEN","ENSG00000146648, ENSG00000141736, ENSG00000148773, ENSG00000171862","protein expression, protein expression, protein expression, protein expression","positive, positive, positive, positive","AND,AND, AND","EGFR PROTEIN EXPRESSION POSITIVE AND HER2 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE AND PTEN PROTEIN EXPRESSION POSITIVE","HER-2-POSITIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","21685235","BiomarkerKG878384404"
"1417","EVEROLIMUS, TRASTUZUMAB","DB01590,DB00072","6442177, 3001322","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression, protein expression, protein expression","negative, negative, positive","AND/OR, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE","HER2-POSITIVE ADVANCED BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","26092818","BiomarkerKG-335517957"
"1418","BEVACIZUMAB","DB00112",NA,"
VEGF-A
","ENSG00000112715","
protein expression
","positive",NA,"VEGF-A PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31564802","BiomarkerKG286515678"
"1420",NA,NA,"56956252","miRNA","ENSG00000037897","gene expression","positive",NA,"MIRNA GENE EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31549595","BiomarkerKG1449458760"
"1421","CABOZANTINIB, TRASTUZUMAB","DB08875,DB00072","25102846, 3001322","VEGFR 2","ENSG00000165197","protein expression","positive",NA,"VEGFR 2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER BRAIN METASTASES (BCBM)","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31541381","BiomarkerKG-338123991"
"1422",NA,NA,"56956252","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression,protein expression,protein expression","negative, negative, negative","AND,AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER (TNBC)","EFO_0005537",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31536530","BiomarkerKG-830123578"
"1423","TAXANE, ANTHRACYCLINE","NA,NA","9548828, NA","ERBB2, CA12, FOXA1,
MLPH, XBP1,
GATA3, MAGED 2","ENSG00000141736, ENSG00000074410, ENSG00000129514, ENSG00000115648, ENSG00000100219, ENSG00000107485, NA","protein expression,  gene expression, gene expression, gene expression, gene expression, gene expression, gene expression","positive, positive, positive, positive, positive, positive, positive","AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR,","ERBB2 PROTEIN EXPRESSION POSITIVE AND CA12 GENE EXPRESSION POSITIVE AND/OR FOXA1 GENE EXPRESSION POSITIVE AND/OR MLPH GENE EXPRESSION POSITIVE AND/OR XBP1 GENE EXPRESSION POSITIVE AND/OR GATA3 GENE EXPRESSION POSITIVE AND/OR MAGED 2 GENE EXPRESSION POSITIVE","HER2-NEGATIVE BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31534839","BiomarkerKG1803961314"
"1425",NA,NA,"56956252","
SNP","ENSG00000145901","
polymorphism","positive",NA,"SNP POLYMORPHISM POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31519601","BiomarkerKG91698316"
"1426","ADRIAMYCIN",NA,"443939","p53, miR-30c,
FANCF, REV1","ENSG00000141510, NA, ENSG00000183161, ENSG00000135945","mutation, gene expression,
protein expression, protein expression","positive, positive, positive, positive","AND,AND,AND","P53 MUTATION POSITIVE AND MIR-30C GENE EXPRESSION POSITIVE AND FANCF PROTEIN EXPRESSION POSITIVE AND REV1 PROTEIN EXPRESSION POSITIVE","P53-MUTATED BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31511498","BiomarkerKG-719443513"
"1427","TAMOXIFEN","DB00675","2733526","ESR1, PGR","ENSG00000091831, ENSG00000082175","protein expression, protein expression","positive,positive","AND/OR,","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31504126","BiomarkerKG1867096133"
"1433",NA,NA,"56956252","SLCO1B3","ENSG00000111700","mutation",NA,NA,"SLCO1B3 MUTATION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31434449","BiomarkerKG869601495"
"1438",NA,NA,"56956252","PD-1","ENSG00000265681","protein expression",NA,NA,"PD-1 PROTEIN EXPRESSION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31357142","BiomarkerKG-1299119812"
"1441","EVEROLIMUS, EXEMESTANE","DB01590,DB00990","6442177, 60198","SP-D, YKL-40","ENSG00000133661, ENSG00000133048","protein expression, protein expression","positive, positive,","AND/OR","SP-D PROTEIN EXPRESSION POSITIVE AND/OR YKL-40 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31325105","BiomarkerKG1786719160"
"1445","TRASTUZUMAB","DB00072","3001322","ERBB2, TGFBI","ENSG00000141736, ENSG00000120708","protein expression & amplification, methylation","positive,positive","AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND TGFBI METHYLATION POSITIVE","HER2+ BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-031420-v5.xlsx","PubMed","31277676","BiomarkerKG-361482268"
"1450",NA,NA,"56956252","ACVR2B-As1","ENSG00000229589","RNA",NA,NA,"ACVR2B-AS1 RNA NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31886217","BiomarkerKG154384678"
"1451",NA,NA,"56956252","MAST2","ENSG00000086015","expression",NA,NA,"MAST2 EXPRESSION NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31882722","BiomarkerKG-168066390"
"1453",NA,NA,"56956252","IL13RA2","ENSG00000123496","expression",NA,NA,"IL13RA2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31823484","BiomarkerKG-1288207342"
"1454",NA,NA,"56956252","PES1","ENSG00000100029","expression",NA,NA,"PES1 EXPRESSION NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31814761","BiomarkerKG1940197675"
"1455",NA,NA,"56956252","CXCL9","ENSG00000138755","expression",NA,NA,"CXCL9 EXPRESSION NA","INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_1001961",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31799781","BiomarkerKG-12999463"
"1458",NA,NA,"56956252","LARP4B","ENSG00000107929","expression",NA,NA,"LARP4B EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31772683","BiomarkerKG-1515924469"
"1459",NA,NA,"56956252","PAR2","ENSG00000164251","expression",NA,NA,"PAR2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31768188","BiomarkerKG-161379523"
"1464",NA,NA,"56956252","CTHRC1","ENSG00000164932","expression",NA,NA,"CTHRC1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31576140","BiomarkerKG-662738514"
"1465",NA,NA,"56956252","CDCA5","ENSG00000146670","expression",NA,NA,"CDCA5 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30497429","BiomarkerKG-1944539337"
"1468",NA,NA,"56956252","HOXD8","ENSG00000175879","expression",NA,NA,"HOXD8 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30941968","BiomarkerKG417577166"
"1469",NA,NA,"56956252","OGDHL","ENSG00000197444","expression/methylation",NA,NA,"OGDHL EXPRESSION/METHYLATION NA","HEPATOCELLULAR CARCINOMA,HEPATOBLASTOMA","EFO_0000707",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31899205","BiomarkerKG-225852284"
"1471",NA,NA,"56956252","UBE2Z","ENSG00000159202","expression",NA,NA,"UBE2Z EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31831168","BiomarkerKG-1484584069"
"1472",NA,NA,"56956252","APOF","ENSG00000175336","expression",NA,NA,"APOF EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31687155","BiomarkerKG919668225"
"1473",NA,NA,"56956252","AKR1B10","ENSG00000198074","serum-level",NA,NA,"AKR1B10 SERUM-LEVEL NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31495535","BiomarkerKG1324516082"
"1474","CISPLATIN","DB00515","135804801","CSF3R","ENSG00000119535","DNA hypermethylation",NA,NA,"CSF3R DNA HYPERMETHYLATION NA","HEPATOBLASTOMA","EFO_1000292",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31894653","BiomarkerKG486191762"
"1476",NA,NA,"56956252","MFAP5","ENSG00000197614","expression",NA,NA,"MFAP5 EXPRESSION NA","INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_1001961",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31775892","BiomarkerKG-1427000489"
"1480","SORAFENIB","DB00398","406563","KPNA3","ENSG00000102753","expression",NA,NA,"KPNA3 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","Multikinase","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31417635","BiomarkerKG-2064357178"
"1481","SORAFENIB","DB00398","406563","BRMS1","ENSG00000174744","expression",NA,NA,"BRMS1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","Multikinase","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31233204","BiomarkerKG1670040668"
"1482","SORAFENIB","DB00398","406563","TARBP2","ENSG00000139546","expression",NA,NA,"TARBP2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","Multikinase","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30657254","BiomarkerKG1374680870"
"1485","ADRIAMYCIN",NA,"443939","YAP1","ENSG00000137693","expression",NA,NA,"YAP1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30111512","BiomarkerKG-766065006"
"1487",NA,NA,"56956252","ORM2","ENSG00000228278","expression",NA,NA,"ORM2 EXPRESSION NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32148378","BiomarkerKG1251373313"
"1494",NA,NA,"56956252","MAGEC2","ENSG00000046774","expression",NA,NA,"MAGEC2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31576142","BiomarkerKG1341892277"
"1495","GEMCITABINE","DB00441","60750","OCT_4","ENSG00000204531","expression",NA,NA,"OCT_4 EXPRESSION NA","CHOLANGIOCARCINOMA","EFO_0005221",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31554372","BiomarkerKG567844236"
"1502",NA,NA,"56956252","UBE2C","ENSG00000175063","expression",NA,NA,"UBE2C EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30914455","BiomarkerKG-899446018"
"1504",NA,NA,"56956252","CES2","ENSG00000172831","expression",NA,NA,"CES2 EXPRESSION NA","CHOLANGIOCARCINOMA","EFO_0005221",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30867471","BiomarkerKG110526552"
"1505",NA,NA,"56956252","DYRK2","ENSG00000127334","expression",NA,NA,"DYRK2 EXPRESSION NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30851422","BiomarkerKG1580755722"
"1506",NA,NA,"56956252","PTK2","ENSG00000169398","expression",NA,NA,"PTK2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30849480","BiomarkerKG8591460"
"1507",NA,NA,"56956252","B3GAT3","ENSG00000149541","expression",NA,NA,"B3GAT3 EXPRESSION NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30847403","BiomarkerKG-1275654331"
"1508",NA,NA,"56956252","FBXO22","ENSG00000167196","expression",NA,NA,"FBXO22 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30808376","BiomarkerKG1156174778"
"1511",NA,NA,"56956252","CDH1","ENSG00000039068","mRNA expression/methylation",NA,NA,"CDH1 MRNA EXPRESSION/METHYLATION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30697077","BiomarkerKG-192796611"
"1514","REGORAFENIB","DB08896","24768591","Pin1","ENSG00000127445","expression",NA,NA,"PIN1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30583078","BiomarkerKG1020446288"
"1515",NA,NA,"56956252","FBP1","ENSG00000165140","expression",NA,NA,"FBP1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30429463","BiomarkerKG-646212029"
"1516","GEMCITABINE","DB00441","60750","SOX9","ENSG00000125398","expression",NA,NA,"SOX9 EXPRESSION NA","INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_1001961",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30420613","BiomarkerKG1316138129"
"1520",NA,NA,"56956252","CD90","ENSG00000154096","expression",NA,NA,"CD90 EXPRESSION NA","INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_1001961",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30196535","BiomarkerKG-1296790552"
"1521",NA,NA,"56956252","S100A11","ENSG00000163191","expression",NA,NA,"S100A11 EXPRESSION NA","INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_1001961","P38","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30182496","BiomarkerKG-827273353"
"1522",NA,NA,"56956252","HUS1","ENSG00000136273","expression",NA,NA,"HUS1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","30182378","BiomarkerKG871129259"
"1523",NA,NA,"56956252","miR22","ENSG00000283824","expression",NA,NA,"MIR22 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32088997","BiomarkerKG-30204942"
"1528",NA,NA,"56956252","HMGA2","ENSG00000149948","expression",NA,NA,"HMGA2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31823639","BiomarkerKG1619172354"
"1531",NA,NA,"56956252","CDKN2B-AS1","ENSG00000240498","expression",NA,NA,"CDKN2B-AS1 EXPRESSION NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31646789","BiomarkerKG-945991805"
"1532",NA,NA,"56956252","CCAT2","ENSG00000280997","expression",NA,NA,"CCAT2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31626095","BiomarkerKG1828644422"
"1533",NA,NA,"56956252","CCT3","ENSG00000163468","proteinexpresson/serum-level",NA,NA,"CCT3 PROTEINEXPRESSON/SERUM-LEVEL NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","3150142","BiomarkerKG696259180"
"1534",NA,NA,"56956252","MAT2B","ENSG00000038274","expression",NA,NA,"MAT2B EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31493275","BiomarkerKG-369426826"
"1535",NA,NA,"56956252","CDHR5","ENSG00000099834","expression",NA,NA,"CDHR5 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31482521","BiomarkerKG-203547922"
"1541",NA,NA,"56956252","X91348","ENSG00000237517","RNA/expression",NA,NA,"X91348 RNA/EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31349749","BiomarkerKG1451964813"
"1542",NA,NA,"56956252","CHD1L","ENSG00000131778","expression",NA,NA,"CHD1L EXPRESSION NA","INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_1001961",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31173252","BiomarkerKG1241341764"
"1544",NA,NA,"56956252","TRMT6","ENSG00000089195","expression",NA,NA,"TRMT6 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31128068","BiomarkerKG-524093173"
"1546",NA,NA,"56956252","ZNF207","ENSG00000010244","protein expression",NA,NA,"ZNF207 PROTEIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31113916","BiomarkerKG406876872"
"1547",NA,NA,"56956252","SPG20","ENSG00000133104","methylation",NA,NA,"SPG20 METHYLATION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31109594","BiomarkerKG444423056"
"1548",NA,NA,"56956252","LINC01152","ENSG00000256124","RNA",NA,NA,"LINC01152 RNA NA","HBV-HEPATOCELLULAR CARCINOMA","EFO_0000707",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31054511","BiomarkerKG1167258547"
"1552",NA,NA,"56956252","RAB34","ENSG00000109113","DNA copy/protein expression",NA,NA,"RAB34 DNA COPY/PROTEIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","29048615","BiomarkerKG-390385391"
"1555",NA,NA,"56956252","c-Met","ENSG00000105976","expression",NA,NA,"C-MET EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31846974","BiomarkerKG-1283507248"
"1556",NA,NA,"56956252","P-glycoprotein","ENSG00000005471","protein expression",NA,NA,"P-GLYCOPROTEIN PROTEIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","8763260","BiomarkerKG1286286134"
"1557",NA,NA,"56956252","TGM3","ENSG00000125780","expression",NA,NA,"TGM3 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","31822388","BiomarkerKG-1413131417"
"1558",NA,NA,"56956252","nm23-H1","ENSG00000239672","expression",NA,NA,"NM23-H1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","7530600","BiomarkerKG-1246232541"
"1559",NA,NA,"56956252","CD15","ENSG00000177697","protein expression",NA,NA,"CD15 PROTEIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","7685236","BiomarkerKG-1820425488"
"1561",NA,NA,"56956252","CD80","ENSG00000121594","gene expression",NA,NA,"CD80 GENE EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","9141426","BiomarkerKG480087418"
"1562",NA,NA,"56956252","ANXA3","ENSG00000138772","expression",NA,NA,"ANXA3 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","24375474","BiomarkerKG-1762974481"
"1564",NA,NA,"56956252","UBE4B","ENSG00000130939","expression",NA,NA,"UBE4B EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25557723","BiomarkerKG1207145573"
"1565",NA,NA,"56956252","FVII","ENSG00000057593","expression",NA,NA,"FVII EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","27551480","BiomarkerKG1506989395"
"1568",NA,NA,"56956252","TLR4","ENSG00000136869","expression",NA,NA,"TLR4 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25511737","BiomarkerKG-712385602"
"1569",NA,NA,"56956252","MCT4","ENSG00000141526","expression",NA,NA,"MCT4 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25446815","BiomarkerKG-1954446592"
"1570","YM155",NA,"11178236","Survivin","ENSG00000089685","expression",NA,NA,"SURVIVIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","Survivin","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25714025","BiomarkerKG353778014"
"1572",NA,NA,"56956252","Kindlin-1","ENSG00000101311","RNA/protein expression",NA,NA,"KINDLIN-1 RNA/PROTEIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25592379","BiomarkerKG-1224639653"
"1573",NA,NA,"56956252","ADAM8","ENSG00000151651","expression",NA,NA,"ADAM8 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","ADAM8","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25585999","BiomarkerKG750763025"
"1574",NA,NA,"56956252","SQLE","ENSG00000104549","expression",NA,NA,"SQLE EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25787749","BiomarkerKG-89639372"
"1575","ASTEMIZOLE","DB00637","2247","Eag1","ENSG00000143473","expression",NA,NA,"EAG1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","Eag1","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25783527","BiomarkerKG1501550519"
"1576",NA,NA,"56956252","VEGF","ENSG00000112715","serum-level",NA,NA,"VEGF SERUM-LEVEL NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25862879","BiomarkerKG-1655115390"
"1577",NA,NA,"56956252","FGFR2","ENSG00000066468","expression",NA,NA,"FGFR2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25834803","BiomarkerKG-1644193225"
"1578",NA,NA,"56956252","FOXF2","ENSG00000137273","expression",NA,NA,"FOXF2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25824262","BiomarkerKG1183513313"
"1579",NA,NA,"56956252","SAMSN1","ENSG00000155307","expression",NA,NA,"SAMSN1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25805236","BiomarkerKG334670"
"1580",NA,NA,"56956252","PKM2","ENSG00000067225","expression",NA,NA,"PKM2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25788265","BiomarkerKG1761267966"
"1581",NA,NA,"56956252","Fascin","ENSG00000186765","expression",NA,NA,"FASCIN EXPRESSION NA","CHOLANGIOCARCINOMA","EFO_0005221",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25882880","BiomarkerKG-232580534"
"1582",NA,NA,"56956252","PTMA","ENSG00000187514","expression",NA,NA,"PTMA EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25865690","BiomarkerKG-1238700699"
"1583",NA,NA,"56956252","GPC3","ENSG00000147257","expression",NA,NA,"GPC3 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","25865688","BiomarkerKG-2073282015"
"1584",NA,NA,"56956252","K19","ENSG00000171345","expression",NA,NA,"K19 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26011233","BiomarkerKG539646965"
"1587",NA,NA,"56956252","AEG-1","ENSG00000147649","expression",NA,NA,"AEG-1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26035424","BiomarkerKG660717779"
"1590",NA,NA,"56956252","PCAT-1","ENSG00000253438","expression",NA,NA,"PCAT-1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26097602","BiomarkerKG1453415312"
"1592",NA,NA,"56956252","TMPRSS4","ENSG00000137648","expression",NA,NA,"TMPRSS4 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26190376","BiomarkerKG-1765945980"
"1594",NA,NA,"56956252","ALDH1A1","ENSG00000165092","expression",NA,NA,"ALDH1A1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26160842","BiomarkerKG-1076942012"
"1596",NA,NA,"56956252","CD44","ENSG00000026508","expression",NA,NA,"CD44 EXPRESSION NA","COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA","EFO_0000707",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26131439","BiomarkerKG1585396015"
"1597",NA,NA,"56956252","FAM83D","ENSG00000101447","expression",NA,NA,"FAM83D EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26125229","BiomarkerKG1713808498"
"1598","OXALIPLATIN","DB00526","71301229","HOX8","ENSG00000120149","expression",NA,NA,"HOX8 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26123838","BiomarkerKG-1363378867"
"1599",NA,NA,"56956252","AJAP1","ENSG00000196581","expression/DNA methylation",NA,NA,"AJAP1 EXPRESSION/DNA METHYLATION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26122373","BiomarkerKG1438629231"
"1600","CISPLATIN","DB00515","135804801","MCL1","ENSG00000143384","expression",NA,NA,"MCL1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26219890","BiomarkerKG1344393703"
"1601",NA,NA,"56956252","KIF1B","ENSG00000054523","expression",NA,NA,"KIF1B EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26217094","BiomarkerKG-549968971"
"1602",NA,NA,"56956252","MUC5AC","ENSG00000215182","expression",NA,NA,"MUC5AC EXPRESSION NA","INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_1001961",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26210654","BiomarkerKG-9526638"
"1603",NA,NA,"56956252","Caveolin-1","ENSG00000105974","expression",NA,NA,"CAVEOLIN-1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26206578","BiomarkerKG-1820469904"
"1604",NA,NA,"56956252","CXCR4","ENSG00000121966","expression",NA,NA,"CXCR4 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26203228","BiomarkerKG-181311181"
"1606",NA,NA,"56956252","miR-21","ENSG00000284190","expression",NA,NA,"MIR-21 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26261620","BiomarkerKG432140462"
"1607",NA,NA,"56956252","MDR1","ENSG00000085563","expression",NA,NA,"MDR1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26261589","BiomarkerKG-398954281"
"1608","DOXORUBICIN","DB00997","443939","SYF2","ENSG00000117614","expression",NA,NA,"SYF2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26260052","BiomarkerKG2076698436"
"1611",NA,NA,"56956252","S100P","ENSG00000163993","expression",NA,NA,"S100P EXPRESSION NA","CHOLANGIOCARCINOMA","EFO_0005221",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26312563","BiomarkerKG187415291"
"1613",NA,NA,"56956252","HAX1","ENSG00000143575","expression",NA,NA,"HAX1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26339377","BiomarkerKG1959264005"
"1614","CISPLATIN","DB00515","135804801","IP10","ENSG00000169245","expression",NA,NA,"IP10 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26336986","BiomarkerKG734281309"
"1616",NA,NA,"56956252","CDT1","ENSG00000167513","expression",NA,NA,"CDT1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26408331","BiomarkerKG-1541808327"
"1617","CISPLATIN","DB00515","135804801","OPN","ENSG00000118785","expression",NA,NA,"OPN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26397192","BiomarkerKG73926707"
"1621",NA,NA,"56956252","DCLK1","ENSG00000133083","expression",NA,NA,"DCLK1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26468984","BiomarkerKG-367941408"
"1623",NA,NA,"56956252","TPD52","ENSG00000076554","expression",NA,NA,"TPD52 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26575170","BiomarkerKG-1954403125"
"1624",NA,NA,"56956252","NRP1","ENSG00000099250","RNA/expression",NA,NA,"NRP1 RNA/EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26563279","BiomarkerKG-1543706913"
"1626",NA,NA,"56956252","MEP1A","ENSG00000112818","expression",NA,NA,"MEP1A EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26660154","BiomarkerKG-548728786"
"1628",NA,NA,"56956252","BANCR","ENSG00000278910","RNA/expression",NA,NA,"BANCR RNA/EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26758762","BiomarkerKG1027896080"
"1630",NA,NA,"56956252","CPE","ENSG00000109472","RNA/expression",NA,NA,"CPE RNA/EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26803519","BiomarkerKG-1736277364"
"1632",NA,NA,"56956252","SFRP1","ENSG00000104332","expression",NA,NA,"SFRP1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26851021","BiomarkerKG-170651369"
"1634",NA,NA,"56956252","DLC1","ENSG00000008226","protein expression",NA,NA,"DLC1 PROTEIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","26846339","BiomarkerKG-1238168591"
"1638","CISPLATIN","DB00515","135804801","BCAT1","ENSG00000060982","expression",NA,NA,"BCAT1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","27246112","BiomarkerKG1013155066"
"1639",NA,NA,"56956252","FCN2","ENSG00000160339","expression",NA,NA,"FCN2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","27177473","BiomarkerKG-768326737"
"1640",NA,NA,"56956252","MBD2","ENSG00000134046","expression",NA,NA,"MBD2 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","27315121","BiomarkerKG-419303295"
"1642","SORAFENIB","DB00398","406563","APEX1","ENSG00000100823","RNA/protein expression",NA,NA,"APEX1 RNA/PROTEIN EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","Multikinase","pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32167932","BiomarkerKG-1093127695"
"1643",NA,NA,"56956252","mLST8","ENSG00000167965","expression",NA,NA,"MLST8 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32157528","BiomarkerKG1445268847"
"1645",NA,NA,"56956252","SPATS2","ENSG00000123352","expression",NA,NA,"SPATS2 EXPRESSION NA","LIVER CANCER","MONDO_0002691",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32118724","BiomarkerKG-1040658256"
"1646",NA,NA,"56956252","BICD1","ENSG00000151746","expression",NA,NA,"BICD1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32088084","BiomarkerKG-1343289573"
"1647",NA,NA,"56956252","OPN","ENSG00000118785","serum-level",NA,NA,"OPN SERUM-LEVEL NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32043608","BiomarkerKG-1643888148"
"1648",NA,NA,"56956252","MITD1","ENSG00000158411","expression",NA,NA,"MITD1 EXPRESSION NA","HEPATOCELLULAR CARCINOMA","EFO_0000182",NA,"pass","Shreya","Liver_PUBMED_200.xlsx","PubMed","32007795","BiomarkerKG-458575455"
